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Gram-negative septic shock is a life threatening disease associated with high
mortality, particularly in immunocompromised patients. The mechanism by which
Gram-negative bacteria induce septic shock is complex, with little direct
experimental evidence to pinpoint a single toxic factor. Endotoxin, a
lipopolysaccharide (LPS) outer membrane component found in all Gram-negative
organisms, has been implicated as a primary mediator of the toxicity associated with
Gram-negative infection. When purified from organisms and injected into
experimental animals, this substance induces many of the same pathophysiological
changes observed during Gram-negative infection. Based on an increasing body of
data, it is now felt that many of the symptoms of septic shock are attributable to the
action of macrophage-derived mediators released following exposure to LPS.
The aim of this project was to investigate the interaction of various forms of LPS-
free, membrane associated and as a component of whole bacteria- with mammalian
cells to determine the cell surface molecules involved and to study the spectrum of
mediators released.
Initially the interaction of various forms of Salmonella minnesota Ra LPS with
mouse peritoneal macrophages (M0s) was investigated. Bacteria were labelled with
fluorescein isothiocyanate (FITC) and the binding to host cells measured by flow
cytometry. The interaction between bacteria and cells was shown to be dose and
time dependant, maximal at 37° C and required divalent cations. Varying the pH
from 6 to 8 had little effect on the binding. M0s elicited by intraperitoneal injection
of thioglycollate bound more bacteria than cells obtained from control animals. To
investigate the role of LPS in the interaction of bacteria with M0s, different forms of
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LPS were used to try to inhibit binding. Pure free LPS and LPS attached to bacterial
outer membranes extracted from S. minnesota inhibited the binding of bacteria to
M0s but whole unlabelled bacteria (5. minnesota) failed to inhibit the binding of
labelled bacteria to the M0s. This finding led to a microscopic study of the effect of
FITC labelling of bacteria on the binding to M0s. FITC labelling enhanced the
binding of bacteria to the M0s as compared to the binding of unlabelled bacteria.
The production of nitric oxide (NO) and other reactive nitrogen intermediates by
cytokine-activated rodent cells is an important component of antimicrobial and/or
antineoplasic activity of these cells. The pathway involves the oxidation of arginine
to citrulline with concomitant release of NO by an inducible form of NO synthase.
Although human cells such as hepatocytes and endothelial cells have been shown to
express inducible NO synthase, the presence of such a pathway in human
monocytes/macrophages has been questioned by many investigators and is the
subject of great controversy. Therefore an attempt was made to investigate whether
human monocytes/MOs produce NO in response to different forms of LPS. NO
production was assayed by measuring nitrite, a stable metabolic product of NO, in
macrophage culture supernatants. Preliminary work was performed using MOs
from several mice strains and different forms of LPS. An immature human MO cell
line (THP-l) was used to investigate NO production in humans. Free LPS failed to
produce any measurable amounts of NO from human cells, but produced small
amounts of NO from mouse cells. LPS attached to outer membranes and whole
bacteria produced significant amounts of NO from both human and mouse cells.
Human peripheral blood monocytes also produced significant amounts of NO when
stimulated with whole bacteria and LPS attached to outer membranes.
Macrophages are the principle source of the endotoxin-induced mediator tumour
necrosis factor (TNF). This cytokine is pyrogenic and when infused into animals
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produces all the clinical and pathological features of septic shock. All forms of LPS
used stimulated THP-1 cells to release TNF as measured by a L929 bioassay.
The characteristics of the production of TNF and NO suggest that a novel pathway
independent of CD 14 and lipopolysaccharide binding protein might be involved.
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The study of endotoxin began at the end of the 19th century when Richard Pfeiffer, a
student of Robert Koch, found that lysates of heat-inactivated Vibrio cholerae contained a
toxic substance which was capable of inducing shock and death in experimental animals.
He termed this heat-stable toxin "endotoxin" to distinguish it from the heat-labile
exotoxins which were actively secreted by V. cholerae. Around the same time two other
scientists, Eugenio Centanni and Hans Buchner, independently isolated the same toxin.
Centanni made two important contributions. First, he observed that this toxin could be
isolated from lysates of many different Gram-negative bacteria, but never from similar
preparations of Gram-positive bacteria. Second, he drew attention to the remarkable
pyrogenic properties of endotoxin. Buchner was the first to demonstrate the association of
endotoxin with leucocytosis and altered host immunity.
In 1935 Boivin and Messrobeanu, using a method of trichloroacetic acid extraction,
determined that the endotoxic activity of Gram-negative bacterial lysates resided in a cell
wall macromolecular complex of protein, lipid and polysaccharide. Two decades later
Westphal and Luderitz commenced their classic studies on the biochemistry of endotoxin.
Protein-free lipopolysaccharide (LPS), prepared by phenol-water extraction and purified,
possessed all the properties of crude endotoxin. Further separation of LPS into water-
soluble polysaccharide fraction led to the finding that the biological activity of the




Lipopolysaccharides (LPS: endotoxins) are major components of the outer membranes of
Gram-negative bacteria (Fig. 1.1) which include human pathogens such as
Enterobacteriaceae and Neisseriaceae. These molecules are essential for the physical
organisation and function of the membranes of each bacteria and thus for bacterial growth
and multiplication. Lipopolysaccharides represent the main surface antigens (O-antigens)
of Gram-negative bacteria. They are targets for bacteriophages, they harbour binding sites
for antibodies and non-immunoglobulin serum factors and therefore are involved in the
specific recognition and elimination of bacteria by the host's defence system. On the other
hand LPS may prevent the activation of complement and uptake of bacteria by phagocytes
and therefore, play an important role in bacterial virulence. Further, LPSs are endowed
with a broad spectrum of biological (endotoxic) activities such as pyrogenicity and lethal
toxicity ( Rietschel et al, 1990).
Septic shock causes approximately 175,000 deaths every year in the United States. Gram-
negative sepsis may account for up to one half of the cases of septic shock. It is a
syndrome characterised by refractory hypotension leading to inadequate organ perfusion,
multi-organ failure, and, frequently, death. The lipopolysaccharide of Gram-negative
bacteria is thought to be responsible for initiating host responses leading to septic shock.
LPS is not intrinsically toxic but acts by inducing myeloid and/or non-myeloid cells to
express a multiplicity of genes encoding proteins with activities that produce the
haemodynamic and haematologic changes observed in septic shock. It is one of the most
potent biological response modifiers known; picomolar concentrations are sufficient to
stimulate cells of the immune/ inflammatory/vascular systems. A vast amount of
information about the molecular mechanisms of host defence responses and the
production of inflammatory mediators has been derived from studies using LPS as a
stimulus. The mechanisms of LPS-induced cell activation were not well understood until







Figure 1.1 The cell envelope of a Gram-negative bacterium. LP: lipoprotein;
LPS: lipopolysaccharide; P: protein; PL: phospholipid, (reproduced from Hancock and
poxton. 1988)
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the discovery of LPS binding protein (LBP), a 60-kDa serum glycoprotein that binds to
the lipid A moiety of LPS molecule. Analysis of LBP by cDNA cloning led to the
recognition of a structure-function relationship among LBP, bactericidal/permeability-
increasing protein (BPI) and other proteins (Ulevitch and Tobias, 1995). This structural
relationship between LBP and BPI has led to the proposed use of BPI as a therapeutic
agent (Marra et ah, 1996). Most importantly, characterisation of LBP function in
determining cellular responses to LPS revealed an unanticipated mechanism for LPS-
induced cell activation that involves a membrane receptor for LPS-LBP complexes. The
second major advance was the identification of this cellular receptor as CD14. CD14 is a
55-kDa glycosyl-phosphatidylinositol (GPI)-anchored membrane protein (mCD14) of
myeloid cells; it is also found as a soluble serum protein (sCD14) lacking the GPI-anchor.
Although other cell surface proteins have been suggested to be LPS receptors, CD14 is the
only protein with fully defined structure that binds LPS and mediates LPS-induced cell
activation. A role for mCD14 has been defined in LPS activation of myeloid cells, while
sCD14 has been shown to participate in activation of nonmyeloid cell types such as
endothelial or epithelial cells that normally do not express mCD14 (Ulevitch and Tobias,
1995).
The pathogenesis of septic shock is complex and is attributable to both microbial and host
factors. Experimental and clinical data have shown that the pro-inflammatory cytokines
TNF-a and IL-1 are important mediators of severe sepsis. TNF-a is present in the
systemic circulation after the administration of live or heat-killed bacteria or endotoxin.
Administration of TNF-a reproduces many of the physiologic changes associated with
severe sepsis, and antibodies against TNF-a have a protective effect in animal models of
severe sepsis. The effects of TNF-a are mediated through cell surface TNF receptors. The
extracellular portions of the receptors are shed in vivo and then bind circulating TNF-a,
thereby blocking its bioavailability. The presence of TNF-a and its ratio to soluble TNF
receptors in plasma are correlated with mortality from sepsis (Fisher et al, 1996).
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Hypotension and hypoxaemia are pivotal in the pathogenesis of multi-organ failure.
Within the lung, cytokine-induced changes can lead to profound hypoxaemia and
respiratory failure. TNF-a, IL-8 and C5a all contribute to neutrophil chemotaxis, whilst
the upregulation of endothelial cell adhesion molecules and neutrophil integrins facilitates
the passage of leucocytes from the circulation into the interstitium and alveolar spaces of
the lung. Acute inflammatory changes occur as a result of abnormal leucocytosis and
neutrophil degranulation leading to acute respiratory distress syndrome (ARDS). Within
the peripheral vasculature, TNF-a, IL-1 and IFN-y can synergistically trigger the
production of nitric oxide (NO) (Sriskandan and Cohen, 1995). Recent studies have
linked NO to the development of hypotension after endotoxaemia and bacteraemia.
Inhibitors of NO synthase (NOS), such as NG-methyl-L-arginine (NMA), can partially
prevent or reverse hypotension secondary to endotoxaemia. Furthermore, hypotension
induced by TNF can be reversed by inhibiting NOS, suggesting that both endotoxin and
TNF induce hypotension through NO-dependent pathway (Fahey et al, 1996).
Bacterial LPS, which is present within the circulation or tissues of the human or animal
host, is more usually referred to as endotoxin. In this study both terms (LPS/ endotoxin)
were used synonymously.
1.1.2 Function of LPS in bacteria
LPS forms a hydrophobic barrier which restricts the entry of noxious substances such as
bile salts, digestive enzymes and certain antibiotics and enables the bacterium to evade
many host defence factors including complement, lysozyme and cationic proteins. The
surface of many unicellular organisms is usually covered with a carbohydrate layer. In
organisms lacking capsules, the O-side chains of LPS form this layer. One important
function of the cell surface carbohydrate is to increase hydrophilicity of the cell surface.
This increase of hydrophilicity is apparently crucial in enabling cells to escape
phagocytosis (Cunningham et al, 1975). Avoiding phagocytosis is necessary for
survival of pathogens of animals such as Salmonella ssp.
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The O-side chains might also mask cell surface components, such as lipid A, which is
capable of activation of the classical complement pathway in the absence of specific
antibody (Morrison and Kline 1977). O-side chains from E. coli. Oil I and Salmonella
species bind complement, but resistance to lysis results from the C3b component being
bound preferentially by longer polysaccharide chains at a distance sufficient to prevent the
insertion of the terminal membrane attack complex (C5b-9) into the bacterial outer
membrane (Joiner et al., 1986; Grossman et al., 1987). Both the length of the O-side
chains and the coverage of lipid A core appear to be important in this respect (Goldman er
al., 1984).
The structure of the exposed LPS (i.e. the O-side chain) often shows a tremendous
diversity. The attachment of specific antibodies to bacterial surfaces enhances
phagocytosis by promoting attachment to the Fc and complement receptors on the
phagocyte surface (Silverstein et al, 1979), and antibodies will also activate complement
leading to increased phagocytosis and lysis of bacteria and stimulation of an inflammatory
response and by decreasing the hydrophilicity of the bacterial surface (van Oss and
Gillman, 1977). The diversity within the O-side chains is advantageous to bacteria since
when each different O-antigenic type enters a host for the first time there will be no
immunological memory to the organism. This will give a significant selective advantage
to pathogenic bacteria, and the diversity is pronounced in animal symbionts and pathogens
(Nikaido and Nake, 1979).
1.1.3 Structure of LPS
Chemically LPS consists of two parts of contrasting chemical and physical properties; a
hydrophilic polysaccharide and a hydrophobic lipid, termed lipid A. The polysaccharide
can be subdivided into the O-specific chain (O-side chain) and the core oligosaccharide.
Several bacterial mutant strains have been isolated in which the O-chain and part of the
core oligosaccharide are missing as a result of a defect in the biosynthesis of the core
region. Because of their colonial morphology such mutant strains are called rough (in
contrast to the smooth colonies of bacteria possessing a full O-side chain). Depending
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on the site of the defect, these mutant strains in Salmonella spp and E. coll are labelled
Ra-Re (Fig. 1.2). Some bacteria produce naturally rough LPS. e.g. Neisseria spp.
1.1.3.1 O-specific chain
The O-specific chain constitutes a polymer of repeating oligosaccharide units which
contain up to eight different, or in some cases identical, sugar residues which are generally
interlinked by glycosidic bonds (Luderitz et al., 1982). A large diversity of the
constituent sugar components of repeating units has been revealed within different
enterobacterial serotypes. The nature, ring form, anomeric configuration and type of
substitution of the individual monosaccharide r::;dues, as well as their sequence within a
repeating unit, is characteristic and unique for a given LPS and the parental bacterial
strain, i.e. a bacterial serotype or species. Because of the diversity of constituents and their
linkages, an enormous number of structures of specific chains is conceivable and verified
in nature. Therefore, an immense structural variability is revealed if the O-specific chains
of different bacterial species are compared. Even within a particular individual clone of
bacteria, variation in O-side chains is found. When LPS samples from a specific organism
are studied by polyacrylamide gel electrophoresis, the number of repeating units may
vary from 0 (= unsubstituted core) to approximately 50 (Hitchcock et al., 1986). The fact
that in a given LPS preparation a family of molecules exists which differ in the presence
or absence of O-specific chains and the degree of polymerisation of repeating units is one
of the reasons for the intrinsic heterogeneity of LPS (Nowotny, 1984).
A variety of nonenterobacterial wild-type strains of pathogenic Gram-negative bacteria
such as Acinetobacter, Bordetella, Campylobacter, Neisseria, Haemophilus and
Chlamydia (Fig. 1.3) form LPS which lacks O-specific chains with repeating units (Griffis
et al, 1988). In their general architecture and behaviour in polyacrylamide gel
electrophoresis these LPSs resemble those of Enterobacterial rough-(R)-mutants.
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Fig. 1. 2 Chemical structure of Salmonella typhimurium LPS showing: A-E
sugar residues; Glc, D-glucose; Gal, D-galactose; GlcNAc, A-acetyl-D-glucosamine;
Hep, L-glycero-D-manno heptose; KDO, 2-keto-3-deoxyoctonic acid. Ra-Re are
incomplete R-form lipopolysaccharide. (Reproduced with modification from
Rietschel and Brade, 1992)
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Enterobacteriaceae








Fig. 1.3 Schematic presentation of lipopolysaccharide of pathogenic Gram-
negative bacteria, (reproduced with modification from Rietschel etal, 1993)
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1.1.3.2 Core oligosaccharide
The core of enterobacterial LPS consists of a hetero-oligosaccharide which can be
formally subdivided into the O-chain proximal (outer core) and the lipid A proximal
(inner core) region. The structure variability of the core within the various species of an
enterobacterial genus is limited. In Salmonella only one core type (Ra core) exists for all
serotypes and in Escherichia coli so far five core types (Rl- R4 and K 12) have been
described for over one hundred different serotypes (Jansson et ah, 1981). Structural
differences between these core types are mainly recognised in the outer region.
The outer core of enterobacterial LPS contains the common hexoses D-glucose (Glc), D-
galactose (Gal) and N-acetyl-D-glucosamine (GlcNAc) and N-acetyl-galactosamine
(GalNAc) in the pyranosidic ring form. The outer core is, therefore, also termed the
hexose region (Fig 1.4 a). In the case of Salmonella and E. coli, the outer core mostly
consists of a branched pentasaccharide which carries Glc (Hex I) at the reducing position
(Fig 1.4 b). Through this Glc residue the outer core is a (1-3)- linked to the inner core
region. The outer core functions as a receptor for core-specific bacteriophages and it
harbours those structures which determine the serological R-specificities. Furthermore, the
outer core, probably through Gal residues, mediates binding of LPS or bacteria to lectin-
like receptors of activated T-lymphocytes. It has been suggested that this interaction plays
a role in the differentiation of T-helper cells or the induction of suppressor cells (Lehmann
et al., 1980), and the removal of bacteria by lymphocytes (Jirillo et al., 1990).
The inner core region of enterobacterial LPS is characterised by the unusual sugars,
heptose (Hep), mainly in the L-glycero-D-manno form though occasionally in the D-
glycero-D-manno configuration, and notably 3-deoxy-D-/?ia«w)-octulosonic acid (2-keto-
3-deoxyoctonic acid, KDO). LPS of Enterobacteriacae and the majority of other bacteria
studied (including those which lack the O-specific chain) contain heptose whereas all
LPS, independent of their bacterial origin, harbour at least one a-bound pyranosidic or
furanosidic KDO residue (or a derivative) with free carboxyl group. The latter residue
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Figure 1.4 Structure of the hexose region of Salmonella and E. coli core types. In
E. coli K-12, GlcNAc is a (3(l-6)-linked to Hexose III (a). A common linear hexose
trisaccharide is recognised in the outer core of Salmonella and E. coli with Glc (Hex I) at
the reducing end (b). (Reproduced from Rietschel et al, 1990)
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Brade, 1992). In this respect the inner core region is structurally rather conserved. Figure
1.5 shows the proposed chemical structure of the inner core region of salmonella LPS.
In recent years, the KDO-containing inner core has been recognised to be of great
significance for the biological activity and function of LPS( Bacteria with a defect in
KDO biosynthesis are not viable showing that KDO (and LPS in general) is essential for
growth and multiplication (Osbom, 1979).
1.1.3.3 Lipid A
Lipid A constitutes the covalently-linked lipid component of LPS. Enzymes which cleave
the polysaccharide-lipid bond are not known and therefore, polysaccharide-deprived free
lipid A can only be prepared by chemical degradation (e.g. by acid catalysed hydrolysis of
LPS). The ketosidic linkage between KDO and lipid A is particularly acid labile and
therefore, free lipid A can be prepared by treatment of LPS with mild acids (Rietschel et
al., 1993). The application of mild organic or mineral acids may cause some degradation
and a certain heterogeneity of free lipid A (Takayama and Qureshi, 1992). Lipid A
exhibits also intrinsic heterogeneity which is due to the presence of partial structures
resulting from incomplete biosynthesis (Nowotny, 1984). Despite this, the primary
structure of enterobacterial and some nonenterobacterial lipid As has been elucidated in
great detail (Takayama and Qureshi, 1992). These structures were, in general, analysed
by using R-form LPS. Figure 1.6 shows the primary structures of the predominant
components of E.coli and Salmonella Minnesota lipid A (Rietschel et al., 1984). In both
cases lipid A is composed of a (3-D-glucosaminyl-(l-6)-a-D-glucosamine disaccharide
which carries two phosphoryl groups, one in position 4' (of the distal glucosaminyl
residue, GlcN II) and one in position 1 (of the reducing glucosaminyl residue, GlcN I).
This hydrophilic lipid A backbone is, in both cases, acylated by four primary acyl groups
i.e., four (R)-3-hydroxytetradecanoic acid residues [14:0(3-OH)] at positions 2, 3, 2' and
3'. As a further common feature, both lipid A molecules contain two unsubstituted
hydroxy 1 groups at position 4 and 6'. The latter primary hydroxyl group is only free in
polysaccharide-deprived free lipid A since in LPS it represents the attachment site of
13
Figure 1.5 Chemical structure of the inner core of Salmonella LPS. Dashed
lines indicate nonstoichiometric substitution. (Reproduced with modification from
Rietschel et al, 1993)
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Figure 1.6 Chemical structure of the lipid A component of E. coll (A) and
Salmonella minnesota (B). The hydroxyl group in position 6' (GlcN II) represents
the attachment site of KDO. Numbers in circles refer to the number of carbon atoms
in acyl chains. Dashed lines indicate nonstoichiometric substitution. (Reproduced
from Rietschel et al, 1993)
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KDO i.e. of the polysaccharide component (Fig. 1.6). In both E. coli and S. minnesota
lipid A, the hydroxyl groups of the two 14-0(3-OH) residues bound to GlcN II (position 2'
and 3') carry, as secondary acyl groups, dodecanoic (12:0) and tetradecanoic acid (14:0),
respectively. (In Salmonella, the latter is some times present as (S)-2-
hydroxytetradecanoic acid). In E. coli, the two 14:0(3-OH) residues at GlcN I are not 3-0
acylated whereas in S. minnesota the amide-linked 14:0(3-OH) of GlcN I is either not
acylated or carries hexadecanoic acid (16:0) (as indicated by the dashed line in Figure
1.6). Therefore, in S. minnesota lipid A two molecular species are recognised, differing in
the substitution of 14:0(3-OH) at GlcN I and therefore, in the number of acyl groups
present. Obviously, one of these species structure'ly corresponds to hexaacyl E. coli Lipid
A. In addition to the main structures shown in Figure 1.6 these lipid A preparations also
contain molecules which possess the phosphorylated glucosamine backbone but a smaller
number of acyl groups (Qureshi et al, 1985). Such acyl-deficient structures are
particularly found in enterobacterial S-form LPS (Jiao et al., 1989). The phosphoryl
residues in position 1 and 4" may be substituted (residue R in Fig. 1.6), and phosphate {E.
coli), 2-aminoethyl(pyro)phosphate and 4-amino-4-deoxy-L-arabinopyranose (S.
minnesota) have been identified as phosphate substituents. These substituents are not
present in stoichiometric amounts which represents a further facet of the intrinsic
heterogeneity of lipid A. The same structure as shown for E. coli lipid A has been
identified in S. typhimurium (Takayama et al, 1984) and this type of lipid A is also
present in other enterobacterial (Rietschel et al, 1984), and nonenterobacterial genera
such as Haemophilis (Helander et al, 1988). Both hexaacyl E. coli lipid A and heptaacyl
S. minnesota lipid A have been chemically synthesised (Galanos et al, 1986) and shown
to be identical in all chemical and physical properties to their purified bacterial
counterpart.
1.2 Sources of endotoxin
Endotoxin is not detectable in the circulation in healthy individuals. The most obvious
association is with Gram-negative septicaemia. Gram-negative bacilli in culture will
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liberate endotoxin into the supernate to varying degrees; in the case of meningococci, it
appears that the extent of endotoxin release correlates with virulence (Anderson and
Solberg, 1984). Spontaneous endotoxin release may well occur in vivo during
bacteraemia, perhaps reflecting cell division and multiplication. Endotoxin might also
seep into the circulation from an enclosed abscess, even if bacteraemia is absent. An
additional major source of endotoxin is the gut, and it is clear that damage to the mucosal
barrier might lead to endotoxaemia independently of bacteraemia (van Deventer er al.,
1988). Several investigators have reported a high incidence of portal endotoxaemia,
suggestive of endotoxin transport (translocation) through the intestinal mucosal barrier.
However, patient groups investigated comp-ised patients with gastrointestinal ulcers,
jaundice (Prytz et al, 1976), liver disease and bowel disease (Jacob er at, 1977). These
studies therefore do not provide conclusive evidence for endotoxin uptake through an
intact intestinal mucosa. In a well designed study using a sensitive chromogenic Limulus
assay and excluding patients with bowel disease revealed no detectable endotoxin in 17
preoperatively collected blood samples (Brearly et ah, 1985). Hence, it is unlikely that
significant portal endotoxaemia is physiological in humans without bowel and liver
disease.
Another interesting possibility is that endotoxin might be released into the circulation as a
result of bacterial lysis, either complement-mediated or as a result of antibiotic
administration. Since most bacteraemic strains of Gram-negative bacteria are serum
resistant (Roantree and Rantz 1960), it must be assumed that antibody and complement-
mediated killing is not an important source of endotoxin in septicaemia. It is more
difficult to judge the potential importance of antibiotic-mediated release of endotoxin.
Clinical observations dating back to the 1940s had led to the suggestion that the sudden
lysis of bacteria, when first exposed to antibiotic, might cause endotoxin release and
symptoms of septic shock. Studies have shown that in vitro exposure of bacteria to
certain classes of bactericidal antibiotics causes significant amounts of endotoxin to be
released promptly into the supernate (Cohen and McConnell. 1986; David et al., 1991).
What was more difficult and is of greater importance is to try and establish if this
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phenomenon is of significance in vivo. Animal studies have produced conflicting results.
In a rabbit model of E. coli sepsis, the use of gentamicin had increased the circulating free
endotoxin in animals receiving the antibiotic up to 2000 fold as compared to control
animals receiving placebo. However the study does not provide evidence pertinent to the
biological significance of antibiotic induced endotoxin liberation (Shenep and Mogan
1984). In contrast, other investigators reported a study in piglets in which gentamicin
4
-induced endotoxin release was clearly associated with adverse effects on cardiac output
and pulmonary-artery pressures (Rokke er al, 1987). In both studies gentamicin was
used and the contrasting results of these studies might be because of the use of different
animal models.
Pure LPS can only be considered a laboratory artefact as when it is released from the
bacterium it will always be associated with other outer membrane components. Once in
the host it is normally complexed immediately with host proteins and lipoproteins. Only
in meningococcal sepsis, where there is an overwhelming mass of endotoxin present, does
the lipooligosaccharide (LOS) appear to be present as micelles or aggregates free from
host molecules (Brandtzaeg er al, 1992).
The physical state of the LPS used in the laboratory also has important consequences.
Neutralisation of acidic LPS obtained by electrodialysis with a base yields the
corresponding uniform salt of the LPS (Galanos and Liideritz, 1975). Different salts of a
given LPS exhibit characteristic differences in their solubility in distilled water and
physiological buffers such as phosphate buffered saline and subsequent different
biological activities in vivo and in vitro.
1.3 Clinical Association
Endotoxins have been implicated in the pathogenesis of a variety of different clinical
disorders such as Gram-negative septic shock (Morrison and Ryan, 1987), liver disease
[fulminant hepatic failure (Liehr, 1982), cirrhosis (Clemente et ah, 1977) and renal failure
in obstructive jaundice (Bailey, 1976)1, inflammatory bowel disease (Wellmann er al.,
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1984), acute renal failure (Wardle, 1975), glomerulonephritis (Tomosugi et al, 1989),
adult respiratory-distress syndrome (Brigham and Meyrick, 1986), major abdominal
trauma (Woodruff et al., 1973), neonatal necrotising enterocolitis (Scheifele et al,, 1985),
radiation injury (Maxwell et al, 1986), graft-verms-host disease (Moore et al, 1987)
and toxic shock syndrome (Stone and Schlievert, 1987). Of these Gram-negative septic
shock is the most familiar, and is the setting in which the role of endotoxin is most clearly
established (Morrison and Ryan. 1987).
Advances in medical therapy, and increased use of invasive medical procedures and
devices are factors contributing to a growing population of chronically ill,
immunocompromised and seriously ill patients at increased risk for sepsis. Sepsis can
occur as a primary disease process resulting from bacterial infection of the mammalian
bloodstream or secondarily complicate other disease states. Gram-negative bacillary
sepsis is a life-threatening infection associated with high mortality, particularly in
immunocompromised patients such as those with malignancy, trauma or AIDS. It is
estimated that in the United States alone more than 90 000 deaths per year are secondary
to Gram-negative sepsis. It is of interest that other organisms including Gram-positive
bacteria, spirochaetes, rickettsiae, mycoplasmas, parasites, fungi and viruses may also
cause a shock-like syndrome indistinguishable from that induced by Gram-negative
bacteria. Recent evidence indicates that, whilst endotoxin is perhaps the most potent
stimulus to mediator production, factors derived from other organisms may also do so
(Bate et al, 1988 ; Jupin etal., 1988).
The mortality associated with Gram-negative septic shock is high. Estimated figures
varying from 31 to 55 percent according to three independent studies carried out in the
United States of America (31 % -Bone et al, 1987), in the United kingdom (49 %
-Ispahani et al, 1987) and in a Swiss-Dutch study (55 % -Calandra et al, 1988). Several
factors have been shown to influence the mortality rates; e.g. age, underlying disease and
the appropriate use of antibiotics (Kreger et at, 1980a). Septic shock is a syndrome
characterised by hypotension, oligurea, hypoxia, acidosis, the development of
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microvascular abnormalities and disseminated intravascular coagulation (Hamill and
Maki, 1986). Multiple organ failure is a common sequel. Studies at necropsy reveal
widespread tissue damage with particular involvement of the liver, lungs, kidneys and
adrenal glands. Tissue lesions include oedema, haemorrhage, inflammatory infiltrates,
fibrin thrombi and areas of tissue necrosis. Identical physiological and pathological
changes may be seen in experimental animals receiving lethal doses of endotoxin
(Bayston and Cohen, 1990).
1.4 Septic shock pathogenesis
Much published data based on in-vitro and in-vivo studies testify to the biological havoc
that endotoxin can cause. It exerts a profound influence on the formed elements of the
blood and, in particular, on the coagulation system. Endotoxin causes metabolic and
pharmacologic effects which account in large part for the pathophysiological changes seen
in shocked patients, and is a powerful immunostimulant with the ability to influence both
cellular and humoral limbs of the immune response (Rapson, 1988).
Much, if not all, of the toxicity of endotoxins is brought about by a series of mediators
rather than by endotoxin itself. These molecules all play important roles in the normal
host response to insult. Their controlled production leads to eradication of foreign
material and tissue repair; however, their inappropriate or over production can have
important consequences for the host. Several of these mediators have been recognised for
some years; the anaphylatoxins C3a and C5a, arachidonic acid derivatives, reactive
oxygen intermediates, endorphins, coagulation factors and platelet activating factor.
Other more recently described procoagulant molecules, such as tissue factor and
intracellular adhesion molecule-1 (ICAM-1), probably also contribute to the development
of shock and, in particular, disseminated intavascular coagulation. What has caused most
interest in the field of endotoxin research in recent years is the discovery of the role of
cytokines in septic shock. Tumour necrosis factor a (TNF a), interferon y (IFN- y),
interleukin 1 (IL-1), interleukin 2 (IL-2), and more recently interleukin 6 (IL-6) have all
been incriminated. Of these, TNF has received most attention.
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The alternative complement pathway can be activated by LPS and Gram-positive cell wall
components. The classical pathway is mainly activated by certain classes of antibodies;
however, certain bacterial cell wall components including LPS are active in this respect.
The anaphylatoxins C3a and C5a that result from activation of these pathways are
responsible for a series of inflammatory events that have been implicated in the
pathophysiology of septic shock. These events include vasodilation and increased
vascular permeability, which may be partly responsible for haemodynamic changes,
platelet aggregation, and aggregation and activation of granulocytes. All these processes
have also been implicated in the pathogenesis of the adult respiratory-distress syndrome
(Jacobs, 1981). An important effect of the stimulation of complement system is the
activation of neutrophils. The subsequent release of arachidonic acid derivatives,
cytotoxic products of molecular oxygen and lysosomal enzymes produces additional local
vasoactive effects on the microvasculature. This in addition to endothelial cell cytotoxicity
results in capillary leakage. Increased concentrations of complement have been associated
with fatal outcome in septic shock of Gram-positive and Gram-negative origin (Hack et
ah, 1989).
It is well known that the derivatives of arachidonic acid metabolism that cause
vasodilation, platelet aggregation, and neutrophil activation may contribute to the
pathogenesis of septic shock. Such derivatives are found in increased concentrations after
experimental endotoxin challenge and in humans with septic shock (Reines er al., 1981).
Activated neutrophils, a key element in the inflammatory response, probably play an
important part in the pathogenesis of septic shock in that they contribute to vascular and
tissue injuries. Activated leucocytes adhere to each other, to endothelial cells, and to
tissues through interactions of receptors (on endothelial cells) and ligands (on
inflammatory cells) that are mediated by specific adhesion molecules. The adhesion
process is essential for most functions of leucocytes such as chemotaxis, phagocytosis and
cytotoxicity (Springer, 1990).
Factor XII (Hageman factor) of the coagulation cascade has long been known to have a
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central role in the pathogenesis of septic shock. It is activated by peptidoglycan residues
and teichoic acid from the cell wall of Gram-positive organisms as efficiently as by LPS
and lipid A from Gram-negative bacilli (Springer et al, 1983). Activated factor XII not
only triggers the intrinsic coagulation pathway (through activation of factor XI) but also
stimulates endothelial cells and macrophages to produce tissue factor, which in turn
activates the extrinsic coagulation pathway. The activation of these pathways may lead to
consumption of coagulation factors and to disseminated intravascular coagulation (DIG).
Tissue factor produced upon stimulation of macrophages and endothelial cells by LPS has
been shown to have a major role in inducing DIC, since anti-tissue factor antibodies
prevented LPS-induced DIC in rabbits (Warr et al., 1990). Tumour necrosis factor (TNF)
is also an activator of the extrinsic pathway of coagulation, and, therefore, may contribute
to the perturbation of coagulation in septic shock (van der Poll et al, 1990).
In addition to being induced by activation of complement and the arachidonic acid
cascade, hypotension in septic shock may also result from LPS-activated factor XII that
converts prekallikrein into kallikrein. Kallikrein in turn cleaves high molecular weight
kininogen to release bradykinin, a potent hypotensive agent (Colman, 1989). Hypotension
also results from release of another potent vasodilator, endothelium-derived relaxing
factor, recently identified as nitric oxide (Palmer et al., 1987). Generation of nitric oxide
occurs in macrophages and in cultured endothelial cells. While it appears that LPS-
induced nitric oxide release by macrophages takes several hours, endothelial cells react
within minutes, a phenomenon that might contribute to the rapid fall in blood pressure
associated with endotoxic shock (Vane et al., 1990).
Endogenous opioid peptides might play a part in septic shock because opioid peptide
secretion can be induced by LPS. In addition the administration of an opioid antagonist,
naloxone, reverses LPS-induced hypotension under some experimental conditions.
However, the importance of endorphins in the pathophysiology of shock is still
incompletely understood (Hackshaw et al, 1990).
Platelet activating factor (PAF) is produced by many cell types, including neutrophils,
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basophils, mononuclear phagocytes, platelets and endothelial cells. It has diverse
biological activities including platelet aggregation and secretion, degranulation of
neutrophils, smooth muscle contraction, increased vascular permeability, hypotension and
can cause death. It plays an important role in anaphylactic shock and might play a role in
endotoxic shock as well (Morrison and Ryan, 1987). Intravenous LPS infusion into rats
results in hypotension within five minutes and detectable levels of PAF in the circulation
in less than ten minutes (Doebber et at, 1985). The direct effects of PAF on endothelial
cells are very likely of great clinical significance. PAF induces the margination of
neutrophils on to endothelial cells. Many of the effects of PAF may stem from its ability
to influence calcium fluxes and thus modulate endothelial cell function (Bussolino et at,
1985). There may also be more complex interactions between endotoxin-stimulated PAF
and other mediators of inflammation. Interleukin-1 (IL-1) is a potent stimulator of PAF
from human endothelial cells. This stimulation occurs following activation of a
membrane-localized acetyltransferase, an enzyme utilized in the generation of biologically
active PAF (Bussolino et at, 1986).
A group of molecules known as colony stimulating factors (CSFs) are a collection of
glycoproteins that regulate the proliferation of bone marrow-derived precursor cells into
functionally active cells and modify the effector functions of the mature cells. Four
separate CSFs have been described in mice (Metcalf, 1986), each of which is both
functionally and biochemically distinct. Granulocyte macrophage-colony stimulating
factor (GM-CSF) stimulates the proliferation and differentiation of both granulocytes and
monocytes. Some of the major effects of CSF on macrophages and monocytes include
stimulation of phagocytic activity, synthesis of prostaglandins, secretion of proteases and
expression of cytolytic activity. It is, therefore, of relevance that bacterial endotoxins are
potent inducers of CSF from both macrophages and B lymphocytes. An indirect
mechanism for endotoxin induced CSF production has also been described in which
endotoxin stimulated monocytes cause T lymphocytes, endothelial cells and fibroblasts to
produce GM-CSF (McCall and Bagby, 1985). The stimulating factor has been identified
as IL-1 in the fibroblast system (Zucali et at, 1986). In addition, endotoxins enhance the
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capacity of CSF to induce colony formation in cultures of macrophage progenitor cells
(Moore et al., 1986). Since endotoxins can also induce the formation of prostaglandins in
these cells, this enhancement is subject to potential feedback inhibition. Thus there are
both direct and indirect means for endotoxins to induce the production of CSFs and,
therefore, the diverse biological activities associated with these glycoproteins.
Tumour necrosis factor (TNF) was orginally characterised as a factor that could be
detected in the serum of BCG-pretreated experimental animals shortly after challenge with
endotoxin, and that could cause lysis of some tumour cell lines (Old, 1985). It is now
generally accepted that TNF may be produced by endotoxin-stimulated macrophages in
the absence of additional external stimuli (Beutler et al, 1985a). It has been established
that TNF is identical to the modulator protein cachectin, which has also been shown to be
produced by mononuclear cells in .responce to endotoxin (Beutler et al, 1985b).
Cachectin was orginally recognised for its potent capacity to inhibit lipoprotein lipase
(Beutler et al, 1985a). The spectrum of biological and immunoregulatory activities
ascribed to TNF/cachectin molecule is impressive and is likely to continue to grow.
TNF is synthesized and secreted very rapidly by macrophages in response to endotoxin
and may be detected in the circulation within one hour of experimental animals being
given endotoxin. Following synthesis, TNF becomes widely distributed in the tissues and
is then rapidly degraded (Beutler et al., 1985c). Dexamethasone inhibits the production
of TNF by endotoxin-stimulated macrophages; however, pretreatment of macrophages
with dexamethasone prior to endotoxin stimulation was essential for effective inhibition
(Beutler er al, 1986). It is of significance that rabbit antibody to TNF partially protects
mice against the lethal effects of endotoxin (Beutler er al., 1985d). Optimal results were
obtained in these studies when the antiserum was administered six hours prior to
endotoxin challenge. This data supports a role for TNF in mediating the lethal effect of
endotoxin and they reveal the macrophage as a critical target cell for the production of
mediators of endotoxic activity.
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TNF may exert indirect as well as direct activities in mediating endotoxic activities. TNF
is intrinsically pyrogenic, similar to interleukin 1 (IL-1). It also has the ability to induce
IL-1 production (Dinarello et al, 1986a) with its consequent spectrum of potent
biological activities. TNF induces IL-1 from both mononuclear cells and endothelial
cells. Furthermore, the interaction of TNF with endothelial cells alters their coagulant
activity (Nawroth and Stern, 1986) and therefore provides an amplification mechanism for
endotoxin elicited TNF and IL-1 in the induction of coagulation. This mechanism can
operate independently of macrophage tissue factor activity.
Interleukin-1 (IL-1) represents a family of cytokines produced and secreted by
mononuclear phagocytes and other cells upon stimulation by a variety of substances
including bacterial endotoxin (Dinarello, 1986). Endotoxin may be one of the more
potent inducers of IL-1 in macrophages with activity at picogram level. A variety of
experiments have strongly suggested that IL-1 plays a central role in mediating host
responses to bacterial infections. This is due both to the intrinsic activity of IL-1 and to
the impressive number of additional mediators that are stimulated by the action of IL-1 on
responsive cell populations. There appear to be at least two IL-1 molecules in humans,
distinguishable on the basis of isoelectrical points and unique amino acid sequences.
Experiments proved that endotoxin induces IL-1 in a uniform manner from cultured
human peripheral monocytes (Bayne era!., 1986).
The biological activities of IL-1 are nearly as complex as the activity of endotoxin itself.
The two classic activities associated with IL-1 are fever production and lymphocyte
activation. These two activities have been confirmed by researchers using a well-defined
recombinant form of human IL-1 (Dinarello et a!., 1986b). Many other activities
associated with IL-1 may play a role in mediating the pathophysiologic sequelae
following exposure to endotoxin. IL-1 interaction with endothelial cells promotes
procoagulant activity and increases endothelial adhesiveness (Bevilacqua et at, 1985).
IL-1 also induces an inhibitor of tissue plasminogen activator, which may contribute to the
intravascular coagulation observed during acute inflammatory processes. IL-1 enhances
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the hepatic production of acute-phase proteins such as serum amyloid A and C-reactive
protein, which may play immunoregulatory roles during infection. Recently, IL-1 was
found to be responsible for the stimulation of cells such as T lymphocytes, endothelial
cells and fibroblasts to produce granulocyte macrophage colony stimulating activity. This
data combined with the well described T lymphocyte and B lymphocyte stimulatory
activities of IL-1, make it increasingly clear that IL-1 often plays a key positive role in
enhancing immunity.
On the other hand, a number of mediators that may be deleterious to the host are also
induced by IL-1 and may therefore be viewed within the framework of second-order
effects of endotoxin. Platelet activating factor and arachidonic acid metabolites, both of
which are also generated directly in response to endotoxin, represent very potent
vasoactive compounds stimulated by IL-1. Therefore IL-1 may be viewed as one of the
more important mediators induced by endotoxin, and may be directly responsible for the
production of other mediators playing critical roles in the hosf s response to bacterial
infections.
Nitric oxide (NO) has recently been recognised as a new class of messenger molecule that
serves a variety of functions in different tissues (Moncada et al., 1991). It is diffusible
and activates biochemical processes inside the producer cell as well as within
neighbouring cells. Nitric oxide is the final product of the oxidation of the guandino
nitrogen of L-arginine by nitric oxide synthase (NOS) (Reiling et al., 1994).
Several NOS isoforms have been identified, representing the products of three separate
genes on distinct chromosomes; these genes have been cloned in rodents and humans
(Morris and Billiar, 1994). The isoforms vary considerably in their intracellular location,
structure, regulation and functions. Two constitutive NOS (cNOS) isoforms, which are
spontaneously expressed in various tissues, have been demonstrated: the neuronal cNOS
(type I NOS) was first identified in the cytosol of central and peripheral neurons; the
endothelial cNOS (type III NOS) is generally membrane bound and is found in
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endothelial cells. Following stimulation by transient calcium fluxes, cNOS isoforms
generate small amounts of NO for short period of time.
Another isoform of NOS, usually absent in resting cells, can be induced by a variety of
stimuli, such as cytokines and lipopolysaccharides, and has been termed inducible NOS
(iNOS; type II NOS). Once expressed, this enzyme generates large amounts of NO over
an extended period. The regulation and function of iNOS are mainly associated with
inflammatory and immune responses (Moncada et al, 1991) and macrophages appear to
play a pivotal role in this process (Nathan, 1987). The production of inducible NO
synthase by endothelial cells or vascular smooth muscle after exposure to LPS, TNF, IL-1
or IFN-y leads to an over production of NO in the vasculature and profound vasodilation.
This might be the cause of sepsis-related hypotension which is characterised by low
vascular resistance and is often refractory to vasopressor therapy (Parker et al,, 1987).
Nitric oxide production plays a role in the induction of nonspecific immunity and the
antimicrobial response to a variety of extracellular parasites and some tumour cells. The
importance of the macrophage and various cytokines such as TNF-cx and IFN-y in
response to parasitic infection is well documented (Liew et al, 1990; Titus et al, 1984).
Further investigation has implicated NO as the final mediator of parasitic defence. Nitric
oxide-dependent mechanisms have been identified in the killing of intracellular
Trypanosoma (Munoz-Fernandez er al., 1992), Mycobacterium, Schistosoma and
Leishmania (Green et al, 1990 ) organisms. The importance of macrophage NO
production in tumoricidal activity has also been described using in vitro models
(Klostergaard et al, 1991; Jiang et al, 1992). The precise mechanism of NO-mediated
killing of these organisms is unknown; however, these observations suggest that
macrophage-derived NO contributes significantly to nonspecific immunity.
1.5 Endotoxin receptors on mammalian cells
During the past twenty years, remarkable progress has been made in understanding the
cellular basis for the diverse immunostimulatory and immunopathological activities of
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bacterial lipopolysaccharides. There exists now abundant experimental evidence that
LPS can interact non-cytotoxically with a variety of host immune and inflammatory
mediator cells and that the consequences of these interactions are the synthesis and
secretion of cytokines and other proinflammatory mediators by these cells. Perhaps one
of the key cells important to the host response to LPS is the macrophage, unequivocally
documented to play a pivotal role in mediating endotoxin lethality (Freudenberg et al,
1986).
There is therefore considerable interest in understanding at the biochemical level the
precise mechanism by which LPS triggers the activation of macrophages leading to
secretion of cytokines. Within the framework of the LPS molecule itself, it has been
recognised for many years that the lipid A component of LPS is sufficient for activation of
many of the macrophage responses attributed to LPS. However, other studies have also
implicated a potential role for inner core oligosaccharides (Haeffner-Cavaillon et al,
1982) ; (Liideritz et ah, 1989).
Fundamental to an understanding of LPS/lipid A macrophage interaction at the molecular
biochemical level is the identification and detailed characterisation of specific membrane-
localised receptors. While remarkably little detailed information was available concerning
LPS receptors as little as ten years ago, recent studies from several laboratories have
provided strong experimental evidence for the existence of several molecules on the
surface of macrophages that can bind LPS and may serve as candidate LPS receptors.
Since recognition of this major constituent of Gram-negative bacterial cell envelopes may
be important to host defence within a number of contexts, there may well be multiple
recognition systems available at the surface of macrophages and other host cells for LPS
binding. The available evidence would in fact support the concept that multiple
recognition pathways exist for LPS on macrophages.
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1.5.1 Direct recognition of lipopolysaccharides
1.5.1.1 CD18 molecules
Many strains of Escherichia coli are recognised by macrophages without the
intervention of the classic opsonins IgG and complement. 1 Several lines of evidence
indicate that this recognition event is due to the presence of CD 18 antigens on the surface
of the macrophage binding LPS in the outer leaflet of the bacterium. Firstly, CD 18
molecules can be down-modulated from the apical surface of macrophages by allowing
the cells to spread on substrates coated with anti-CD 18 monoclonal antibodies (mAbs).
Such treatment prevents macrophages from binding E. coli (Wright and Jong, 1986).
Therefore CD18 molecules are necessary for recognition of bacteria. Secondly, spreading
of cells on substrates coated with purified LPS (to deplete LPS receptors) depletes the
capacity of macrophages to bind E. coli. Spreading on LPS also down-modulates CD 18
molecules (Wright and Jong, 1986). Therefore, the CD 18 receptors on macrophages that
recognise E. coli are among the receptors that bind LPS. Finally, binding of LPS to
macrophages may be directly assayed by incorporating LPS into the outer leaflet of the
membrane of erythrocytes. The binding by macrophages of these LPS-coated
erythrocytes directly correlates to the dose of LPS in the erythrocytes, and the binding of
LPS-coated erythrocytes is inhibited by down-modulating CD 18 molecules (Wright and
Jong, 1986). Taken together, these studies indicate that CD18 molecules recognise
surface-bound LPS.
The CD18 antigens comprise a family of three closely related, dimeric cell-surface
glycoproteins (Detmers and Wright, 1988). Each is composed of a unique a-chain of
approximately 180 kD (the CD11 antigen) non-covalently linked to an invariant (3-chain
of 95 kD (the CD18 antigen). Lymphocyte function-associated antigen, LFA-l
(CDlla/CD18), is present on all leucocytes, complement receptor type 3 (CR 3)
(CDllb/CD18, also known as Mac-1 or the iC3b receptor), is present principally on
phagocytes, and pi50,95 (CDllc/CD18) is abundant on mononuclear phagocytes and is
expressed at low levels on polymorphonuclear neutrophils. The role of the CD 18 antigens
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in the recognition of LPS has been confirmed by investigation of cells from patients with
a genetic deficiency in CD18 (the common (3-chain) (Todd and Fryer, 1988). Because of
the absence of the (3-chain, mature a-(3 dimers are not expressed on leucocytes.
Monocytes and macrophages from these patients are unable to recognise unopsonised E.
coli and unable to recognise LPS-coated erythrocytes (Wright et al, 1990a).
Additional studies suggest that each of the three members of the CD18 family are capable
of binding LPS. Down modulation of any one member or even any two members of the
CD18 family by specific mAbs attached to the substrate has little effect on binding E. coli
or LPS-coated erythrocytes to macrophages, but down modulation of all three members
with a cocktail of antibodies against the three a-chains in the CD18 family completely
inhibits binding (Wright and Jong, 1986).
The portion of the LPS molecule recognised by CD18 resides in the lipid A region
because a truncated LPS with no O-antigen and incomplete core (Re) is recognised
(Wright and Jong, 1986). In addition, a biosynthetic precursor of lipid A, lipid IVa is also
recognised (Wright et al, 1990a). Because LPS resides in a lipid bilayer, it is likely that
the exposed glucosamine phosphates and not the hydrophobic chains of LPS buried within
the bilayer, constitute the site that is recognised by CD 18. This view is strengthened by
the observation that CD 18 appears to recognise additional phosphosugars in other
microorganisms. The pathogenic yeast Histoplasma capsularum has a cell wall rich in
sugar phosphates and is recognised by each of the three CD18 molecules (Bullock and
Wright, 1987). The parasite Leishmania mexicana expresses a complex glycolipid,
lipophosphoglycan (LPG) rich in phosphosugars and two of the CD18 molecules (CR 3
and pl95,95) have also been shown to recognise purified LPG (Taiamas-Rohana et al,
1990). The hydrophilic sugar phosphate structure of LPG can be enzymatically released
and purified away from the hydrophobic portion of the molecule. This soluble
phosphosugar competitively blocks binding of LPG and LPS-coated particles to
macrophages (Taiamas-Rohana etal, 1990).
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Recognition of LPS on whole E. coli by CD18 molecules on phagocytes results in
adhesion, subsequent phagocytic engulfment and delivery to a degradative compartment.
Recognition of LPS by CD 18 may play an important role in killing and clearing of
organisms from the circulation. In contrast, a role for CD 18 molecules in the secretory
responses to LPS is less certain.
Circumstantial evidence does suggest that CD 18 molecules might participate in synthetic
responses. Spreading of macrophages on protein-coated substrates requires CD 18
molecules (Todd and Fryer, 1988) and has long been known to cause synthesis of
cytokines such as IL-1 (Fuhlbrigge et al, 1987). Moreover, anti-CD 1 lb/CD 18 antibodies
have been shown to prevent spreading-induced synthesis of IL-1 in murine macrophages
(Labadia et al, 1988), and surface-bound anti-CD18 antibodies have been found to
stimulate the synthesis of cell-associated IL-1 (Couturier et al, 1989). However, only
membrane IL-1 is induced by either spreading or anti-CD18 mAbs, and neither IL-1 nor
TNF secretion is observed. Furthermore, the anti-CDllb antibody that blocks spreading
induced synthesis of IL-1 has no effect on LPS induced synthesis of IL-1 (Couturier et al.,
1989).
More direct experiments have shown that a full secretory response to LPS can be observed
in the complete absence of CD 18 antigens. Mononuclear cells from CD18-deficient
patients show normal or exaggerated synthesis of TNF-a and IL-1 in response to LPS
(Wright et al., 1990a). Also treatment of normal mononuclear cells with anti-CD 18
antibodies does not interfere with secretion of TNF (Wright et al., 1990b). These data
indicate that CD18 molecules are not necessary for secretory response of leucocytes to
LPS. The CD 18 molecules might be important in the removal of LPS/ Gram-negative
bacteria from the body but their role of cytokine production is unclear.
1.5.1.2 Scavenger receptor
Other investigators have sought LPS receptors through different means. The binding
behaviour of sonicated dispersions of radiolabelled lipid IVa, a lipid A precursor has been
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studied. This probe which closely resembles lipid A but is chemically synthesised, may
be labelled to very high specific activity and forms small stable vesicles in the presence of
albumin at physiological pH. Radioactive lipid IVa showed specific, saturable binding to
intact murine macrophage-like tumour cells (Hampton et al, 1988). Further studies,
using western blots, showed that the radioactive lipid IVa binds to a 95 kD membrane
protein derived from macrophages and therefore implicating an individual protein in this
specific binding (Hampton et al, 1988).
While the molecular weight of the lipid IVa-binding protein is identical to the molecular
weight of the CD 18 (3-chain (both 95 kD), Golenbock and co-workers (1990) have shown
that these two species are not identical: binding of LPS to CD18 requires divalent cations
while binding of lipid IVa does not; simultaneous staining for CD18 and lipid IVa binding
in a single gel lane shows a slight but clear difference in mobility of the two activities; and
in the most telling experiments, normal binding of radiolabeled lipid IVa is observed
using CD18 deficient leucocytes (Golenbock et al, 1990). Therefore, the receptor
molecule identified by binding of vesicular LPS differs from that identified by binding of
LPS on the surface of E. coli. It is possible that the size of the structure bearing LPS may
dictate the choice of receptors. Whole bacteria (size approximately 1pm) are recognised
by CD18 molecules but vesicles (size approximately 0.01pm) are recognised by different
receptors.
More recent studies have identified the acetyl-low-density lipoprotein (acetyl-LDL) or
scavenger receptor as the molecule that binds radiolabeled lipid IVa (Hampton et al,
1991). Acetylated LDL and other ligands of the scavenger receptor competitively block
the binding of lipid IVa to the RAW macrophage-like cell line, and lipid IVa blocks
binding of labelled acetylated LDL.
As with CD18, it appears that the interaction of lipid IVa with the scavenger receptor does
not stimulate secretory responses. Acetyl-LDL binds RAW cells but does not initiate
TNF synthesis. Moreover, blockade of lipid IVa binding to RAW cells by acetyl-LDL
does not block the normal induction of TNF synthesis by LPS ((Hampton et al,, 1991).
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The scavenger receptor is a trimeric transmembrane glycoprotein composed of cysteine-
rich carboxy-terminal exoplasmic domains connected to a trans-membrane domain by a
collagen-like stalk (Kodama et ah, 1990). It recognises a wide range of anionic ligands
including maleylated serum albumin, polyvinyl sulphate, dextran sulphate and
polyinosine. The receptor is capable of rapidly carrying these substances to lysosomal
compartment. The scavenger receptor is found in large amounts in the liver (Kupffer cells
and sinusoidal endothelial cells), and is well placed to remove endotoxin entering from the
gut.
1.5.1.3 Additional receptors for LPS
A cross-linking approach was used to identify another potential LPS receptor. Purified
LPS was derivatised with an iodinated, photo-activatable probe and then incubated with
mouse splenocytes. After photolysis, a single species of 80 kD and pi of 6.5 was labelled
(Lei and Morrison, 1988a). Several lines of evidence suggest that this labelled species
may be an LPS receptor. Firstly, the molecule is found in a membrane fraction of
splenocytes. Secondly, cross-linking plateaus at high concentration of LPS suggests
saturation of binding sites. Finally, cross-linking of labelled LPS to the 80 kD species is
partially inhibited by unlabelled LPS preparations (Lei and Morrison, 1988b). In more
recent studies, the 80 kD murine protein was partially purified and used to immunise
hamsters. An IgM monoclonal antibody (mAb5D3) was obtained (Bright et al., 1990).
Addition of mAb5D3 to cultures of murine bone marrow-derived macrophages activated
these cells to become tumouricidal for mastocytoma cells in vitro and the results of
several experiments established that the observed LPS-like activity of mAb5D3 was not
due to contaminating endotoxin (Chen era!., 1990). These results when considered with
those of Bright and co-workers (1990) and the previous work of Lei and Morrison (1988a
&b), provide a support for the concept that the 80 kD LPS- binding protein might serve as
a specific functional receptor for LPS on murine macrophages.
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The ability of mAb5D3 to mimic the effects of LPS in activating murine bone marrow-
derived macrophages for tumour cell killing in the absence of secondary stimuli, like LPS,
suggests that the 80 kD membrane LPS-binding protein recognised by mAb5D3 may be at
least one of the entities through which activation for tumour killing is regulated (Chen et
al, 1990).
1.5.2 Recognition of LPS complexed to lipopolysaccharide binding protein
Recent studies suggest that leucocytes may recognise LPS by a novel mechanism in which
a serum protein first binds to LPS and the LPS-protein complex then associates with
specific receptors on the cell surface. A serum protein has been described with the ability
to bind endotoxin (Tobias et al, 1986). This protein, lipopolysaccharide binding protein
(LBP), forms high-affinity stoichiometric complexes with LPS from a number of bacterial
species (Tobias et al, 1989). LBP is a 60 kD protein synthesised in the liver as an acute
phase reactant (Shumann et al, 1990). The concentration of LBP is roughly estimated to
be 200 ng.mL1 in resting serum and greater than 50 jug.ml"1 in acute phase serum of
rabbits. The ability of LBP to bind LPS enables it to function as an opsonin (Wright et
al, 1989). It binds stably to LPS-bearing particles such as living Gram-negative bacteria
or LPS-coated erythrocytes, and strongly enhances the attachment of these particles to
macrophage. LBP bridges LPS-coated particles to macrophage by first binding to LPS,
then binding to the macrophage. Pretreatment of LPS-coated erythrocytes with LBP
enables binding to the macrophage, but pretreatment of the macrophage has no effect.
Moreover, macrophages do not recognise erythrocytes coated with LBP unless LPS is
added, suggesting that macrophages recognise complexes of LBP with LPS but not LBP
alone (Wright et al, 1989).
Binding of particles coated with LPS-LBP complexes is mediated by receptors found on
blood monocytes and macrophages but not on lymphocytes or umbilical vein endothelium
(Wright et al, 1989). The receptors are mobile in the plane of the membrane as binding
activity of macrophages is down-modulated upon spreading of cells on surfaces coated
with LPS-LBP complexes.
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Studies have shown that the receptor that recognises LPS-LBP complexes is identical with
CD14, a differentiation antigen of monocytes and macrophages (Wright et al, 1990b).
Down-modulation of CD14 by any of several surface bound anti-CD14 mAbs prevent
binding of erythrocytes coated with LPS-LBP complexes to macrophages. Furthermore,
addition of some (but not all) anti-CD14 mAbs in solution blocks binding of erythrocytes
coated with LPS-LBP complexes: Finally purified CD14 adsorbed to non-blocking mAbs
retains the capacity to bind LPS-LBP complexes. These observations indicate that LPS
may interact with a soluble binding protein and subsequently become cell associated
through interaction with the membrane glycoprotein, CD 14,
CD14 is a 55kD cell surface glycoprotein which has long been recognised as a marker for
monocytes and macrophages. It has been cloned and sequenced from both mouse and
man (Setoguchi et al., 1989).
Like CD18 and the scavenger receptor, LBP andCD14 appear to be capable of
delivering LPS to a digestive compartment. In contrast with CD 18 and the scavenger
receptor, interaction of LPS-LBP complexes with CD14 on macrophages appears to be
coupled to the secretory responses of leukocytes. Fig. 1.7 summarises the role of multiple
receptors in binding and response to LPS.
1.6 Septic shock therapy
The immediate approach to management of the patient in septic shock is institution of
corrective measures that are designed, firstly, to confirm and characterise the condition
and to correct rapidly any potential reversible factors, and secondly, to begin specific
therapy of the underlying cause.
It is essential to ensure adequate oxygenation and to establish suitable means to monitor
the haemodynamic status. Modern management practice in shock emphasises that the
administration of fluid, inotropes and vasopressors must be tailored to the needs of each












Figure 1.7 Role of multiple receptors in the description and response to
lipopolysaccharide. (Reproduced from Wright, 1991)
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et al, 1990). Metabolic abnormalities such as hypoxaemia or severe acidosis need to be
identified and treated. Every effort must be made to identify the source of sepsis in order
to drain abscesses and choose the most appropriate empirical antimicrobial therapy.
Although it will seldom be possible to use an antibiotic directed against just one bacterial
species, outcome is improved by choosing a regimen that proves to be active against the
infecting organism (Kreger et al, 1980b).
1.6.1 High dose steroids
Corticosteroids are anti-inflammatory and antipyretic. They induce a feeling of well-
being in the patient which can give a subjective sense of improvement. Furthermore, they
have profound effects on many of the mediator systems implicated in the pathogenesis of
septic shock, and it is not difficult to understand why many doctors felt strongly that high-
dose steroids given early in shock were beneficial (Sheagren 1985). Although there were
experimental data that tended to confirm this impression, clinical findings were confused.
Most early trials were flawed in design, but in the last ten years three major studies have
overcome many of the early difficulties.
The effects of methylprednisolone (30 mg/kg), dexamethasone (6 mg/kg, one or two
doses), and no steroids in patients with severe established shock were compared (Sprung
et al, 1984). Steroids delayed death but did not reduce overall mortality. In addition,
patients given dexamethasone had an increased incidence of bacterial superinfections.
Subsequently, two further studies have evaluated the effect of early intervention with
high-dose methylprednisolone in septic shock (Hinshaw et al., 1987) and (Bone et al,
1987).
Both studies were placebo-controlled, and both were careful to control for the many
variables that can influence outcome. Importantly, both trials insisted that patients only
be enrolled if they could be treated within 2 h of shock being recognised. Results of the
two trials were strikingly similar. Neither found any evidence of benefit from steroids,
and steroid recipients had significantly more secondary bacterial infections.
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Taken together, these studies provide no support for the routine use of high-dose steroids
in septic shock.
1.6,2 Natural antibodies to endotoxin
1.6.2.1 Antibodies to O-specific side chain
The virulence of Gram-negative bacteria is not solely attributable to infectivity of
pathogens, but is also determined by the host's susceptibility to endotoxin. In many cases
endotoxaemia, presumably with endotoxin derived from gut commensals, occurs without
bacteraemia (van Deventer et al, 1988). It has often been difficult to distinguish
between the distinct roles of anti-endotoxin antibodies in their effects on infectivity or
endotoxicity. Antibodies to O-specific chains offer specific protection against infectionby
Gram-negative pathogens. The phenomenon of acquired tolerance to endotoxin has been
known since late last century, but it has only lately been recognised that late-phase
tolerance is O-specific and is mediated by serotype-specific antibodies following an
immune resonse to the O-polysaccharide of administered endotoxin (Johnston and
Greisman, 1984).
1.6.2.2 Antibodies to core and lipid A
A number of studies have confirmed that circulating natural antibodies to the LPS core
and lipid A are common in healthy humans (Barclay and Scott, 1987; Barclay et al,
1989).
With an LPS-polymyxin ELISA system, it has been found that there is an epitope in the
inner core of LPS (Re-LPS) to which antibodies are found in many healthy individuals.
There is another epitope in the inner core expressed on Rc-LPS but not on Re-LPS to
which many other healthy individuals have antibodies (Barclay and Scott, 1987). It
appears that different individuals have different dominant patterns of immunity to
common epitopes in the LPS core. It is not known how these patterns are engendered, but
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they may arise from early formative encounters with endotoxin and be boosted through
continuous exposure (Barclay, 1990).
1.6.3 Antibodies to endotoxin in Gram-negative septic shock
1.6.3.1 Antibodies to O-specific side chain
Treatment using antibodies directed against the O-polysaccharide component of endotoxin
has produced antibacterial effects (complement-dependent bactericidal and
opsonophagocytic activities) and increased survival (Sagawa et ah, 1990). Because the O-
polysaccharide antigen is structurally different for each strain of Gram-negative bacteria,
antibodies directed at this antigen are serotype-specific and therefore, only protect against
infection from a homologous strain of bacteria. Consequently, the future success of this
therapy would probably require faster identification of the infecting organism and a
stockpile of antibodies against potentially pathogenic organisms. Alternatively, patients
could be given a combination of effective serotype-specific monoclonal antibodies before
identification of the organism to protect against the most likely infectious organisms
(Baumgartner, 1990). Partly because of these problems, researchers have not actively
pursued O-antibody therapy, and the researchers efforts concentrated on " cross-reactive"
antibodies directed against core and lipid A regions of endotoxin.
1.6.3.2 Antibodies to core and lipid A
Antibodies directed against core and lipid A antigens were developed because they might
possibly neutralise the toxic effects of or increase clearance of endotoxin (Ziegler er a!.,
1982). Unlike the O-polysaccharide antigen, core and lipid A antigens are more
phylogenetically conserved and similar among all Gram-negative bacteria. Consequently,
a core or lipid A antibody that protectes against infection from one strain of Gram-
negative bacteria might also cross-protect against a different strain or species of Gram-
negative bacteria (Baumgartner er al., 1987). This cross-protective feature has led
researchers to investigate whether core or lipid A antibody therapies might improve the
survival of patients with diverse Gram-negative bacteria infection.
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1.6.3.2.1 Polyclonal antibodies to core and lipid A
In the early 1980s, investigators produced human antiserum directed against core
structures of endotoxin. Serum was extracted from human volunteers immunised with
heat-killed E. coli J5, a rough (Rc-like) mutant bacterium (Ziegler er al., 1982).
Therefore, the endotoxin from this bacteria contains only inner core and lipid A antigens.
This therapy was tested in a multicentre trial of patients with presumed Gram-negative
infection. In the double-blind study, researchers compared the effects of serum obtained
after E. coli J5 immunisation (J5 antiserum) with those of serum obtained before J5
immunisation (control serum). Treatment with J5 antiserum was associated with decreased
mortality in patients with Gram-negative bacteraemia (22% vs. 39%) and in patients who
had been in shock before randomisation (44% vs. 77%) (Ziegler er al, 1982). These
results could not be explained by the investigators, who found no significant relationship
between anti-J5 antibody levels and improved outcome. After the study was published,
other scientists questioned whether the extremely high mortality rate in the control group
with shock (77%) indicates an imbalance of pretreatment randomisation such that sicker
patients were more frequently assigned to the control group (Baumgartner, 1991).
Therefore it is not known whether factors other than the cross-protective effects of
endotoxin antibodies contributed to the differences between treatment groups.
In another double-blind trial, investigators examined whether prophylactic J5 immune
plasma decreases infection rates in high-risk surgical patients (Baumgartner er al., 1985).
Results from this study revealed that patients given J5 immune plasma as compared with
controls did not have lowered rates of Gram-negative infections, but showed a
nonsignificant trend toward decreased rates of Gram-negative septic shock (5% vs. 11%)
and death from Gram-negative septic shock (2% vs. 7%).
Three subsequent studies using polyclonal antibodies directed at core and lipid A
structures have shown no beneficial effect for prophylactic treatment of Gram-negative
infections (Girardin er al, 1992; Calandra er al, 1988 and Cometta er al., 1992).
Cometta and coworkers (1992) compared standard intravenous immune globulin, core
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endotoxin immune globulin (a preparation of standard immune globulin with more anti-
core endotoxin antibodies) and human serum albumin (controls) as possible therapies to
prevent infection in high-risk surgical patients. In a large collaborative study Cometta and
colleagues (1992), found that patients receiving standard immune globulin had fewer
infections and pneumonias and shorter hospital stay than patients receiving control
therapy. Interestingly, patients receiving core endotoxin immune globulin therapy, as
compared with controls, had no improved outcome. Thus, the core endotoxin immune
globulin did not improve outcome above standard immune globulin. In fact, patients who
received core endotoxin immune globulin did not do as well as those who received
standard immune globulin. The reason for this unexpected finding is not fully explained
by the data.
The use of monoclonal antibodies directed against core structures of endotoxin is probably
a better option than polyclonal antiserum therapy. Moreover, such monoclonal antibody
therapy circumvents problems in the production and use of human polyclonal J5
antiserum such as the toxicity produced during vaccination of serum donors, the variable
antibody content of antiserum preparations, and transmission of infection from serum
donors to patients (Smith et al, 1992).
1.6.3.2.2 Monoclonal antibodies to lipidA
In animal studies investigators found that a murine monoclonal antibody directed against
lipid A (E5) diminished the effects of endotoxin challenge in sheep and protected mice
challenged with live bacteria (Wheeler et al, 1990).
Other researchers have reported that a human monoclonal antibody (HA-1A) directed
against lipid A decreased mortality of mice challenged with bacteria and diminished the
dermal Shwartzman reaction in rabbits challenged with endotoxin (Teng et al, 1985).
However, independent investigators have not been able to confirm these results
(Baumgartner et al., 1990).
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In a placebo-controlled trial, the murine antibody E5 was tested in patients with presumed
Gram-negative sepsis (Greenman et al., 1991). In this trial, 486 patients (316 with Gram-
negative infections) were enrolled. Researchers found that E5 did not improve survival in
patients with Gram-negative infection or in the subgroup of patients with Gram-negative
infection and shock. However, E5 significantly increased survival (70% vs. 57%) and
improved organ function in a subgroup of patients with Gram-negative infection who
#
were not in refractory shock.
The monoclonal antibody HA-1A has also been tested in a randomised placebo
-controlled trial of patients with presumed Gram-negative sepsis (Ziegler et al, 1991). In
a study of 543 patients, investigators found that HA-1A had no effect on patients with
sepsis or patients with only Gram-negative infection. However, the investigators reported
that HA-1A significantly increased the survival of a subgroup of patients with Gram-
negative infection and bacteremia. Based on these results, HA-1A was approved for use
in patients with presumed Gram-negative sepsis in several European countries.
In the United states, results from this study have caused considerable debate among the
scientific community (Warren et al, 1992). These concerns were heightened when the
results of a blinded, controlled study of HA-1A using a canine model of septic shock were
published (Quezado et al., 1993). The original purpose of this study was to confirm a
therapeutic benefit of HA-1 A in a large animal model and to discover what mechanisms
were associated with its reportedly beneficial effects. All animals were infected with an
intraperitoneal clot containing E. coli Ol 11:B4, the nonmutant form of the E. coli J5 used
to generate the heteromyloma cells that synthesise HA-1A. Unexpectedly, results from
the study showed HA-1 A treatment significantly decreased survival. Only 2 of 13
animals in the HA-1A group, compared with 8 of 14 animals in the control group,
survived. Animals in the HA -1A group also had more severe cardiovascular dysfunction
and organ injury. Furthermore, HA-1 A had no effect on bacteremia or endotoxemia.
After consideration of the available clinical and animal data, HA-1 A did not seem to
benefit patients with presumed Gram-negative sepsis or septic shock. Consequently, HA-
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1A was withdrawn from the European market and is not being considered for approval by
the FDA for patients with Gram-negative sepsis.
1.6.4 Anti-TNF monoclonal antibodies
Murine monoclonal antibodies raised against human recombinant TNF, prepared as the
F(ab' )2 fragments, have been shown to neutralise baboon serum TNF bioactivity in the
L929 cell cytotoxicity assay (Tracey eta,]., 1987). In the same study baboons were given
lethal doses (LDioo) of live Escherichia coli via intra-aortic infusion. Experimental
animals were passively immunised with anti-TNF F(ab' ,)2 one hour before bacterial
infusion, whereas control animals received carrier vehicle at a similar time.
Pretreatment with anti-TNF F(ab' abrogated the serum levels of immunoreactive TNF
(Tracey et ai., 1987). Control animals not receiving anti-TNF antibodies uniformly
succumbed to septic shock, pulmonary oedema and multiple organ failure within hours
(13.3 + 3.5). Anti-TNF F(ab' )2 administered one hour before bacteria prevented the
development of hypotension and shock, but did not prevent later organ injury and death.
The investigators reasoned that adequate tissue penetration of the antibodies had not
occurred in only one hour, and that the production of nonneutralised TNF mediated the
development of subsequent toxicity, tissue injury and death (Tracey et al, 1987).
Therefore a second group of animals was immunised 2 hours before bacteraemia and the
results were dramatic. The baboons were completely protected against the development of
shock and tissue injury, and did not succumb to the LDioo dose of bacteria. Complete
neutralisation of TNF in the protected animals prevented the appearance of elevated serum
levels of catabolic stress hormones (Tracey et ai., 1987).
Other investigators using anti-TNF antibody (TN3-19.12) have confirmed the importance
of this cytokine in animal models of endotoxic shock. Silva and co-workers (1990)
neutralised the TNF-a produced in mice during lethal endotoxaemia caused by
Escherichia coli OIII. TN3-19.12 prevented death in mice receiving an LD90 dose of E.
coli if given 1.5 h before or 30 min after the challenge. Mice treated prophylactically with
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TN3-19.12 showed 97% survival at 24 h compared with 47% of control mice (received
irrelevant antibody). At the end of the experiment (72 h), 75% of the TN3-19.12-treatd
mice survived compared to 6% of the control mice. In the same study two groups of mice
were treated therapeutically. Mice given TN3-19.12 0.5 h after bacterial challenge had
79% at 72 h compared with 12% of control mice. In the second group where TN3-19.12
was administered 2.5 h after bacterial challenge, only 25% of TN3-19.12-treated mice
survived compared to 12% of control mice. Similar survival improvements in E. coli
endotoxaemic baboon model have been observed following immunisation against TNF-a
(Emerson etal., 1992).
1.6.5 TNF antagonism
Since TNF is a proximal mediator of septic shock, there are efforts to neutralise its toxic
effects. Because antibody therapies in humans has its limitations, attention has been
focused on the use of soluble receptors for TNF. These are naturally-occurring proteins
which represent the extracellular domains of the two TNF receptors. They are thought to
act as natural TNF antagonists. The administration of soluble TNF receptors has
prevented E. coli induced shock in baboons (van Zee et al, 1992) and death in mice
(Lesslauer etal, 1991).
1.6.6 TNF processing inhibitors
TNF is initially synthesised as a 26 kD type II transmembrane propeptide which is
proteolytically cleaved at the cell surface, releasing the mature 17 kD cytokine assembled
as a homotrimer (Kriegler er al., 1988). Although both cell surface and secreted forms of
TNF appear to be biologically active, it is soluble TNF released into the circulation which
is of primary importance in deleterious physiological responses, such as cachexia or septic
shock (Perez etal, 1990). Blocking the cleavage of the cell surface TNF could be of a
therapeutic benefit in septic shock. In support of this concept, a potent and selective
metalloprotease inhibitor which blocks cleavage of cell surface TNF in activated
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macrophages and T cells has been shown to reduce serum TNF levels and increase
survival in mice challenged with lethal doses of endotoxin (Mohler et at, 1994).
1.6.7 IL-1 antagonism
The kinetics of TNF and IL-1 stimulation during sepsis suggests that any attempt to treat
sepsis by modulating TNF production may have to occur soon after onset of shock. At
least in principle, there are hours in which to block the activities of IL-1. In support of
this hypothesis lies in the results of a study in which IL-1 receptor antagonist (IL-1 RA)
reduced the mortality rates in rabbit model of septic shock (Wakabayashi et al., 1991).
IL-1 RA is a naturally-occurring protein which binds to the human IL-1 receptor but has
no agonist activity (Eisenburg^r al., 1990; Hannum et al., 1990). The administration of
IL-1 RA even a few hours after the onset of shock might be beneficial.
1.7 Aims of the study
More knowledge is needed about the interaction of LPS with host cells and the consequent
production of cytokines and secondary mediators. Such knowledge might be helpful in
developing new strategies for septic shock treatment.
The primary aim of this study was to investigate:
-the direct interaction of different forms of LPS (pure LPS, LPS attached to bacterial outer
membranes, and LPS attached to intact bacterial cells) with host leucocytes.
-Cytokines and other mediators released from host leucocytes upon stimulation with
different forms of LPS. Measurement of the release of these molecules in response to
various forms of LPS affords a different approach to study LPS-host cell interaction.
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Chapter 2
General materials and methods
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2.1 Buffers
All chemicals were analytical grade obtained from BDH Chemicals Ltd. (Poole, Dorset,
UK) unless otherwise stated.
2.1.1 Dulbecco's phosphate-buffered saline (PBS)
PBS was prepared by dissolving one PBS tablet (Oxoid, Basingstoke, Hampshire, UK) in
100 ml distilled water.
2.1.2 Phosphate buffered saline, solution B
Solution B was prepared by dissolving 2.09 g CaCl2 and 2.09 g MgCl2 in 100 ml distilled
water (solution B). Phosphate buffered saline + B (PBS + B) was prepared by adding 0.5
ml of solution B to 100 ml PBS.
2.2 Culture media
2.2.1 10% RPMI
RPMI 1640 (Gibco, Paisley, UK) was supplemented with 10% foetal calf serum, 100 U
ml"1 penicillin G, 100 jug ml"1 streptomycin sulphate (Sigma, Poole, Dorset) and 1 mM L-
glutamine (Gibco, Paisley, UK).
2.2.2 10% DMEM
DMEM (Sigma, poole, Dorset) was supplemented with 10% FCS, 100 U ml"1 penicillin G,
100 jug ml"1 streptomycin sulphate (Sigma, Poole, Dorset) and ImM L-glutamine (Gibco,
Paisley, UK).
2.3 Cells
C3H male mice (Transgenic Unit, Medical School, Edinburgh University,UK) which
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are conventionally used in the field of lipopolysaccaride studies were chosen as the major
source of macrophages in this study. Other mouse strains obtained from the same source
were also used. A human monocyte/macrophage cell line, THP-1, (European Collection of
Animal Cell Culture, Salisbury, UK) and human peripheral blood monocytes were also
used.
2.3.1 Collection of mouse peritoneal macrophages
Mice were killed by cervical dislocation and the peritoneal cavity was washed twice with
PBS containing 10 U ml"1 heparin (Sigma, Poole, UK). Each mouse was injected with 5
ml PBS and the peritoneum was massaged to release the macrophages into the PBS. Using
a 0.8 mm gauge needle the PBS containing the macrophages was collected and placed in a
sterile plastic universal. The cells were centrifiiged at 300 g for 10 min, the supernatant was
discarded and the cell pellet suspended in a known volume of PBS, PBS + B or 10%
DMEM. A 50 pi sample was diluted in 450 pi white cell diluting fluid (0.1% gentian violet
in 1% acetic acid) and counted using a haemocytometer. Cells were then adjusted to the
required number.
2.3.2 Collection of THP-1 cells
THP-1 cells were grown routinely in 10% RPM1 1640 at 37° C in a humidified 5% CO2
containing incubator in tissue culture flasks. THP-1 cells were harvested by centrifugation
at 300 g for 10 min and resuspended either in PBS, 10% RPMI 1640 or 10% DMEM,
counted and adjusted as mouse peritoneal macrophages.
2.3.3 Collection of human peripheral blood monocytes
Freshly drawn heparinised blood (from healthy volunteers) was diluted 1: 2 using sterile
PBS. The diluted blood (15 ml) was then layered carefully on histopaque (5 ml) (Sigma,
Poole, UK) in sterile plastic centrifuge tubes and centrifuged for 25 min at 300 g.
Mononuclear leucocytes were collected from the interface, washed once with pyrogen free
PBS + B or 10% DMEM and adjusted to the desired count.
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2.4 Bacterial strains
All bacteria strains used in this work and their growth conditions are listed in table 2.1.
Salmonella minnesota Ra-R 60 a rough mutant with complete core was the main organism
used in this study.
2.4.1 Standardisation of bacterial count
# '
Bacterial concentrations were calibrated by comparison of numbers (several dilutions)
detected by counting chamber (Thoma) with spectrophotometric reading at 525 nm. A
standard curve was prepared from the OD versus total count of bacterial dilutions and used
for further determination of the bacteria concentrations.
2.5 Extraction of pure LPS
Pure LPS was extracted by the aqueous phenol, chloroform and petroleum spirit method of
Galanos et al, (1969) as described by Hancock and Poxton (1988) from Salmonella
minnesota Ra-R 60.
2.5.1 Deionization of LPS
S. minnesota Ra LPS was deionized by the method of Galanos and Ltideritz (1975) using a
two cell apparatus developed by ISCO for the electrophoretic concentration of proteins as
described by Hancock and Poxton (1988).
The LPS solution/suspension (5-10 mg ml-1) in distilled water was placed in the ceil and
distilled water placed in the two electrode chambers. The apparatus is ideally kept cool
(below 10° C) in a cold room. A voltage of up to 500 V is maintained across the cell. The
pH in the cathodic chamber rose; when it reached 9-10 the contents were replaced with fresh
distilled water. This was repeated several times over 3-4 h. The free acid form of the LPS
(deionized) precipitated from solution and was deposited as a gel on the membrane at the
anodic end of the cell. It was recovered from the cell by draining off the excess water
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Aerobically at 37° C in an
orbital incubator for 18 h




Aerobically at 37° C in an





MNYC Aerobically at 37° C for 48 h
Staph, epidermidis MPRL 7944 Blood agar Aerobically at 37° C for 18 h
BacteroidsfragHis NCTC 9343 PPY broth Anaerobically at 37° C for 48 h
MPRL (Microbial Pathogenicity Research Laboratory, Department of Medical
Microbiology, University of Edinburgh, UK). NCTC (National Collection of Type
Culture, London, UK), l&l (Infection and Immunity Laboratory, Department of Medical
Microbiology, University of Edinburgh, UK).
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from the chamber, dismantling the apparatus, gently scraping off the gel and suspending it
in pyrogen free water.
2.6 Extraction of bacterial outer membranes (OM)
Outer membrane fraction was extracted from S. minnesota Ra. Log phase bacteria (2 litres)
were harvested by centrifugation at 16 000 g for 10 min and washed once in 0.01 M Hepes
buffer, pH 7.4, containing 10 mM MgC^ then suspended in 40 ml Hepes containing 10
mM Mg CI2. Bacterial cells were broken by passage through a French pressure cell
(Aminco, Silver Springs, MD, USA) at 6000-7000 p.s.i. Unbroken cells were removed by
2 cycles of centrifugation at 6000 g for 10 min.
Sarkosyl treatment was by a modification of the method of Filip et al. (1973). Sarkosyl
(30% w/v solution of sodium AMauryl sarcosinate) (Sigma) was added to the broken cell
suspension to a final concentration of 0.7% (w/v) sodium AMauryl sarcosinate. The
suspension was then centrifuged at 50 000 g for 1 h, and the pellet ofOM was washed once
in water and finally suspended in 2 ml of pyrogen free water.
2.6.1 Determination of LPS content in bacterial outer membrane fraction
(OM)
An assay for 3-deoxy-D-manno-octulosonic acid (KDO) was used to determine the amount
of LPS in the bacterial OM fraction. This assay determined the amount of KDO present in
LPS. By comparing the amount of KDO in a known concentration of pure LPS with the
amount of KDO in an OM preparation, it was possible to estimate the amount of LPS in the
OM preparations. The thiobarbituric acid KDO assay was performed as described by
Hancock and Poxton (1988).
LPS samples containing from 1-20 jug of KDO were mixed with 1 ml of 0.125 M sulphuric
acid and heated in a boiling water bath for 8 min. If insoluble material is present, it is
removed by centrifugation. Samples (0.5 ml) of the acid hydrolysate were mixed with 0.25
ml of periodic acid reagent (25 mmol periodic acid in 62.5 mmol H2SO4) and incubated at
37° C for 30 min. The samples were cooled and 0.25 ml of sodium arsenate solution (2%
w/v sodium arsenate in 0.5 M HC1) was added to each sample, mixing until the brown
colour of iodine disappeared. Thiobarbituric acid (0.25 ml) (0.6% thiobarbituric acid
adjusted to pH 9 with sodium hydroxide) was added per sample and the samples were
heated at 100° C for 7.5 min. While the reaction mixture was still hot, dimethyl sulphoxide
(1 ml) was added. The samples were then cooled and the absorption was measured against
a reagent blank at 548 nm.
2.7 Determination of LPS content in whole bacteria
The content of LPS in whole S. minnesota Ra bacteria was estimated considering that R-
LPS constitutes 1-2% of bacterial dry weight (personal communication. Dr. Poxton,
Medical Microbiology Dept., Medical School, University of Edinburgh, UK). Bacteria
grown overnight were washed three times in PBS, resuspended in a known volume of PBS
and counted then the total number of bacterial cells in the sample was calculated. The
sample was centrifuged at 1000 g for 20 min and the PBS was discarded. The bacterial
pellet was freeze dried overnight and the lyophilized bacteria were weighed. The amount of




Binding of LPS to host cells
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3.1 Introduction
Mononuclear phagocytes and neutrophils provide a defence against microbial
invasion. Neutrophils, in general, are more efficient phagocytes, except when the
particle is larger in relation to them or when the particle load is greater (Cohn 1968).
Under these circumstances mononuclear phagocytes are more effective than
neutrophils. Macrophages, therefore, represent a major defence against invasion of
the host by a wide variety of micro-organisms. Macrophages move toward the
microbial particles guided by a gradient of chemotactic molecules. Engulfment then
begins with the macrophage advancing pseudopodia over regions of the micro¬
organism that are coated with opsonins which bind to specific sites on both micro¬
organisms and macrophages. Opsonins are of various types, but the most studied are
IgG and fragments of the third component of complement (C3). Macrophages
possess surface receptors which bind specifically to the Fc domain of various
subclasses of IgG and to several catabolites of C3 (Adams and Hamilton, 1984).
Many micro-organisms have the ability to activate the complement system
generating complement fragments that opsonise the organism. The macrophage is an
important source of complement components and macrophage-derived complement
factors can opsonise micro-organisms for their subsequent destruction in the absence
of other sources. The process of internalisation of micro-organisms is initiated after
binding with the appropriate ligand (Nathan et al., 1980). Attachment can also occur
in the absence of opsonins if the micro-organism possess surface determinants that
can be recognised directly by the macrophage such as the interaction of macrophage
mannose-fucose receptor with carbohydrate residues (Sung et al., 1983) and "lectin-
like" receptors with glucose and galactose (Freimer etal., 1978).
Macrophages secrete large amounts of oxygen and arachidonic acid metabolites
when phagocytosis is mediated by Fc receptors (Rouzer et al., 1980). In contrast,
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ligation of C3 receptors fails to release either arachidonic acid or oxygen metabolites
from mononuclear phagocytes (Aderem et al., 1985 ; Wright and Silverstein, 1983).
Macrophages also have receptors for the anaphylatoxin C5a. Occupancy of this
receptor induces the secretion of IL-1 and initiates chemotactic phenomena
(Goodman et al., 1982). The ingestion of particles by mononuclear phagocytes may
occur over a broad pH range and is accompanied by enhanced glucose oxidation
similar to that which occurs when phagocytosis is mediated by neutrophils (Cline et
al, 1978).
Many micro-organisms are phagocytosed and destroyed by macrophages, but there
are certain pathogens that can replicate within macrophages and parasitise them.
When the macrophage is activated, these intracellular pathogens may be inhibited or
destroyed. Salmonella, Brucella, Listeria, Chlamydia, Mycobacterium, Rickettsia,
Toxoplasma, Leishmania and Trypanosoma species and Legionella pneumophilia
have the capability of invading and inhabiting nonactivated macrophages (Nathan et
al., 1980). Mycobacterium tuberculosis may release sulpholipids that interfere with
the fusion of primary lysosomes with phagosomes and therefore avoid exposure to
the lysosomal enzymes of the macrophage (Shurin and Stossel, 1978).
Mycobacterium lepraemurium and Leishmania survive within secondary lysosomes
despite exposure to lysosomal enzymes, this might be because of the resistance of
the microbial cell wall to the macrophages' degradative enzymes (Nathan et al.,
1980).
The aim of this chapter was to investigate the direct interaction of LPS from S.
minnesota Ra with host macrophages by answering the following questions:
Does LPS play a role in mediating the attachment of Gram-negative bacteria to host
macrophages in the absence of serum opsonins ?
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Do different forms of LPS (Purified LPS, LPS attached to bacterial outer
membranes, and LPS attached to intact bacterial cells) bind to the same receptor/s on
host macrophages ?
Does LPS from different organisms bind to the same receptor/s on host
macrophages ?
Do host macrophage receptors recognise a common ligand on different LPS types ?
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3.2 Materials and methods
3.2.1 Buffered paraformaldehyde
1% paraformaldehyde was prepared by dissolving lOg of sodium cacodylate in one
litre distilled water and the pH adjusted to 7.2 with HC1, then lOg of
paraformaldehyde were added and dissolved by boiling the solution.
3.2.2 Serum-free Eagles medium
Serum-lfee Eagles medium was prepared by dissolving 1 g of Eagles medium
powder (Gibco BRL, Paisly, UK) in 100 ml distilled water, then 1 ml 4.4% sodium
bicarbonate and 0.5 ml 1M Hepes were added. The medium was incubated at 37° C
in 5% CO2 for 30 min to equilibrate the pEh
3.2.3 Labelling bacteria with FITC
This method is a modification of that described by Wright and Jong (1986). A heavy
suspension of bacteria in PBS was prepared from bacteria grown overnight in
nutrient broth by centrifugation at 1000 g for 20 min. Bacteria were washed three
times in PBS by centrifugation at 1000 g for 20 min. Four hundred micrograms of
fluorescein isothiocyanate (FITC) (Sigma, Poole, UK) were dissolved in 1 ml
coupling buffer (0.05 M sodium carbonate + 0.1 M sodium chloride, pH 9.2) and
added to the bacterial pellet. The mixture was incubated at 37° C for 20 min. Free
FITC was removed by washing three times with PBS at 1000 g for 20 min. In some
experiments bacteria were treated as above but the FITC was omitted.
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3.2.4 Activation of mouse peritoneal macrophages
Three different preparations were used to activate mouse peritoneal macrophages and
were prepared as follow: Glycogen was dissolved in distilled water to a final
concentration of lmg ml-1. Thioglycollate (Difco, Surrey - UK) was dissolved in
distilled water to a final concentration of 10% (w/v). C. parvum (Wellcome
Biotechnology Limited, Beckenham- England) was diluted in normal saline to a final
cocnentration of lmg ml"1.
Mice were injected intraperitoneally (ip) with 1 ml glycogen or thioglycollate or with
0.25 ml C. parvum. Four days after the injection of the above preparations mouse
peritoneal cells were collected in PBS + B as described in section (2.3.1).
3.2.5 Binding assay for flow cytometry
Salmonella minnesota strain R 60 directly conjugated with FITC was used in this
assay. After labelling, the bacterial count was adjusted to give the required ratios of
bacteria to cells in the final mixture. 100 pi of cell suspension was mixed with 100 pi
of each dilution of bacteria or PBS + B (control) in 15 ml centrifuge tubes and
incubated under the desired incubating conditions. The macrophages were washed
three times with PBS + B by centrifugation at 300 g for 10 min and fixed by final
resuspension in 1% (w/v) buffered paraformaldehyde. Experiments were performed
to study the effect of bacterial dose response, time course effect, temperature effect,
divalent cation requirement, pH effect and macrophage activation state effect on the
binding of S. minnesota Ra to macrophages. The pH effect was assessed by
adjustment of the PBS to the desired pH by addition of NaOH or HC1. Divalent
cation requirement was assessed by using PBS containing both 0.5 mM CaCh and
0.5 mM MgCl2, PBS containing 0.5 mM CaCl2, PBS containing 0.5 mM MgCl2 or
PBS containing 10 mM EDTA. All concentrations stated here are final
concentrations.
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3.2.6 Analysis of cells by flow cytometer
Analysis of binding was performed on an EPICS 'C' flow cytometer (Coulter
Electronics, Luton, UK) equipped with a 5 watt laser using a power output of 300
mw at 488 nm. The cells were selected from a display of forward angle light scatter
versus 90° light scatter by means of a bit map (Fig. 3.1a). More than 1000 cells were
analysed from each sample. The percentage of cells showing fluorescence greater
than the background level was recorded on a one parameter histogram, measuring
fluorescence on a logarithmic scale. The mean fluorescence channel values for the
positive cells were acquired from a one parameter histogram, measuring fluorescence
on a linear scale. The results were analysed by .the immuno analysis program
(Coulter).
In some experiments results were expressed as an attachment index obtained by
multiplication of the percentage of positive cells by the mean fluorescence. This
value gives an indication of the total fluorescence in a cell sample.
3.2.7 Inhibition assay for flow cytometry
Bacteria and macrophages were adjusted to give the desired ratio of bacteria per cell.
Macrophges were incubated with different forms of LPS (free LPS, LPS attached to
bacterial outer membranes and whole bacteria) for 30 min at 4° C. FITC-labelled
bacteria were added to macrophages and incubated for a further 30 min at 4 °C. The
macrophages were washed three times with PBS + B by centrifugation at 300 g for
10 min and fixed in 1 % (w/v) buffered paraformaldehyde. Results were expressed as
percentage inhibition of attachment compared to cells incubated in PBS + bacteria as
measured by using flow cytometry.
3.2.8 Binding assay for microscopy




Forward angle light scatter
Green fluorescence
Figure 3.1a: (A) bit map of macrophages (i) and lymphocytes (ii), (B) histogram of
negative control (macrophages without FTTC-labelled bacteria) and (C) histogram of
positive macrophages (cells with FTTC-labelled bacteria attached to them) of a typical
binding experiment
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and washed thoroughly with distilled water. Water was then drained and the cover
slips were then immersed in 70% ethanol until used. Cover slips were flamed to dry
and placed in 24 well tissue culture plates (Greiner Labortechnik Ltd, Dursley,
Gloucestershire, UK). Peritoneal cell suspension in serum-free Eagles medium (1 ml
at 4 x 10 5 cells/ ml) were placed in each well and incubated in a humidified 37° C
incubator containing 5% CO2 for 45-60 min to allow macrophages to adhere to the
glass coverslips. Non-adherent cells were removed by washing three times with
PBS+B. FITC-labelled and unlabelled bacteria (originally from the same preparation
of bacteria) were suspended in PBS + B and their concentrations adjusted to give
four ratios of bacteria to cells (30:1, 100:1, 300:1 and 1000:1). Bacteria were added
to macrophage monolayers and incubated for 90 min at 4° C in the presence of
divalent cations. Both preparations were treated identically in the binding assay.
Duplicate coverslips from each bacteria dose of both preparations were prepared.
Coverslips were then washed ten times with PBS, shaking the plates until hearing
the rattling of the coverslips each time. Coverslips were dried out of the plates (on a
pad of tissues), and replaced in a new plate and fixed with methanol for at least 20
min and dried. The coverslips were then stained with May Griinwald stain for three
min, washed with tap water and stained for further three min with Giemsa stain. The
coverslips were allowed to dry and finally mounted by inversion with DPX onto
microscope slides and examined under the microscope. Results were expressed as
percentage of macrophages with bacteria attached at two or more discrete points. At
least 200 macrophages were counted per coverslip.
3.2.9 Inhibition assay for microscopy
Free LPS was added at different concentrations to macrophage monolayers and
incubated for 30 min at 4° C. Free excess LPS was removed by washing with PBS,
bacteria were added to macrophage monolayers and incubated for 60 min at 4° C.
Unattached bacteria were removed by washing, and the monolayers fixed, stained
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and mounted as described in section 3.2.9. Results were expressed as percentage
inhibition of binding compared with untreated controls.
3.2.10 Statistics
The student's t-test was used for all statistical analysis.
The percentage inhibition of binding was calculated by using the formula:
a) for flow cytometry results:
[(Attachment index of control - attachment index of test)/ attachment index of
control] x 100.
b) for visual assay results:
[(% binding of control - % binding of test)/ % binding of control] x 100.
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3.3 Results
3.3.1 Optimisation of binding conditions
3.3.1.1 Bacterial dose response
The effect of varying the bacterial concentration on the attachment of FITC-labelled
S. minnesota Ra to mouse peritoneal macrophages was studied by using four ratios
of bacteria to macrophages at a temperature of 4° C and an incubation time of 30
minutes. The mean attachment index of three experiments is shown in Fig. 3.1. The
attachment increased slightly and steadily when the bacterial to cell ratio was
increased from 30 : 1 to 300 : 1. There was a sharp increase in the attachment
when bacterial dose was increased to 1000 : 1. The percentages of macrophages
binding bacteria at 1000: 1, 300: 1, 100: 1 and 30: 1 were 84%, 67%, 47% and 20%
respectively. At a dose of 300 : 1 the attachment was significant and was at a point
which allowed detection of increases or decreases in attachment. Therefore the dose
of 300 : 1 was used in further attachment experiments.
3.3.1.2 Time course
The effect of incubation time on the attachment of S. minnesota Ra to mouse
peritoneal macrophages was studied by using five incubation times at a temperature
of 4° C and a bacterial dose of 300 : 1. The mean attachment index of three
experiments is shown in Fig. 3.2. There was an initial rapid increase in the binding
between 5 and 15 min, then the rate of binding slowed down until 60 min. After 60
min there was a rapid increase in the attachment which had not dropped or slowed
down by 120 min incubation time, when the experiment was terminated. The
percentages of macrophages binding bacteria at 30, 60 and 120 min were 72%, 72%
and 77% respectively. Incubation for 30 min gave a significant attachment of
















30 : 1 100 : 1 300 : 1 1000 : 1
Bacteria to cell ratio
Figure 3.1: The effect of bacterial dose on the attachment of S. minnesota
Ra to mouse peritoneal macrophages at 4° C and 30 min incubation time. Each
point represents the mean attachment index of three experiments + SEM
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Time in minutes
Figure 3.2 The effect of incubation time on the attachment of S. minnesota
Ra to mouse peritoneal macrophages at 4° C by using bacterial dose of 300 : 1
macrophage. Each point represents the mean attachment index of three experiments
+ SEM
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attachment. With incubation times greater than 30 min, the number of cells
recovered decreased. Therefore 30 min incubation time was selected for further
attachment experiments.
3.3.1.3 Effect of temperature
The effect of temperature on binding of S. Minnesota Ra to mouse peritoneal
macrophages was studied by using three incubation temperatures and a bacteria to
macrophage dose of 300 : 1 when incubated for 30 min. The mean attachment index
of three experiments is shown in Fig. 3.3. The number of bacteria binding to cells
rose as the incubation temperature was increased. The percentages of macrophages
binding bacteria at 37° C , 20° C and 4° C were very similar, 66%, 65% and 63%
respectively. The mean fluorescence level was higher at high temperatures, therefore
the degree of binding was higher at higher temperatures than that at low
temperatures. Although the lowest level of binding was seen at 4° C, the attachment
at this temperature was significant and at a levels where increases or decreases of
attachment can easily be detected. At this temperature phagocytosis would not occur
and therefore the fluorescence signal would not be quenched by internalisation.
Therefore 4° C was continued to be used in all further experiments.
3.3.1.4 Requirement for divalent cations
The role of divalent cations in the binding of 5. minnesota Ra to mouse peritoneal
macrophages was studied by using PBS (control) and PBS + EDTA (to deplete
cations from the buffer). Ca2+ and Mg2+ were added separately and in combination
to PBS. The assay was carried at 4° C and by using a bacterial dose of 300 : 1 and an
incubation time of 30 min. The mean attachment index of three experiments is
shown in Fig. 3.4. The attachment increased significantly by addition of Ca2+ as
compared to control and the increase was statistically significant (P < 0.05). Mg2+
increased the attachment to a small degree, but this increase was not statistically
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Temperature (° C)
Figure 3.3: Temperature effect on the binding of S. minnesota Ra to mouse
peritoneal macrophages at an incubation time of 30 minutes by using bacterial dose







Figure 3.4: Effect of divalent cations on the binding of S. minnesota Ra to
mouse peritoneal macrophages at 4° C and an incubation time of 30 min using a
bacterial dose of 300 : 1 macrophage. Each column represents the mean attachment
index of four experiments + SEM
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significant. The combination of both cations increased the attachment to a higher
degree than Ca2+ did on its own and the increase was statistically significant (P <
0.02). EDTA gave similar results to the control suggesting that there were no cations
available in control samples medium. Taking the above results together, divalent
cations were used in all further experiments.
3.3.1.5 Effect of pH
The effect of pH was studied by using three pH values at 4° C and a bacterial dose of
300 : 1 and an incubation time of 30 min. The mean attachment index of three
experiments is shown in Fig. 3.5. The attachment of bacteria to macrophages did not
show a significant variation over the range used, therefore the physiological pH (7.2)
was used in following experiments.
3.3.1.6 Effect of macrophage activation state on binding
Macrophages were elicited by ip injection of three different preparations in order to
study the effect of state of mouse peritoneal macrophages activation on the binding
of S. minnesota Ra. Bacterial dose of 300: 1 was used and an incubation time of 30
min at 4° C in the presence of divalent cations. The mean attachment index of three
experiments is shown in Fig. 3.6. Glycogen and Corynebacterium parvum
activation of macrophages increased the binding to a small degree and in both cases
the increase was not statistically significant as compared to control macrophages
(normal macrophages). Thioglycollate activation of macrophages increased the
binding significantly and the increase was statistically significant as compared to
control macrophages (P < 0.02). Administration of glycogen, C. parvum or
thioglycollate resulted in a substantial increase in the number of macrophages

























Figure 3.5: The effect of pH on the attachment S.minnesota Ra to mouse
peritoneal macrophages at 4° C and an incubation time of 30 min by using a bacterial
dose of 300 : 1 macrophage. Each point represents the mean attachment index of
three experiments + SEM
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4000-.
Normal Glycogen Thioglycollate C. parvum
Figure 3.6: The effect of the state of macrophage activation on the
attachment of S. minnesota Ra at 4° C and an incubation time of 30 min using
bacterial dose of 300 : 1 macrophage. Each column represents the mean attachment
index of three experiments + SEM
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3.3.1.7 Binding of S. minnesota Ra human macrophage cell line (TIIP-1)
THP-1 is a human immature macrophage cell line. The binding of S. minnesota Ra to
THP-1 cells was investigated to find out if these cells display similar binding
characteristics to those of mouse macrophages. The binding of S. minnesota Ra to
THP-1 cells was tested by using four doses of bacteria at 4° C and an incubation
time of 30 min. The mean attachment index of three experiments is shown in Fig.
3.7. The attachment of bacteria to THP-1 rose as the dose of bacteria was increased.
There was a slight increase in the attachment between the doses 30: 1 and 300: 1
followed by a sharp increase in the attachment up to a dose of 1000: 1. The
percentages of THP-1 binding bacteria at 1000: 1, 300: 1, 100: 1 and 30: 1 were
58%, 19%, 8% and 5% respectively.
3.3.1.8 Binding of S. minnesota Ra human peripheral blood monocytes and
neutrophils
The binding of S. minnesota Ra to human peripheral blood monocytes and
neutrophils was investigated in a few experiments. Mouse peritoneal macrophages
were used for comparison. The binding of human monocytes and neutrophils and
mouse macrophages were tested using four ratios of bacteria : cells at 4° C and
incubation time of 30 min. The percentages binding and the mean fluorescence level
of two experiments are shown in table 3.1. In experiment one the binding of human
neutrophils was higher than the binding of human monocytes and mouse
macrophages. The binding of human monocytes was slightly higher than that of
mouse macrophages. In experiment two (sample from different individual) the
binding of human monocytes was much higher than the binding of mouse
macrophages. The percentage binding of human monocytes was similar to the
percentage binding of human neutrophils, but the mean level fluorescence of the















30: 1 100:1 300 : 1 1000 : 1
Bacteria to cell ratio
Figure 3.7: The binding of S.minnesota Ra to the human cell line, THP-1, by
using four doses of bacteria to cells at an incubation time of 30 min. at 4° C. Each
point represents the mean attachment index of three experiments + SEM
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bact.: cell % binding mean % binding mean % binding mean
1000:1 57 22 61 36 64 194
300:1 60 21 59 30 95 88
100:1 42 10 46 13 91 41










bact.: cell % binding mean % binding mean % binding mean
1000:1 78 17 91 225 96 78
300:1 56 12 85 145 91 56
100:1 34 7 73 84 79 27
30:1 19 6 51 36 58 12
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3.3.2 Inhibition studies
3.3.2.1 Inhibition of binding of S. minnesota Ra to mouse peritoneal
macrophages by using free LPS
Mouse peritoneal macrophages were incubated with various concentrations of
purified S. minnesota Ra LPS then different numbers of bacteria were added to th'e
macrophage suspension. The binding of LPS treated macrophages was compared to
control macrophages (untreated macrophages). The results are expressed as
percentage inhibition of attachment compared to control (see section 3.2.10). The
mean percentage inhibition of binding of three LPS concentrations and two doses of
bacteria per macrophage is shown in Fig. 3.8. All concentrations of LPS used gave
significant inhibition of binding. At low dose of bacteria (100: 1 macrophage), the
greatest level of inhibition (80%) was seen with the highest concentration of LPS
(lmg ml"1) and was statistically significant (P < 0.005). By using the same dose of
bacteria and lower concentration of LPS (O.lmg ml"1), the level of inhibition was
decreased a little (61 %) and was statistically significant (P < 0.025). Further decrease
in LPS concentration (0.01 mg ml"1) resulted in more decrease in the level of
inhibition (50%) that was still statistically significant (P < 0.02). At a higher dose of
bacteria (300: 1 macrophage) the level of inhibition was 77% with LPS
concentration of lmg ml-1 (P < 0.005), 58% with LPS concentration of O.lmg ml"1
(P < 0.05) and 35% with LPS concentration ofO.Olmg ml-1 (P < 0.02).
Both the percentage of macrophages binding bacteria and the mean fluorescence
level were notably decreased at higher concentrations of LPS. Lowering the
concentration of LPS and increasing the bacterial dose led to a decrease in the level
of inhibition. The percentages of macrophages binding bacteria rose gradually until
they nearly matched the control. For example, in one experiment where a bacterial
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Figure 3.8: The inhibition of attachment of S. minnesota Ra to mouse
peritoneal macrophages by purified LPS. Two bacterial doses were used and assay
performed at 4° C. The attachment index of positive controls of three experiments at
a ratio of 300 bacteria: cell were 1650, 1869 and 3933, and at a ratio of 100 bacteria:
cell were 508, 540 and 1768. Each column represents the mean percentage
inhibition of attachment of three experiments + SEM
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(untreated macrophages) was 74% and the percentages binding of LPS treated
macrophages were; 41% by using lmg ml"1 LPS, 58% by using 0.1mg ml'1 LPS and
65% by using 0.0lmg ml"1 LPS. The mean fluorescence level increased when the
concentration of LPS was lowered but never matched the mean fluorescence level of
controls in any experiments.
3.3.2.2 Inhibition of binding of S. minnesota Ra to mouse peritoneal
macrophages by using bacterial outer membranes (OM)
Mouse peritoneal macrophages were incubated with various concentrations of
bacterial outer membranes prepared from S. minnesota Ra prior to incubation with
FITC-labelled bacteria. The results were expressed as percentage inhibition of
attachment (see section 3.2.10). Fig. 3.9 shows the mean percentage inhibition of
binding using three outer membrane concentrations and a bacterial dose of 300 : 1.
The LPS content of the outer membrane preparations was determined (see section
2.6.1) and the concentrations adjusted to give the same concentrations of LPS as in
3.3.2.1. Similar to free LPS, all outer membrane preparation concentrations
significantly inhibited the binding. The greatest level of inhibition (64%) was seen
with the highest concentration of OM (lmg ml"1) and was statistically significant (P
< 0.02). Lowering the OM concentration resulted in a decrease in the level of
inhibition; 48% with OM concentration of O.lmg ml"1 (P < 0.05) and 32% with OM
concentration of O.Olmg ml"1 (P < 0.01). Both the percentage of macrophages
binding bacteria and the mean fluorescence level were decreased at a high
concentration ofOM. The percentage of macrophages binding bacteria was increased
as the OM concentration was decreased until it nearly matched the percentage
binding of the control. In one experiment the percentage binding of the control was
70% and the percentage binding of OM treated macrophages were; 36 %, 58 % and
68 % by using OM concentrations of lmg ml"1, O.lmg ml"1 and O.Olmg ml"1








Concentration of LPS in each outer membrane
preparation (mg ml "*)
Figure 3.9: The inhibition of binding of S. minnesota Ra to mouse peritoneal
macrophages by outer membrane preparations. Bacterial dose of 300 : 1 macrophage
at 4° C. Each column represents the mean percentage inhibition of attachment of
three experiments + SEM
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was decreased but did not match the mean fluorescence level of control even at the
lowest OM concentration used in any experiments.
3.3.2.3 Inhibition of binding of S. Minnesota Ra to TIIP-1 cells by free LPS
The binding of S. Minnesota Ra to LPS treated THP-1 cells was compared to control
cells (untreated cells) and the results expressed as percentage inhibition of
attachment. The mean percentage inhibition by three LPS concentrations at two
doses of bacteria per cell is shown in Fig. 3.10. Again the greatest inhibition of
binding was observed with the highest LPS concentration and the lower ratio of
bacteria to cells. At bacterial dose of 300: 1 THP-1 cell the percentage inhibition by
using 1 mg ml"1 LPS was 44% (p < 0.01). The lowest inhibition of binding (10.7%)
observed was at bacterial dose of 1000: 1 THP-1 cell and LPS concentration of 0.01
mg ml"1 (p < 0.02).
3.3.2.4 Inhibition by using whole bacteria
Whole unlabelled bacteria (S. Minnesota Ra) were incubated with mouse peritoneal
macrophages prior to the addition of FITC labelled bacteria. In eleven experiments
whole unlabelled bacteria failed to inhibit the binding of labelled bacteria even when
unlabelled bacteria were used at a dose of 10,000 : 1 macrophage (300 times excess
unlabelled bacteria compared with labelled bacteria). This finding raised the
question, has FITC labelling of bacteria enhanced the capacity of macrophages to
bind bacteria ? To answer this question the effect of FITC labelling of bacteria on





LPS concentration (mg ml_1)
Figure 3.10: The percentage inhibition of binding of S. minnesota Ra to
THP-1 cells by purified LPS at two bacterial concentrations, at 4° C. Each column
represents the mean percentage inhibition of attachment of three experiments + SEM
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3.3.3 Effect of FITC labelling of bacteria on the binding to mouse
peritoneal macrophages
To study the effect of FITC labelling on the binding, a method which would allow
the detection of the binding of unlabelled bacteria was necessary. Transmitted light
microscopy was selected for this part of the thesis.
3.3.3.1 Effect of FITC labelling of S. minnesota Ra on the binding to mouse
peritoneal macrophages
Initially two preparations of bacteria were used, FITC-labelled and unlabelled
bacteria.
FITC labelling of bacteria considerably enhanced the binding of bacteria to
macrophages at all bacterial doses used (Fig. 3. 11). The increase in the attachment
of all doses of FITC-labelled bacteria used was statistically significant as compared
to the attachment of similar doses of unlabelled bacteria, at a dose of 3xl09 ml""1 (p <
0.001), at 3xl08 ml"1 (p < 0.01), at 3xl07 ml"1 (p < 0.02) and at 3X106 ml"1 (p <
0.01). Equivalent binding of the two bacteria preparations was seen when the
unlabelled bacteria were used at approximately 100-fold higher concentration than
FITC-labelled bacteria. In one experiment the percentage binding of FITC labelled
bacteria at dose of 3xl07 ml"1 was 27% and the percentage binding of unlabelled
bacteria at a dose of 3x109 ml"1 was 26%.
This finding was further examined to find out whether the enhancement of the
binding was related to the FITC dye itself or was related to the high pH of FITC
coupling buffer. Also the effect of FITC labelling on the binding of other bacterial
species was examined.
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* FITC labelled bact.
-• Unlabelled bact.
3 x 10 6 3 x 10 7 3 x 10 8 3 x 10 9
Bacterial dose
Figure 3.11: Comparison between the binding of FITC labelled and
unlabelled S. minnesota Ra to mouse peritoneal macrophages at 4° C and an
incubation time of 90 min in the presence of divalent cations. Each point represents
the mean percentage binding of four experiments + SEM
82
3.3.3.2 FITC effect on the binding of bacteria to mouse peritoneal macrophages
Bacteria harvested from the same preparation were split into three parts. One part
was labelled with FITC as normal. The other two samples where treated as the first
but without FITC. One of these samples was incubated in PBS and the other in FITC
coupling buffer. The four different bacterial species used were treated in this way.
A dose of 3 x 109 ml-1 was used for all bacterial species. Bacteria were added to
monolayers of macrophages and incubated for 90 min at 4° C. Fig. 3.12 shows the
binding of S. minnesota Ra, E. coli K 12, A. meningitidis and Staph, epidermidis to
macrophage monolayers. FITC dissolving buffer treated bacteria showed no
enhanced binding compared to PBS treated bacteria for all species used; however
FITC labelling enhanced the binding of all species compared to PBS treated bacteria
and the enhancement of binding of FITC labelled bacteria was statistically
significant forS. minnesota Ra (p <0.05), E. coli K 12 (p < 0.05), N. meningitidis (p <
0.05) and 'tor Staph, epidermidis (p < 0.05).
3.3.3.3 Inhibition of binding of FITC-labelled and unlabelled S. minnesota Ra
by purified LPS to mouse peritoneal macrophages
FITC-labelled bacteria at 3.0 x 107 ml"1 and unlabelled bacteria at 3.0 x 109 ml"1
were added to macrophage monolayers previously incubated with purified LPS for
30 min at 4° C. The bacteria were incubated with treated macrophage monolayers
for 60 min at 4° C. The mean percentage inhibition of binding of both bacterial
preparations is shown in Fig. 3.13. The inhibition of binding was similar between
both preparations of bacteria at all LPS concentrations used. The more LPS used the
greater the inhibition. The binding of unlabelled bacteria at a dose of 3.0 x 109 ml"1
was inhibited by all LPS concentrations used. At a high concentration of LPS (lmg
ml"1) the inhibition level was (33%) and was statistically significant (P < 0.005).








S. minnesota E. coli
□ FITC labelled bact.
■ Unlabelled bact. (PBS)
□ Unlabelled Baet. (FITC buff.)
□ FITC labelled bact.
E3 Unlabelled bact. (PBS)
H Unlabelled Bact. (FITC buff.)
N. meningitidis Staph, epidermidis
Figure 3.12: Effect of labelling bacteria with FITC on their binding to
mouse peritoneal macrophages. (A) Salmonella minnesota Ra and Escherichia coli K
12. (B) Neisseria meningitidis and Staphylococcus epidermidis. Bacterial
concentration of 3 x 109 ml-1 and macrophage concentration of 4 x 105 ml"1. The
assay was at 4° C and an incubation time of 90 min in the presence of divalent
cations. Each column represents the mean percentage binding of four experiments +
SEM
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LPS concentration (mg ml"1)
Figure 3.13: Comparison of the percentage inhibition of binding of FITC
labelled S. minnesota Ra at a dose of 3.0 x 107 ml"1 and unlabelled S. minnesota Ra
at a dose of 3.0 x 109 ml"1 to mouse peritoneal macrophages by purified LPS. Each
column represents the mean percentage inhibition of four experiments + SEM
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decreased (9.7%) and was statistically significant (P < 0.005). Further decrease in
LPS concentration (0.0 Img ml-1) resulted in a greater decrease in the level of
inhibition (7.8%) which was still statistically significant (P < 0.02). By using
FITC-labelled bacteria at a dose of 3.0 x 107 ml-1 the level of inhibition was 27.3%
with LPS concentration of lmg mL1 (P < 0.02), 9.8% with LPS concentration of
O.lmg ml"1 (P < 0.001) and 5.6% with LPS concentration of O.Olmg ml"1 (P <
0.005).
3.3.3.4 Detection of the binding of unlabelled bacteria using monoclonal
antibodies (mAb)
In one experiment the binding of unlabelled S. minnesota Ra at a dose of 1000:1
mouse peritoneal cells was detected using two concentrations of murine anti
Salmonella LPS mAb (250 pg ml"1 and 25 pg ml"1) and two concentrations of FITC
conjugated anti-mouse immunoglobuln. The percentages binding and the mean
level fluorescence of samples are shown in Table 3.1. The highest percentage of
binding obtained using this method was 48% and the mean fluorescence level of this
sample was 45. In the same experiment S. minnesota Ra (from the same bacterial
preparation) directly labelled with FITC at a dose of 1000:1 macrophages was used
for comparison. The percentage binding of FITC labelled S. minnesota Ra to
macrophages was 92% and the mean fluorescence level was 294.
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Table 3.2: Detection of the binding of S. minnesota Ra to mouse peritoneal





FITC conjugated antibody concentration
1/50 1/200
250 pg/ml 42 (54) 34 (22)
25 pg/ml 48 (45) 30 (21)
FITC-labelled bacteria 92 (294)
Bacteria were used at a ratio of 1000: 1 macrophage. Numbers in brackets represent
the mean fluorescence of the samples
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3.4 Discussion
This work aimed to investigate the role of LPS in mediating Gram-negative bacteria
attachment to leucocytes. The First stage was to measure direct interaction of Gram-
negative bacteria with mononuclear phagocytes; therefore a flow cytometric assay to
measure attachment of Salmonella minnesota Ra to mouse peritoneal macrophages
was used. C3H mouse strain, conventionally used in the field of LPS studies, was
mainly used in this work. Collection of mouse peritoneal macrophages was a more
convenient source of macrophages than human peripheral blood monocytes. This
species also allowed in-vivo modulation of the macrophage population. Therefore
mouse macrophages were selected for this work.
The use of flow cytometry in studying phagocyte functions was described by
Bjerknes and co-workers (1989). Other investigators have used flow cytometry to
study bacterial attachment to different cell types. Raza and co-workers (1993)
reported that the infection of human epithelial cell line (HEp-2) with respiratory
syncytial virus (RSV) significantly enhanced the binding of three strains of Neisseria
meningitidis and two strains of Haemophilus influenzae using flow cytometry.
Others (Raybourne and Bunning, 1994) used flow cytometry to study phagocytosis
by macrophage cell line (J774A.1) and short-term survival of Salmonella
typhimurium and Listeria monocytogenes.
Flow cytometry was used to determine the attachment of bacteria to macrophages.
By using this method the percentages of cells binding bacteria as well as the mean
level of binding were obtained. This method apparently overcame some of the
difficulties associated with studying the binding of bacteria to the cells. First, unlike
counting bacteria bound to cells by light microscopy, attachment assessed by the
flow cytometer is objective. Second, large number of cells (> 1200 cells in each
sample) can be analysed in a short period of time.
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The initial work in this study was to optimise the conditions for investigating the
binding of S. minnesota Ra to mouse peritoneal macrophages.
Under the experimental conditions used, attachment of bacteria to macrophages was
increased when the ratio of bacteria to macrophage was increased. Similar
observation using a visual assay had been reported by Weir and co-workers (1981).
By increasing incubation time the level of attachment was increased due to allowing
more time for the attachment to occur. The attachment was greater at physiological
temperatures than that at lower temperatures, and this result was in agreement with
the work of Wright and Jong, (1986). They reported the presence of receptors on
human macrophages that bind E. coli by recognising LPS. The presence of Ca2+
and Mg2+ ions plays a role in part of the interaction between bacteria and
macrophages. This might indicate the involvement of lectin-like interaction, in
which the presence of Ca2+ is known to be required (Cook and Bugg 1975), and this
result was in agreement with the work ofWright and Jong, (1986) who reported the
requirement of divalent cations for the binding of E. coli to human macrophages.
Over the pH range tested, attachment of bacteria to macrophages did not show
significant variation.
Activated macrophages differ from resting macrophages morphologically,
biochemically and functionally. They attach more rapidly to glass and plastic and
also exhibit increased rate and speed of phagocytosis, probably due to increased
expression of receptors. They are able to destroy microorganisms intracellularly and
large parasites or tumour cells extracellularly.
The possibility of using activated macrophages in this study was investigated.
Following in vivo activation there are increased number of macrophages present in
the peritoneal cavity which means fewer mice are required for experimental work.
Activation of macrophages with glycogen and C. parvum increased attachment to a
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small degree but this increase was not statistically significant. Activation of
macrophages with thioglycollate increased the attachment to a high degree and was
statistically significant compared to control macrophages. These results were in
disagreement with other investigators (Glass et al, 1983) who were investigating
membrane changes in murine macrophages after in-vivo stimulation or activation.
They reported that activated mouse peritoneal macrophages bound fewer
unopsonised bacteria compared to normal macrophages. The increase in bacterial
binding mediated by thioglycollate activated macrophages was of interest, but
because the mechanism was not clear and because the increased binding of bacteria
mediated by activated macrophages conTasted with the work of Glass and co¬
workers (1983), it was felt that it would be safer to use normal macrophages in
further experiments.
The attachment of S. minnesota Ra to the human macrophage cell line THP-1 was
tested under similar conditions to those used for mouse macrophages to find out if
human cells have similar binding characteristics to mouse macrophages. THP-1 cells
showed similar binding patterns to mouse macrophages although THP-1 cells bind
bacteria to a lower extent. The low bacterial binding capacity of THP-1 cells as
compared to mouse peritoneal macrophages might be because of their maturation
state. THP-1 are an immature macrophage cell line and might express fewer
receptors than mouse peritoneal macrophages.
Human peripheral blood monocytes and neutrophils were used in a few experiments
to compare their binding characteristics with mouse peritoneal macrophages.
Human monocytes and neutrophils from different individuals showed variable
binding characteristics. Binding of human monocytes to S. minnesota Ra showed
similar levels of binding to mouse peritoneal macrophages in a few experiments.
Human peripheral blood neutrophils showed much higher levels of binding to S.
minnesota Ra than that of mouse peritoneal macrophages in these experiments. In
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other experiments human monocytes showed higher levels of binding than that of
human neutrophils and mouse macrophages. There, therefore, appears to be
differences in the binding ability of cells from different individuals. This could be
due to genetic or environmental factors. There might be inherited differences in the
degree of expression of receptors for bacteria and the levels of expression or affinity
might be altered by environmental factors such as infection or exposure to certain
f
stimuli.
After setting up the optimal experimental conditions for binding, the role of LPS in
the attachment of bacteria to macrophages was investigated. Various forms of LPS
(free LPS, LPS attached to bacterial outer membranes and LPS attached to whole
bacteria) were used. The use of different forms of LPS was because of LPS might
be present in the form of whole bacteria inside the host circulation or LPS might be
found attached to bacterial outer membranes as a result of bacterial lysis. LPS might
also shed free from bacteria as a result of bacterial growth and multiplication or
translocate from the gut into the circulation. On reaching the host circulation free
LPS is normally complexed immediately to host proteins and lipoproteins. Free LPS
inhibited the binding of bacteria significantly. The inhibition of binding was greater
when high concentrations of LPS and low ratios of bacteria to macrophages were
used. LPS attached to bacterial outer membranes (at similar concentrations to free
LPS as determined by KDO assay) inhibited the binding of bacteria to macrophages
in a similar way to free LPS. These results indicated that LPS was involved in the
interaction between bacteria and cells in the assay system used. Attachment of
bacteria to THP-1 cells was also inhibited by using free LPS at a similar
concentrations used to inhibit the binding of bacteria to mouse macrophages.
Because of variation in day to day level of binding it was necessary to express results
as percentage inhibition of binding. This standardised the data from day to day and
allowed comparisons to be made.
91
As part of the inhibition study, whole unlabelled bacteria (as another form of LPS)
were pre-incubated with mouse peritoneal macrophages before FITC-labelled
bacteria were added. The results were unexpected, whole unlabelled bacteria failed
to inhibit the binding of FITC-labelled bacteria. This finding raised a number of
questions about the assay. Were there enough whole unlabelled bacteria to inhibit
the binding of FITC-labelled bacteria ? This was investigated by increasing the dose
of whole unlabelled bacteria to macrophages while keeping the ratio of FITC-
labelled bacteria to macrophages unchanged. Whole unlabelled bacteria failed to
inhibit the binding of FITC-labelled bacteria even when the ratio of whole unlabelled
bacteria to macrophages was 300 times greater than the ratio of FITC-labelled
bacteria to macrophages. This indicated that the failure of whole unlabelled bacteria
to inhibit the binding of FITC-labelled bacteria was not due to shortage of whole
unlabelled bacteria. Also previous studies using a visual assay (Glass et al., 1983)
with activated macrophages showed contrasting results to ours. These workers
found that murine peritoneal macrophages activated by C. parvum and glycogen
bound fewer bacteria than untreated controls. The present study found that murine
peritoneal macrophages activated by C. parvum and glycogen bound bacteria to a
similar level as untreated controls. Also in this study thioglycollate activated murine
peritoneal macrophages bound much greater numbers of bacteria than untreated
controls. At this point the ability of mouse peritoneal macrophages to bind to
unlabelled S. minnesota Ra was questioned. Therefore another method which would
enable the detection of unlabelled bacteria was sought. By using a murine
monoclonal antibody directed against S. minnesota Ra LPS and FITC conjugated
antimouse immunoglobulin it was possible to detect the binding of unlabelled S.
minnesota Ra to mouse peritoneal macrophages by flow cytometry. The sensitivity
of this method for detecting bacterial attachment was lower than that obtained by
using bacteria directly labelled with FITC. This method gave positive results, and
although it confirmed that unlabelled S. minnesota Ra were binding to macrophages
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in the absence of serum, it was not practical to use it in further studies. Low level of
binding detected was one problem. More importantly it was not possible to use this
method for inhibition experiments. In these experiments different forms of LPS
were used as an inhibitors of the binding of S. minnesota Ra to mouse peritoneal
macrophages. Because the monoclonal antibody was directed against S. minnesota
Ra LPS it was not possible to use it in inhibition experiments using various forms of
S. minnesota Ra LPS.
Other questions concerning the specificity of the binding of FITC-labelled bacteria to
macrophages were raised by the lack of inhibition by whole unlabelled bacteria.
First, does the high pH (9.2) of FITC coupling buffer affect the binding of bacteria to
the macrophages ? Second, does the FITC itself affect the binding of bacteria to
macrophages ? These questions led to a study on the effect of FITC labelling of
bacteria on the binding to macrophages. To study the effect of FITC labelling of
bacteria on the binding, a visual assay was used. This method allowed direct
comparison between the binding of FITC-labelled bacteria and unlabelled bacteria to
macrophages. Visual assays were used in the past by other investigators to study
bacterial binding to different cell types, mouse peritoneal macrophages (Freimer et
al., 1978; Glass et at, 1983), buccal epithelial cells (Bagg et ai, 1982) and human
macrophages (Wright and Jong, 1986).
By using the visual assay FITC-labelled bacteria were found to bind to macrophages
to much higher levels compared to unlabelled bacteria. To obtain similar levels of
binding of unlabelled and FITC-labelled bacteria to macrophages, unlabelled bacteria
had to be used at concentrations 100 times higher than FITC-labelled bacteria. This
observation was further investigated to find out whether the enhancement of the
binding seen with FITC-labelled bacteria was specific to the FITC itself or to the
FITC coupling buffer. The effect of FITC labelling on the binding of different
bacterial species, including Gram-positive bacteria was also investigated. The
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bacteria used to investigate the effect of FITC labelling of bacteria on the binding to
macrophages were selected because they were previously used by other investigators
who used FITC-labelled bacteria in their studies. E. coli K 12 was used by Wright
and Jong (1986), Neisseria meningitidis has been used in a number of studies (Raza
et ai, 1993; Zorgani et al, 1994) and Saadi et al, (1993) used Staphylococcus
aureus. FITC labelling of all bacterial species used enhanced the binding of bacteria
to macrophages as compared to the binding of control bacteria (bacteria suspended in
PBS). FITC coupling buffer did not affect the binding of any bacterial species used
as compared to the binding of control bacteria (bacteria suspended in PBS). These
results indicated that the enhancement of the binding seen with FITC-labelled
bacteria was specific to the FITC and not to the FITC coupling buffer. The
enhancement of the binding was not specific to the strain of S. minnesota Ra used in
this study, but also applied to other bacterial species.
The enhancement of binding shown by FITC-labelled E. coli K 12 in this work is in
disagreement with previous studies (Wright and Jong, 1986) in which the
investigators used fluorescence microscopy to detect the binding of FITC-labelled
E. coli K 12 to human macrophages. This method allowed easy distinction between
fluoresceinated bacteria and similarly sized macrophage organelles. They claimed
that in control experiments in which transmitted-light microscopy was used to
measure the binding of bacteria to macrophages after Wright-Giemsa staining of
samples indicated that FITC did not alter the extent or specificity of binding. This
data was not shown in their paper. Although the level of enhancement of binding of
FITC-labelled E. coli K 12 in our work was the lowest among the bacteria used, it is
still significant.
The enhancement of binding of FITC-labelled bacteria might be due to non-specific
recognition of the FITC by the macrophages. Alternatively it might be because
FITC is altering the structure of bacterial cell surface component/s or having some
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kind of charge effect. It might also be changing the hydrophobicity of bacterial cells.
The exact mechanism for the enhanced binding of FITC-labelled bacteria is not
known; however, it was felt that this line of investigation could not be continued as
the physiological significance of studying the interaction between host cells and
FITC-labelled bacteria had been called in question.
The inhibition of binding of S. Minnesota Ra to mouse peritoneal macrophages was
investigated using the visual assay. The binding of S. minnesota Ra to macrophages
was inhibited using different concentrations of free LPS. When similar
concentrations of LPS were used to inhibit the binding of FITC-labelled and
unlabelled bacteria, similar levels of inhibition were seen for both preparations of
bacteria although unlabelled bacteria were used at a concentration 100 times higher
than FITC-labelled bacteria. The level of inhibition was greater when higher
concentrations of LPS were used.
The binding of S. minnesota Ra to macrophages in the absence of serum is shown in
this chapter. The involvement of LPS in the interaction with host cells was also
shown in that LPS inhibited the binding of S. minnesota Ra to macrophages.
Planned work could not be continued using flow cytometry because of the problems
concerning FITC labelling of bacteria. Also it was not practical to continue the work
using visual assay. The visual assay is time consuming and subjective to some
extent; therefore, further investigations about the direct interaction of LPS with host
cells such as the binding of different Gram-negative bacteria to host cells, the
inhibition of binding of these Gram-negative bacteria to host cells using different
forms and types of LPSs, and investigation of whether different types of LPSs bind
to the same receptor/s on host cells could not be continued.
At this point the study moved on to investigate the release of cytokines and
mediators from host cells as another form of their interaction with LPS.
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Chapter 4
Production of tumour necrosis factor (TNF) and nitric oxide (NO) in
response to various forms of LPS
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4.1 Introduction
Upon stimulation with bacterial products, including LPS, mononuclear phagocytes
release a variety of cytokines and mediators including tumour necrosis factor and nitric
oxide.
TNF includes two structurally and functionally related proteins, TNF-a or cachectin
(Beutler et al, 1985b) which is mainly produced by monocytes and/or macrophages and
TNF-(3 or lymphotoxin (Ruddle and Waksman, 1968) which is the product of lymphoid
cells. The close relationship between these two proteins was not known until 1984 when
cloning of the cDNAs for human TNF and lymphotoxin revealed that they are about 30%
homologous at the amino acid level (Gray et al, 1984; Pennica?r al, 1984). TNF-a and
TNF-|3 bind to the same cell surface receptor (Aggarwal et al, 1985) and they are very
similar (but not identical) in the spectra of their activities. TNF-a and TNF-(3 (especially
TNF-a), originally thought of as an anti-tumour agents, are now grouped among the
major inflammatory cytokines, i.e. they are characteristically produced at the sites of
inflammation by infiltrating mononuclear cells. They play a beneficial role as
immunostimulants and important mediators of host resistance to many infectious agents
and malignant tumours (Old, 1985; Havell, 1987). On the other hand TNF-a has been
shown to be identical to cachectin and has been postulated to mediate wasting during
chronic infections (Beutler et al, 1985). There is increasing evidence that over
production of TNF-a during infections leads to severe systemic toxicity and even death.
TNF-a is a major factor in the development of septic shock following infection with
Gram-negative bacteria (Tracy et al, 1987). TNF-a also has been implicated in the
pathogenesis of some autoimmune disorders (Pujol-Borrell et al, 1987) and of graft-
versus-host disease (Piguet et al, 1987).
Nitric oxide (NO), synthesised from L-arginine, is a potent effector molecule produced by
many mammalian cell types (Moncada et al, 1991). Nitric oxide accounts for the
biological activity of the endothelium-derived relaxing factor produced by endothelial
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cells (Palmer et al,, 1987). Macrophage-derived NO functions also as a cytotoxic
molecule active against invading microorganisms (Adams et al,, 1990: Adams et al,
1991; Green et al, 1990) as well as tumour cells (Drapier and Hibbs, 1988; Stuehr and
Nathan, 1989). NO released from Kupffer cells and hepatocytes has inhibitory effects on
the total protein synthesis of these cells (Curran et al., 1989). Recent reports have
suggested that NO synthesis in these cells may serve to reduce hepatic damage during
acute murine endotoxaemia (Harbrecht et al., 1992). Large amounts of NO formation
might cause significant nitrosation of amines, which have been implicated in
carcinogenesis (Kosaka et al,, 1989).
Regulatory mechanisms for NO oxide production have been studied intensively, and two
types of NO synthases were characterised (Stuehr and Griffith, 1992). One is constitutive
and Ca2+ and calmodulin dependent. The other is Ca2+ and calmodulin independent and
inducible after immunological activation of macrophages, endothelial cells and some
other cell types. Bacterial LPS can increase both blood NO concentration in vivo and
production of NO by macrophages in vitro (Stuehr and Marietta, 1985). The production
of inducible NO synthase by endothelial cells or vascular smooth muscle after exposure
to LPS, TNF, IL-1 or IFN-y leads to an over production of NO in the vasculature and
profound vasodilation. This might be the cause of sepsis-related hypotension which is
characterised by low vascular resistance and is often refractory to vasopressor therapy
(Parker et al., 1987).
All three types of interferon (IFN-a, (3 and y) are able to enhance LPS-induced NO
(Amber et at,, 1988 ; Ding et al., 1988). IFN-y in combination with IL-la and/or TNF-
a/(3 can interact synergistically to initiate NO production (Amber et al., 1988 ; Ding et
al,, 1988). Among many cytokines tested, including IL-1 (3, 1L-2, IL-3, IL-4, IFNs,
macrophage CSF, GM-CSF, TNF-a/(3 and transforming growth factor beta (TGF-(3), only
IFN-y has been reported to be capable of inducing NO production by itself under some
experimental conditions in certain murine macrophages (Drapier et al., 1988 ; Stuehr and
Marietta, 1987). Other cytokines such as IL-10, TGF-|31, TGF-(32, TGF-(33 and
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macrophage deactivating factor have been shown to inhibit the induction of NO
production (Ding et al., 1990 ; Gazzinelli et al, 1992). The anti-inflammatory reagents
hydrocortisone and dexamethasone have also been shown to prevent NO formation (Di
Rosa et al, 1990 ; Knowles et al., 1990). These studies indicate that inducible NO
production is tightly regulated and that a fine functional balance between different
microbial stimuli, host-derived cytokines and hormones in the microenvironment is very
important for this regulation. Different regulatory pathways might exist for inducible NO
production. First, different macrophage cell lines respond differentially to IFN-y
activation in terms of NO production (Stuehr and Marietta, 1987). Second, LPS-induced
NO production has been observed with both CBA/N and nude mice. CBA/N mice lack
mature B cells and nude mice lack functional T cells. This indicates that neither mature B
cells nor functional T cells are required for the response that is initiated by LPS in vivo
(Stuehr and Marietta, 1985).
Although the importance of NO synthesis in rodent macrophages is well established, the
existence of similar pathway in human mononuclear phagocytes is not accepted by many
investigators and is a subject of great controversy.
Because of the difficulties concerning the study of direct interaction of LPS with host
cells (discussed in section 3.4), studying mediators released in response to various forms
of LPS provided an indirect approach to study the interaction between LPS and host cells.
The aims of this chapter were:
1- to measure TNF-a production from THP-1 cells in response to various forms of LPS to
determine which form is the most potent in stimulating host cells;
2- to investigate the involvement of CD 14 in signalling host cells to release TNF-a after
stimulation with various forms of LPS;
3- to determine if there are other pathways for LPS induced-signalling of host cells in
addition to CD 14;
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4- to determine if all forms of LPS induce cell signalling through the same pathway;
5- to measure NO production from peritoneal macrophages from different mouse strains
in response to various forms of LPS and different bacteria to determine if differences
exist between different genetic backgrounds in their response to various forms of LPS
and different organisms;
6- to determine whether human cells possess NOS activity as part of their antimicrobial
armoury.
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4.2 Materials and methods
4.2.1 Buffers
4.2.1.1 Tris- HC1 buffer (stock soln.)
This solution was prepared by dissolving 0.6 g of Tris and 0.85 g of NaCl in 100 ml
distilled water, then the pH of the buffer adjusted to 7.4 using HC1.
4.2.1.2 Tris-buffered saline (working soln.)
This buffer was prepared freshly before use by diluting Tris-HCl buffer (stock soln.) 1:
10 with normal saline and adding normal rabbit serum (SAPU, Carluke, UK) to a final
concentration of 2% (v/v).
4.2.2 Bacterial strains
S. minnesora Ra and E. coli were grown in nutrient broth for 18 h, N. meningitidis was
grown on MNYC agar for 48 h, B. fragilis was grown in PPY broth anaerobically for 48
h and Staph, epidermidis was grown on blood agar for 18 h. Gram-negative bacteria were
harvested, washed three times with PBS, counted spectrophotometrically and
subsequently fixed with 1% formaldehyde in saline at 37° C for 1 h. The killed bacteria
were washed three times in RPMI 1640 (Gibco) or DMEM (Sigma) without antibiotics
and resuspended in RPMI 1640 or DMEM containing 10% FCS without antibiotics.
Staph, epidermidis were treated as above except 2% formaldehyde was used to kill them.
Sterility was confirmed by incubation of killed S. minnesota Ra and E. coli on nutrient
agar plates overnight, N. meningitidis on MNYC agar plate overnight, B. fragilis on blood
agar plate anaerobically for 48 h and Staph, epidermidis on blood agar plate overnight.
In some experiments all bacteria used were heat killed for 30 min at 60° C in PBS and
then treated as above.
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4.2.3 Stimulation of host cells
4.2.3.1 Stimulation of THP-1 cells to release TNF
THP-1 were harvested (as described in section 2.3.2), resuspended in 10% FCS RPMI
1640 without antibiotics and adjusted to 2-OxlO6 ml"1. Cells were placed in 96 well
tissue culture plates (100 pi /well), then various forms of LPS (suspended in RPMI 1640
containing 10% FCS without antibiotics) at different concentrations, whole bacteria at
different doses or diluent controls were added (100 pl/well) and incubated for the desired
time in a 37° C in a humidified 5% CO2 containing incubator. After incubation the plates
were then centrifuged at 300 g for 10 min, supernatants were collected and used directly
to estimate the amount of TNF. Control samples were treated the same way except that
they received 100 pi of medium in place of stimuli. In some experiments THP-1 cells
were incubated in 10% FCS RPMI 1640 with antibiotics and containing 0.1 mM 1, 25-
dihydroxyvitamin D3 (ICN, Biomedicals Ltd, Oxfordshire, UK) for 72 h to enhance the
expression of CD14 prior to stimulation of the cells. In some other experiments THP-1
cells were incubated with three dilutions (1/50, 1/100 and 1/200) of anti-CD14 (SAPU)
monoclonal antibody prior to stimulation of the cells.
4.2.3.2 Stimulation of mononuclear phagocytes to release nitric oxide (NO)
Murine peritoneal cells were harvested (as described in section 2.2.1) in pyrogen free
PBS, washed once in DMEM without antibiotics and resuspended in DMEM containing
10% FCS without antibiotics at 2.0X106 ml"1. THP-1 cells were harvested, washed once
in DMEM without antibiotics, resuspended in 10% FCS DMEM without antibiotics and
adjusted to 2.0x106 ml*1. Human peripheral blood monocytes were obtained from two
healthy individuals (as described in section 2.2.3). The cells were resuspended in 10%
FCS DMEM without antibiotics at l.OxlO7 ml"1. Cells were placed in 96 well tissue
culture plates (100pl/ well), incubated for 1 h at 37° C in a humidified incubator
containing 5% CO2. After incubation, non-adherent cells were removed by washing
gently with DMEM without antibiotics. Various forms of LPS (suspended in DMEM
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containing 10% FCS without antibiotics) at different concentrations and whole bacteria at
different doses were added (100|ul/ well) to the mononuclear phagocytes and incubated
for 24 h in a 37° C humidified 5% C02 containing incubator. Plates were then
centrifuged at 300 g for 10 min. Supernatants were collected and used directly to
estimate the amount of nitrite in each sample. Control samples were treated the same
way except for that they received lOOpl of medium in place of stimuli. In some
experiments THP-1 cells were incubated for 72 h in the presence of 0.1 juM 1,25-
dihydroxyvitamin D3 to enhance the expression of CD14 prior to stimulation with various
forms of LPS. In some other experiments various forms of LPS were incubated with
monoclonal antibodies (SZ 27.19, Blood Transfusion Service, Edinburgh and WN1, gift
from Dr. Ian Poxton) for 20 min before adding to cells. Both antibodies were directed
against the core region of Salmonella and E. coll LPS.
4.2.4 TNF bioassay
L929 mouse fibroblast cell line obtained from the European collection of animal cell
culture (ECACC, Salisbury, UK) was cultured in growth medium (10% FCS DMEM)
and sub-cultured twice a week. L929 cells were dislodged by 0.1% trypsin (Gibco) to
avoid cell clumping, washed, resuspended in growth medium and adjusted to 3.0x105
ml"1. Cells were placed in flat-bottomed 96 well tissue culture plate at 100 pi/ well and
incubated in a 37° C humidified 5% COy containing incubator for 24 h. The growth
medium was discarded and replaced with 100 pl/well (triplicate wells) of test
supernatants after being diluted 1: 1 in assay medium, DMEM containing 5% FCS, 1 mM
L-glutamine and 2 pg ml"1 actinomycin D (Sigma). A standard of recombinant human
TNF (NIBSC, Hertfordshire, UK) was diluted serially 1: 3 in assay medium containing 1
pg ml"1 actinomycin D at a starting concentration of 1000 IU/ml and 100 pi was added to
triplicate wells. TNF standard was used in every plate. Control wells (6 wells) received
100 ul assay medium containing 1 pg ml"1 actinomycin D. Blanks were included in each
plate (6 wells without L929 cells), and were treated identically to the test samples. Plates
were then incubated in a 37° C humidified 5% CO2 containing incubator for 24 h. The
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supernatant in each well was removed and replaced with 50 pi crystal violet stain (0.5%
crystal violet in 20% methanol in distilled water, filtered through Whatman no 1 filter
paper) for 2 min to stain surviving cells. The plates were then washed vigorously with
tap water and allowed to dry, then each well received 50 pi/ well 20% acetic acid to
solubilise the stained cells. Any air bubbles were removed and plates were read at 570
nm using MR 700 microplate reader (Dynatech Laboratories). The amount of TNF in
each sample was determined relative to a TNF standard curve and results were expressed
in IU/ml.
4.2.5 Nitric oxide assay
Nitric oxide production was assessed by measuring nitrite, a stable metabolic product of
NO, in mononuclear phagocytes' culture supernatants (as described by Stuehr and
Marietta, 1987). In brief, Griess reagent, (1:1, v/v) mixture of 0.1% N-[ 1
naphthyljethylenediamine dihydrochloride [Sigma] in H20~l% sulfanilamide [Sigma] in
5% H2PO4) was added to 96 well tissue culture plates at 100pl/ well. An equal volume
of mononuclear phagocytes culture supernatants was then mixed with the Griess reagent
and incubated for 10 min at room temperature, then the absorbance was determined on a
MR 700 microplate reader (Dynatech Laboratories) at 570 nm. The nitrite amount was
then calculated from NaN02 standard curve. The amount of measured nitrite in pmol
was related to the number of cells per well per 24 h This technique enabled the
measurement of amounts of nitrite as little as 0.1 pmol.
4.2.6 Nitric oxide production enhancement by Interferon-gamma (IFN-y)
Human recombinant IFN-y (NIBSC, Hertfordshire, UK) was suspended in DMEM
containing 10% FCS and used at a final concentration of 200 pg ml"1.
4.2.7 Inhibition of TNF and NO production with polymyxin B sulphate
Polymyxin B sulphate (Sigma) was dissolved in RPMI 1640 containing 10% FCS or 10%
FCS DMEM to the desired concentrations. Initially, polymyxin B at various
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concentrations was incubated with THP-1 cells for 24 h. After incubation, the viability of
cells was checked by using Trypan blue exclusion. Polymyxin B concentrations that
permitted cell viability of more than 95% were used. Polymyxin B was added to free S.
minnesota Ra LPS, outer membrane (OM) preparations or whole bacteria and incubated
at room temperature for 25 min then added to cells. Two controls were used, cells plus
medium only and cells plus medium containing the highest polymyxin B concentration
used.
4.2.8 Detection of CD14 receptors on THP-1 cells
THP-1 cells were harvested and resuspended in Tris-buffered saline containing 2%
normal rabbit serum, counted and adjusted to 2-3x106 ml-1. The cell suspension (100 jul)
was placed per well in a 96 well V bottomed microtiter plate. Normal rabbit serum was
added at 25 pi per well and the plate was incubated for 20 min on ice. The plate was
centrifuged at 300 g for 10 min and the supernatants were discarded by inverting the plate
over a container. Cells were then resuspended in residual medium and 20 jul of mouse
anti-CD14 monoclonal antibody (SAPU) at two concentrations (undilute and 1/10) were
added to each well and incubated for 30-45 min on ice. The plate was washed three times
by centrifugation at 300 g for 10 min using Tris-buffered saline containing 2% normal
rabbit serum each time. The cells were then resuspended in residual medium and 50 pi of
F1TC conjugated F(abv)2 sheep anti-mouse IgG (Sigma) was added to each well and
incubated for 30 min on ice. The plate was then washed three times by centrifugation at
300 g for 10 min using Tris-buffered saline containing 2% normal rabbit serum each
time. After the last wash the cells were resuspended in residual medium and fixed with
150 pi 1% buffered paraformaldehyde and transferred to tubes using 100 pi PBS.
Samples were then analysed using flow cytometry as described in section 3.2.6.
4.2.9 Statistics
The student's t-test was used for all statistical analysis. The significance of the effect is
related to the amount of TNF or NO released from control cells (untreated cells).
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S. minnesota Ra cells at a dose of 108 ml-1 were used as an internal standard in every
single experiment because of the variation in day to day results. The amount of NO
produced in response to this challenge was converted to 100%, then the amount of NO in
every sample was converted to a percentage using the formula:
[Amount of NO in test sample (in pmol/106 cells/ day) /amount of NO in 108 ml"1 S.
minnesota Ra(]umol/106 cells/ day)] x 100.
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4.3 Results
4.3.1 TNF production after different stimulation times from THP-1 cells in response
to different concentrations of free LPS
The level of TNF produced by THP-1 cells was measured at 2, 4, 6 and 24 h after
stimulation with several concentrations of free S. minnesota Ra LPS. Results are shown
in Figure 4.1. After 2 h of stimulation, THP-1 cells produced measurable amounts of
TNF in response to the highest three concentrations of LPS (10, 30 and 100 ng ml"1) but
not to the two lower concentrations of LPS (1 and 3 ng ml"1). TNF production peaked
after 4 h of stimulation of THP-1 cells for all LPS concentrations used. Increasing the
stimulation time to 6 h led to a drop of TNF level produced by THP-1 cells in response to
all LPS concentrations used. Further increase in stimulation time to 24 h resulted in TNF
levels produced by THP-1 cells in response to all LPS concentrations to drop back to base
line ( > 1 lU/ml). TNF production from THP-1 cells in response to free LPS was dose
dependent. Stimulation of THP-1 cells for 6 h with free LPS induced the production of
TNF amounts of: 8.3 IU/ml (p < 0.02) in response to a dose of 1 ng ml"1,14.3 IU/ml (p <
0.05) in response to a dose of 3 ng ml"1, 38 IU/ml (p < 0.02) in response to a dose of 10
ng ml"1, 80 lU/ml (p < 0.01) in response to a dose of 30 ng ml"1 and 108 IU/ml (p <
0.025) in response to a dose of 100 ng ml"1. From this work 6 h stimulation time was
selected for further work on TNF production.
4.3.2 TNF production from THP-1 cells in response to S. minnesota Ra OM
preparations
TNF levels produced by THP-1 in response to several concentrations of OM preparations
from S. minnesota Ra (OM preparation concentrations stated here represent the
concentration of LPS attached to each OM preparation as determined by KDO assay)
were investigated by stimulation of the cells for 6 h. Free 5. minnesota Ra LPS at several
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Figure 4.1: TNF production from THP-1 cells in response to several
concentrations of free S. minnesota Ra LPS over 24 hours. Each point represent the
mean TNF release of three experiments + SEM
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concentrations was used for comparison. THP-1 cells produced significant amounts of
TNF in response to all OM preparations used except for lng ml"1 concentration and TNF
levels produced were dose dependent (Figure 4.2 ). OM preparation stimulated THP-1
cells to produce TNF amounts of: 30 IU/ml (p < 0.02) in response to a dose of 3 ng ml"1,
51 IU/ml (p < 0.02) in response to a dose of 10 ng ml"1, 86 IU/ml (p < 0.025) in response
to a dose of 30 ng ml"1, 150 IU/ml (p < 0.02) in response to a dose of 100 ng ml"1.
4.3.3 TNF production by THP-1 cells in response to whole S. minnesota Ra and
whole Staph, epidermidis
Five concentrations of S. minnesota Ra and Staph, epidermidis were used to stimulate
TNF production from THP-1 cells for 6 h. Results are shown in Figure 4.3. Whole S.
minnesota Ra stimulated the production of significant amounts of TNF from THP-1 cells
at all doses of bacteria used. Again as for the other forms of LPS, TNF production in
response to whole S. minnesota Ra was dose dependent. At low doses (10, 103 and 105
ml-1) Staph, epidermidis did not stimulate THP-1 cells to produce TNF. Staph,
epidermidis at a dose of 107 ml"1 stimulated THP-1 to produce small amounts of TNF;
and only at a dose of 109 ml"1 did Staph, epidennidis stimulated the production of
significant amounts of TNF (38 IU/ml) from THP-1 cells (p < 0.02).
4.3.4 TNF production from normal and CI)14-enhanced THP-1 cells in response to
various S. minnesota Ra LPS forms
To find out if CD14 receptors were involved in the induction process of TNF from THP-1
cells, CD14-enhanced THP-1 cells and normal THP-1 cells (without CD14-enhancement)
were stimulated for 6 hours with various forms of S. minnesota Ra LPS. Normal and
CD14-enhanced THP-1 cells produced significant amounts of TNF in response to all S.
minnesota Ra LPS forms used. There were no significant differences in TNF levels
produced from normal THP-1 cells as compared to CD14-enhanced THP-1 cells (Figure
4.4). The percentage of THP-1 cells which expressed CD14 was determined by flow
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Figure 4.2: TNF production from THP-1 cells in response to several
concentrartions of S. minnesota Ra outer membrane fraction (OM) and free LPS
when stimulated for 6h. Each point represents the mean TNF release of three
experiments + SEM
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Figure 4.3: TNF production from THP-1 cells in response to several doses
ofwhole S. minnesota Ra and Staph, epidermidis when stimulted for 6 h. Each point
represents the mean TNF release of three experiments + SEM
111
□ 10 ng ml'1 free LPS
IS 10 ng ml"1 OM














Figure 4.4: Comparison between TNF levels produced by CD14-enhanced
THP-1 cells and normal (untreated) THP-1 cells in response to various forms of S.
minnesota Ra LPS at 6 h incubation time. Each column represents the mean TNF
release of three experiments + SEM
(OM = outer membrane fraction of S. minnesota Ra).
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Experiment 1 6 (314) 32 (374)
Experiment 2 4 (280) 20 (325)
Experiment 3 9 (319) 37 (386)
Figures in brackets represent the mean fluorescence level of samples.
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with 1,25-dihydroxyvitamin D3 expressed more CD14 receptors than untreated cells both
in terms of percentage positive and level of expression.
4.3.5 Inhibition of TNF production from THP-1 cells by anti-CI)14 monoclonal
antibody (mAb)
Anti-CD14 mAb was used at three dilutions (1/50, 1/100 and 1/200) to inhibit the
*
production of TNF from THP-1 cells when stimulated for 6 h with a concentration of 30
ng ml-1 free S. minnesora Ra LPS (Figure 4.5). Anti-CD14 at all three dilutions used did
not inhibit the production of TNF from THP-1 cells in response to free S. minnesora Ra
LPS.
4.3.6 Inhibition of TNF production from THP-1 cells by polymyxin B sulphate
Polymyxin B sulphate was used at three concentrations to inhibit TNF production from
THP-1 cells in response to various forms of S. minnesora Ra LPS (Figure 4.6). All three
concentrations of polymyxin B used (0.1, 1, 10 pg ml"1) blocked TNF production from
THP-1 cells in response to a concentration of 10 ng ml"1 free LPS and the results were
statistically significant (P < 0.05 for all polymyxin concentrations) as compared to
controls (free LPS without polymyxin B treatment). Polymyxin B at concentrations of
0.1, 1, 10 pg ml"1 also blocked TNF production from THP-1 cells in response to a
concentration of 10 ng ml"1 OM preparation and results were statistically significant (p <
0.025, P < 0.025 and p < 0.02 respectively) as compared to untreated controls . There
was no inhibition of TNF production from THP-1 in response to a dose of 107 ml"1 whole
S. minnesora Ra at any polymyxin B concentration used as compared to untreated control.
4.3.7 Nitric oxide release from peritoneal macrophages of CBA mouse
Peritoneal macrophages of CBA mice were stimulated with various forms of LPS and
various bacteria including Gram-negative anaerobic and Gram-positive bacteria.
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E3 No antibody
m 1/50 anti CD 14
m 1/100 anti CD 14
□ 1/200 anti CD 14
Figure 4.5: Inhibition of TNF production by anti CD14 antibody. THP-1
cells were stimulated by a concentration of 10 ng ml"1 free S. minnesota Ra LPS for
6 h. Three dilutions of anti CD14 mAb were used. Each column represents the mean
TNF release of three experiments + SEM
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Concentration of polymyxin B sulphate (pg.ml"1)
Figure 4.6: Inhibition of TNF production by polymyxin B. THP-1 cells
were stimulated for 6 h with various forms of S. minnesota Ra LPS using three
concentrations of polymyxin B sulphate. Each column represents the mean TNF
release of thiee experiments + SbM
(OM = outer membrane fraction of 5. minnesota Ra).
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4.3.7.1 Nitric oxide release from peritoneal macrophages of CBA mice in response to
various forms of LPS
Peritoneal macrophages of CBA mice were stimulated with several concentrations of free
LPS and LPS attached to outer membrane preparations extracted from S. minnesota Ra.
At high concentration of free LPS and OM preparation (100 jug ml"1) there was no
production of NO and that was probably because these high concentrations were killing
the cells. At a concentration of 10 pg ml"1 of free LPS, peritoneal macrophages of CBA
mice produced small but measurable amounts of NO and when compared to non-
stimulated controls results were statistically significant (p < 0.02) (Figure 4.7). At a
concentration of 10 pg ml"1 of OM preparation peritoneal macrophages of CBA mice
produced a slightly higher amount of NO than that obtained by using similar
concentration of free LPS and results were statistically significant (p < 0.05) compared to
non-stimulated controls. The response to whole bacteria is also shown in Fig. 4.7. At a
dose of 108 ml"1 of whole S. minnesota Ra there was a substantial release of NO. An
internal standard has to be used in every experiment because of day to day variations in
the results. Whole S. minnesota Ra was used in this work as a standard at a dose of 108
ml"1. The mean amount of NO produced in response to this dose was 14 pmol/ 106 cells/
day. Lower concentrations of free LPS and OM preparation (1 pg ml"1 and 0.1 pg ml"1)
failed to stimulate the cells to produce any measurable amounts of NO from peritoneal
macrophages of CBA mice.
4.3.7.2 Nitric oxide release from peritoneal macrophages of CBA mice in response
to three different Gram-negative aerobic bacteria
S. minnesota Ra, N. meningitidis and E. coli were used in these experiments. Three doses
of each bacteria were used to stimulate peritoneal macrophages of CBA mice to produce
NO. Figure 4.8 shows the relative release of NO from peritoneal macrophages of CBA
mice in response to the different bacteria used. S. minnesota Ra at a dose of 108 ml"1
gave the highest amount of NO and again was used as internal standard. The mean























E3 108 ml"1 S. minnesota Ra
13 10 jiig ml-1 free LPS





Figure 4.7: NO release from peritoneal macrophages of CBA mice in
response to various forms of LPS from S. minnesota Ra. Each column represents the
mean NO release + SEM of four to seven experiments.















Figure 4.8: NO release from peritoneal macrophages of CBA mice in
response to S. minnesota Ra (A), N. meningitidis (B) and E. coli (C). Each column
represents the mean NO release + SEM of four to seven experiments.
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106 cells/ day. At a dose of 107 ml"1, S. minnesota Ra stimulated peritoneal macrophages
of CBA mice to produce measurable amount of NO and the results were statistically
significant (p < 0.005). S. minnesota Ra at the highest dose (109 ml"1) failed to stimulate
the production of any measurable amounts of NO from macrophages and that was
probably because the high dose of the bacteria was killing the cells. N. meningitidis
stimulated peritoneal macrophages of CBA mice to produce measurable amounts of NO
at all three doses used. The highest amount of NO was produced in response to a dose of
108 ml"1 and was statistically significant (p < 0.05). At a dose of 107 ml"1 N.
meningitidis stimulated macrophages to produce significant amounts of NO and results
were statistically significant (p < 0.05). At a dose of 109 ml"1 N. meningitidis stimulated
the production of significant amounts of NO similar to those produced in response to a
dose of 107 ml"1 (p < 0.005). E. coli stimulated peritoneal macrophages of CBA mice to
produce measurable amount of NO at all three doses used. Again the highest amount of
NO was produced in response to a dose of 108 ml"1 and was statistically significant (p <
0.01). NO production in response to a dose of 107 ml"1 was comparable to that produced
in response to a dose of 108 ml"1. At a dose of 109 ml"1 the least amount of NO was
produced and that was probably because excess bacteria killed most of the cells.
4.3.7.3 Nitric oxide release from peritoneal macrophages of CBA mice in response to
Gram-negative anaerobic and Gram-positive bacteria
B. fragilis and Staph, epidermidis were used to stimulate peritoneal macrophages of CBA
mice to produce NO. Figure 4.9 shows relative NO release in response to both
microorganisms compared to the standard stimulus of 108 ml-1 S. minnesota Ra. B.
fi'agilis at a dose of 107 ml"1 stimulated peritoneal macrophages of CBA mice to produce
low levels of NO. The amount of NO produced in response to a higher dose (108 ml"1)
was slightly increased and was statistically significantly higher than controls (p < 0.005).
Staph, epidennidis. at doses of 107 ml"1 and 108 ml"1 stimulated peritoneal macrophages





Figure 4.9: NO release from peritoneal macrophages of CBA mice in
response to two doses ofB.fragilis (B) and Staph, epidermidis (C). S. minnesota Ra
(A) was used as a standard. Each column represents the mean NO release + SEM of
four to seven experiments.
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this set of experiments by the internal standard (a dose of 108.ml_1 S. minnesota Ra) was
10 jumol/106 cells/ day.
4.3.8 Nitric oxide release from peritoneal macrophages of BALB/c mice
Several different bacteria, in addition to S. minnesota Ra free LPS, were used to stimulate
NO production from peritoneal macrophages of BALB/c mice. Figure 4.10 compares
NO release in response to a dose of 108 ml"1 of all bacteria used and a concentration'of
10 pg ml"1 of free LPS. Peritoneal macrophages of BALB/c mice produced substantial
amounts of NO in response to free LPS at a concentration of 10 jug ml"1 and the results
were statistically significant (p < 0.025). Peritoneal macrophages of BALB/c mice
produced the highest amount of NO in response to whole S. minnesota Ra at a dose of
108 ml"1. This dose was used as an internal standard and the mean amount of NO
produced in response to this dose was 22.4 pmol/106 cells/day. Both N. meningitidis and
E. coli stimulated BALB/c mice peritoneal macrophages to produce similar substantial
amounts of NO and results were statistically significant (p < 0.02 for both micro¬
organisms). Stimulation of BALB/c mice peritoneal macrophages with B. fragilis and
Staph, epidermidis, resulted in the production of the lowest amounts of NO. Results were
statistically significant (p < 0.05 for both microorganisms).
4.3.9 Nitric oxide release from macrophages of LPS hyporesponsive mice
(C3H/HeJ)
The ability of various forms of S. minnesota Ra LPS and several other different bacteria
to stimulate peritoneal macrophages of C3H/HeJ mice to produce NO was investigated.
Figure 4.11 compares NO release from peritoneal macrophages of C3H/HeJ mice. In
response to a concentration of 10 pg ml"1 free LPS, peritoneal macrophages of C3H/HeJ
mice failed to produce any significant amounts of NO. In fact the amount of NO released
in response to free LPS was less than 1 pmol/106 cells/day. OM preparation at a
concentration of 10 pg ml"1 (this concentration represents the amount of LPS attached to
the OM preparation) was more potent than free LPS in stimulating these
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S3 10 jug ml-1 free LPS
EH 108 ml"1 S. minnesota Ra
EH 108 ml"1 E. coli
0 108 ml"1 N. meningitidis
□ 108 ml"1B. fragilis
^ □ 108 ml"1 Staph, epidermidis
Figure 4.10: NO release from peritoneal macrophages of BALB/c mice in
response to two forms of LPS from S. minnesota Ra (free LPS and whole organism)




10 jug ml"1 free LPS
10 jug ml"1 OM
108 ml"1 S. minnesota Ra
108 ml"1 E. coli
108 ml"1 N. meningitidis
108ml"1 B.fragilis
108 ml"1 Staph, epidermidis
Figure 4.11: NO release from peritoneal macrophages of C3H/HeJ mice in
response to various forms of S. minnesota Ra LPS and different bacteria. Each
column represents the mean NO release + SEM of four to eight experiments.
(OM = outer membrane fraction of S. minnesota Ra).
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peritoneal macrophages of C3H/HeJ mice to produce significant amounts of NO and
results were statistically significant (p < 0.01). Whole S. minnesota Ra at a dose of 108
ml"1 was used as an internal standard, it was more potent than other forms of LPS in
stimulating peritoneal macrophages of C3H/HeJ mice to produce NO. The mean amount
of NO released in response to whole S. minnesota Ra was 9 pmol/106 cells/ day. N.
meningitidis at a dose of 108 ml"1 stimulated peritoneal macrophages of C3H/HeJ mice to
release significant amounts of NO and results were statistically significant (p < 0.005). E.
coli at a dose of 108 ml"1 was the most potent of the tested organisms in stimulating
peritoneal macrophages of C3H/HeJ mice to produce NO and results were statistically
significant (p < 0.05). B.fragilis and Staph, epidermidis at a dose of 108 ml"1 stimulated
peritoneal macrophages ofC3H/HeJ mice to produce low but measurable amounts of NO.
The results of both microorganisms were statistically significant above control levels (p <
0.02 for B. fragilis and p <0.005 for Staph, epidermidis).
4.3.10 Nitric oxide release from a human macrophage cell line (T1IP-1)
The ability of the human macrophage cell line (THP-l) to produce NO in response to
various forms of S. minnesota Ra LPS was investigated. Several other bacteria were also
used to stimulate THP-l cells to produce NO.
4.3.10.1 Nitric oxide release from THP-l in response to various forms of S.
minnesota Ra LPS
Different concentrations of free LPS, OM preparation and whole S. minnesota Ra were
used to investigate the production of NO from THP-l cells (Figure 4.12). All
concentrations of free LPS used failed to stimulate THP-l cells to release any significant
amounts of NO. THP-l cells released substantial amounts of NO in response to all three
concentrations of OM preparation in a dose-dependent fashion. Results were statistically
significant for all three concentrations of OM preparation used, for a concentration of 1
pg ml"1 (p < 0.0 2), for 10 pg ml-1 (p < 0.01) and for 100 pg ml"1 (p < 0.01). THP-l
cells also released substantial amounts of NO in response to whole S. minnesota Ra at all
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Figure 4.12: NO release from THP-1 cells in response to three different
concentrations ot various forms of S. minnesota Ra LPS: free LPS (A), outer
membrane fraction (B) and whole organism (C). Each column represents the mean
NO release + SEM of four to fifteen experiments.
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three doses used. The highest release of NO from THP-1 cells was seen in response to
whole S. Minnesota Ra at a dose of 108 ml"1 which was used as an internal standard. The
mean amount of NO released in response to this dose was 19.2 pmol/106 cells/ day. The
amount of NO released in response to a dose of 107 ml"1 (p < 0.001) was lower than that
released in response to a dose of 109 ml"1 (p < 0.001).
4.3.10.2 Nitric oxide release from THP-1 cells in response to different bacteria
The ability of different Gram-negative bacteria, including an anaerobe and one Gram
-positive bacterium to stimulate THP-1 cells to produce NO was investigated. Figure
4.13 shows release of NO from THP-1 in response to various bacteria. S. Minnesota Ra
was used as standard at a dose of 108 ml"1. All bacteria were used at the same dose as S.
Minnesota Ra. The mean amount of NO released from THP-1 in response to 5.
Minnesota Ra was 22 pmol/106 cells/ day. THP-1 cells released low levels of NO in
response to N. Meningitidis, B. fragilis and Staph, epidermidis and results were
statistically significantly different from the background release, p < 0.05, p < 0.02 and p <
0.02 respectively. E. coli was more potent in stimulating THP-1 cells to release
substantial amounts of NO (p < 0.005) compared with the other microorganisms used
except for 5. Minnesota Ra.
4.3.11 Nitric oxide release from human peripheral blood monocytes
Human peripheral blood monocytes were stimulated with different concentrations of
various forms of S. Minnesota Ra LPS. Relative release of NO from human peripheral
blood monocytes is shown in Figure 4.14. In response to three concentrations of free
LPS, human peripheral blood monocytes failed to release any significant amounts of NO.
Results for all three LPS concentrations were less than 1 pmol/106 cells/day. OM
preparations at a dose of 1 pg ml"1 stimulated human peripheral blood monocytes to
produce small but significant amounts of NO (p < 0.02). Increasing the concentration of
OM preparation to 100 pg ml"1 resulted in an increase in the amount of NO released by
human peripheral blood monocytes (p < 0.02). Human peripheral blood monocytes
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Figure 4.13: NO release from THP-1 cells in response to different bacteria
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B
Figure 4.14: NO release from human peripheral blood monocytes in response
to different concentrations of various forms of S. minnesota Ra LPS: free LPS (A),
outer membrane fraction (B) and whole organism (C). Each column represents the
mean NO release of three experiments + SEM
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released small amounts of NO in response to a dose of 107 ml"1 of whole S. minnesota
Ra. Again the dose of 108 mHS. minnesota was used as an internal standard and the
amount of NO released in response to this dose was 3.1 pmol/106 cells/day. Increasing
the dose of S. minnesota Ra to 109 ml"1 resulted in an increase in the amount of NO
released from human peripheral blood monocytes (p < 0.01).
4.3.12 Effect of the method of killing of bacteria on NO release from THP-1 cells
*
All previous work on NO release in response to whole bacteria was performed using
formaldehyde killed bacteria. Heat is another method of killing of bacteria. To
investigate the effect of both methods of killing of bacteria on NO production from cells,
S. minnesota Ra and Staph, epidermidis killed using both methods were used at similar
doses to stimulate THP-1 cells to release NO. Results of all doses of both preparations
(heat- killed and formaldehyde-killed) of the two bacterial species used are shown in
Figure 4.15. Formaldehyde-killed S. minnesota Ra at a dose of 108 ml"1 was used as an
internal standard and NO released in response to this dose was 6.7 pmol/106 cells/day.
Although the amounts of NO released in response to heat-killed S. minnesota Ra and
Staph, epidermidis were slightly higher than those released in response to formaldehyde-
killed bacteria, there were no significant differences between the amounts of NO released
in response to both preparations at all bacterial doses used.
4.3.13 Nitric oxide release from THP-1 and human peripheral blood monocytes in
response to stimulation with recombinant interferon-gamma (rlFN-y) by itself and
in combination with various LPS forms
Human peripheral blood monocytes and THP-1 cells were stimulated with human
recombinant interferon-gamma (rlFN-y) with or without a second stimulus (various forms
of LPS). Results of a representative experiments are summarised in Table 4.2. Neither
THP-1 cells nor human peripheral blood monocytes produced any measurable amounts of
NO in response to stimulation with rlFN-y by itself or in combination with free LPS.
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Figure 4.15: Comparison between NO release in response to formaldehyde-
killed bacteria and heat-killed bacteria from THP-1 cells using different doses of
Gram-negative and Gram-positive bacteria. Each column represents the mean NO
release of four experiments + SEM
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Table 4.2: NO release from IFN-y activated THP-1 and human blood monocytes.
Cells Pre-treatment for 24 h. NO (jumol/106
cells/day)
Human blood monocytes None < 1
LPS < 1
OM 3.8





rIFN-y + OM 3.5
rlFN-y + Whole S. minnesota Ra 2.1
THP-1 cells None < 1
LPS < 1
OM 5.3





rlFN-y + OM 5.1
rlFN-y + Whole S. minnesota Ra 11.3
rlFN-y - human recombinant interferon-y (200 ng ml""1)
LPS - S. minnesota Ra LPS (10 jag ml-1)
OM - outer membranes of S. minnesota Ra (10 jug ml""1)
Whole S. minnesota Ra (10s ml"1)
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rlFN-y did not enhance the ability of either OM preparation or whole bacteria to stimulate
either THP-1 cells or human peripheral blood monocytes to release NO.
4.3.14 Nitric oxide release from CD14-enhanced THP-1 cells in response to various
LPS forms
To study the role of CD14 receptors in NO production, the expression of CD14 on THP-1
cells was enhanced by treating the cells with 1,25-dihydroxyvitamin D3, the cells were
then stimulated with various forms of LPS and the amount of NO produced measured.
Figure 4.16 shows relative release of NO from both CD14-enhanced and normal THP-1
cells. Enhancement of the expression of CD 14 receptors on THP-1 cells did not gave the
cells the ability to produce NO in response to free LPS. There was no significant
difference between NO production in response to a concentration of 10 pg ml"1 of OM
preparation or a dose of 108 ml"1 whole S. minnesota Ra from CD14-enhanced THP-1
and from normal THP-1 (without enhancement for CD14). THP-1 cells treated with
1,25-dihydroxyvitamin D3 were found to express more CD14 receptors than normal
THP-1 cells (see section 4.3.4).
4.3.15 Inhibition of release of NO from THP-1 cells by polymyxin B sulphate.
Polymyxin B sulphate was used at several concentrations to inhibit the production of NO
from THP-1 cells when stimulated with OM preparation or whole S. minnesota Ra.
Figure 4.17 shows NO relative release in response to a concentration of 10 pg ml"1 of
OM preparation and a dose of 108 ml"1 whole S. minnesota Ra. There was no inhibition
of NO release from THP-1 cells in response to whole S. minnesota Ra even with the
highest concentration of polymyxin used as compared to control (whole 5. minnesota Ra
and without polymyxin treatment). The amount of NO released from THP-1 in response
to whole 5. minnesota Ra was 9.8 pmol/106 cells/ day. At a concentration of 0.1 pg ml"1,
polymyxin B inhibited the release of NO from THP-1 in response to OM preparation, but
this inhibition in NO release was not significant. Increasing the concentration of
polymyxin B to 1 pg ml"1 significantly inhibited (p < 0.01) NO release from THP-1 cells
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Figure 4.17: Inhibition of NO release by polymyxin B. THP-1 cells were
stimulated by outer membrane fraction (OM) at a concentration of lOpg ml"1 or
whole S. minnesota Ra at a dose of 10s ml"1 in the presence of different
concentrations of polymyxin B sulphate. Each column represents the mean NO
release of three experiments + SEM
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Normal THP-1 Vit. D3 treated
cells THP-1 cells
Figure 4.16: NO release from CD14-enhanced THP-1 and normal THP-1
cells in response to various forms of 5. minnesota Ra LPS. Each column represents
the mean NO release of three experiments + SEM
(OM = outer membrane fraction).
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in response to the OM preparation as compared to control (OM without polymyxin B
treatment). Further increase in polymyxin concentration to 10 pg ml"1 and 100 pg ml"1
completely blocked NO production from THP-1 in response to OM preparation. The




The aim of this study was to investigate the interaction between LPS and host cells. In
the previous chapter an attempt was made to determine the direct interaction between
various forms of LPS with host cells by studying the binding of bacteria to cells. This
approach was abandoned due to the major technical difficulties in the use of FITC-
labelled bacteria and the time consuming direct microscopic technique. The outcome of
the interaction between LPS and host cells is the release of cytokines and other mediators
by host cells. Measurement of the release of these molecules in response to various LPS
preparations afforded a different approach to study the LPS-host cell interaction. Here
the release of TNF and NO from host cells was investigated.
In addition to its potential role as a regulator of the normal immune response, TNF is also
known to play a major role in systemic toxicity associated with sepsis (Tracey and
Cerami, 1994). TNF might also be involved in the pathogenesis of AIDS (Folks et al.,
1989) as well as a number of autoimmune and inflammatory diseases.
The L929 mouse fibroblast bioassay for TNF quantitation was originally described by
Flick and Gifford (1984) and has been used by many other investigators (Mohler et al,
1993: Delahooke et al., 1995). This assay is sensitive and relatively cheap. The L929
target cells also grow rapidly and are undemanding to culture.
THP-1 cells produced significant amounts of TNF in response to all forms of S.
minnesota Ra LPS used. Whole S. minnesota Ra and OM fraction from S. minnesora Ra
were more potent than free S. minnesota Ra LPS in stimulating the production of TNF
from THP-1 cells. TNF production peaked after 4 hours of stimulation and was dose
dependent for all forms of LPS used. Other investigators (Simon et al, 1991) used THP-
1 cells in their work. They reported that THP-1 cells produced TNF in response to free E.
coli LPS and also to filtrates of E. coli killed by different antibiotics. They concluded that
differences exist among bactericidal antibiotics in their ability to generate products
capable of stimulating THP-1 cells to release TNF.
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Gram-positive bacteria were used by other investigators (Timmerman et al, 1993) to
induce human peripheral blood monocytes to release TNF. These investigators reported
that whole staphylococci and purified peptidoglycans isolated from three Staph,
epidermidis and three Staph, aureus strains stimulated human monocytes to release TNF
in a dose-dependent fashion. This is in agreement with this work in which Staph,
epidermidis stimulated THP-1 cells to produce TNF in a dose-dependent fashion.
CD14 has been reported to be responsible for signalling mononuclear phagocytes to
produce TNF and other cytokines when these cells interact with LPS (Shumann et al.,
1990; Dentener et al., 1993), therefore a role of CD14 in signalling THP-1 cells to
produce TNF was investigated. CD14 receptors appears not to be involved in the process
of TNF production from THP-1 cells in response to all forms of LPS used. This is
because of: a) THP-1 cells with increased expression of CD14 receptors released
comparable amounts of TNF as compared to THP-1 cells without enhancement for CD14
and b) anti-CD14 mAb did not inhibit TNF release from THP-1 cells. Other
investigators (Delahooke et al., 1995) have used Bacteroides LPS to stimulate TNF
production from THP-1 cells (with and without enhancement for CD14) in their work.
They studied the capacity of LPS extracted by aqueous phenol method from four species
of Bacteroides to induce TNF. They reported friat there was no difference in TNF
production by B. fragilis NCTC 9343 LPS from THP-1 cells with or without
enhancement for CD14. The same workers reported that anti-CD14 mAb did not inhibit
TNF production from THP-1 cells with or without enhancement for CD14 in response to
Bacteroids fragilis LPS. They suggested that TNF production from THP-1 cells in
response to Bacteroids fragilis LPS was independent of CD14. These results are in
agreement with my work on TNF production from THP-1 cells in response to various
forms of LPS from S. minnesota Ra.
The role of S. minnesota Ra LPS, in all forms used (free LPS, OM and whole bacteria) in
inducing THP-1 cells to produce TNF was investigated using polymyxin B sulphate, an
agent known to bind to lipid A region of LPS molecule. Polymyxin B sulphate at
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concentrations of 0.1,1, 10 jug ml-1 completely blocked TNF release from THP-1 cells in
response to free S. minnesota Ra LPS and OM preparation from S. minnesota Ra.
Polymyxin B sulphate at all concentrations used however, did not inhibit TNF production
from THP-1 in response to whole S. minnesota Ra. One possible explanation for this is
that free LPS and OM fraction bind to the surface of THP-1 cells and trigger TNF and
therefore their affect was neutralised by polymyxin. Whole bacteria trigger by another
method, perhaps by being internalised where polymyxin is released or inactivated.
In addition to other activities NO has been proposed as an antimicrobial and antitumoural
effector system of mononuclear phagocytes of laboratory animals. Over the last five
years more observations on the antimicrobial and cytotoxic effects of NO and the
regulation of its production by macrophages have appeared in the literature, pointing to
the increased interest in this effector system (Nathan and Hibbs, 1991; Moncada et al,
1991; Nathan 1992 ). The increasing knowledge of the NOS of rodent macrophages
contrasts with the scarcity of data on a counterpart of this enzyme system in human
mononuclear phagocytes
NO production is measured by a colorimetric assay in which nitrite is measured in the
supernatants of mononuclear phagocytes in culture. This method has been used by many
other investigators to measure NO in the supernatants of mouse macrophage cell lines
stimulated with E. coli LPS, BCG, lymphokines, IFN-y and Zymosan (Stuehr and
Marietta, 1987), peritoneal macrophages of different mouse strains stimulated with E. coli
LPS ( Zhang et al., 1994) and human, mouse and rabbit macrophages stimulated with E.
coli LPS and IFN-y (Schneemann et al., 1993).
This part of the study used the production of NO to investigate the interaction of mouse
peritoneal macrophages with various forms of LPS and different bacterial species. Three
mouse strains including the LPS hyporesponsive strain, C3H/HeJ, were used in the
investigation.
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Peritoneal macrophages of CBA mice produced measurable amounts of NO in response
to all forms of LPS used. OM preparations were more potent than free LPS in
stimulating peritoneal macrophages of CBA mice to produce NO. The most potent
stimulus for NO production was whole S. minnesota Ra. High concentrations of free
LPS, OM preparation (100 jug ml"1) and whole S. minnesota Ra (109 ml"1) apparently
killed the cells because there was no measurable amounts of NO in the supernatants of
macrophages stimulated with these concentrations. Low concentrations of free LPS and
OM preparation (1 jug ml"1) failed to stimulate macrophages to produce NO. E. coli and
N. meningitidis stimulated peritoneal macrophages of CBA mice to produce NO at all
bacterial doses used. NO production was the highest at a dose of 108 ml"1 for both
microorganisms. B. fragilis and Staph, epidennidis stimulated peritoneal macrophages of
CBA mice to produce small amounts of NO. There therefore appear to be variation in the
ability of different bacteria and LPS preparations to stimulate NO production.
Peritoneal macrophages of BALB/c mice were stimulated with various forms of LPS and
also with different bacteria to see the effect of a different genetic background on NO
production. Peritoneal macrophages of BALB/c mice produced larger amounts of NO
than those produced by peritoneal macrophages of CBA mice in response to free LPS,
whole 5. minnesota Ra and all other bacteria used. The best stimulus of NO for both
strains of mice was whole 5. minnesota Ra at a concentration of 108 ml-1. In another
study (Schneemann et ai, 1993) resident and thioglycollate elicited peritoneal
macrophages of BALB/c and C3H/HeN mice were used to study NO production in
response to free E. coli LPS alone or in combination with IFN-y. The workers reported
that thioglycollate elicited peritoneal macrophages of BALB/c and C3H/HeN produced
NO (10.5 jumol/106 cells/day) in response to free LPS alone. Their finding is in
agreement with this work in which resident BALB/c peritoneal macrophages produced
NO amounts of 12.3 pmol/106 cells/day in response to free LPS. They also reported that
IFN-y enhanced the production of NO (51.3 pmol/106 cells/day) from thioglycollate
elicited peritoneal macrophages of BALB/c and C3H/HeN in response to LPS. Other
forms of LPS were not used in their study.
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Having tested peritoneal macrophages of CBA and BALB/c mice with various stimuli,
the ability of peritoneal macrophages of the hyporesponsive mouse (C3H/HeJ) to produce
NO was tested using the same stimuli. The C3H/HeJ mouse strain is a mutant inbred
strain which has been demonstrated to be refractory to the in vivo inflammatory and
lethal effects of LPS (Sultzer 1968). This hyporesponsiveness to LPS is manifested in B
and T lymphocytes, fibroblasts and macrophages of C3H/HeJ mouse strain (Morrison
1986).
The most potent form of S. minnesota Ra LPS in stimulating peritoneal macrophages of
C3H//HeJ was whole S. minnesota Ra at a dose of 108 ml"1. OM preparation stimulated
peritoneal macrophages of C3H/HeJ to produce significant amounts of NO and was more
potent than free LPS which stimulated peritoneal macrophages of C3H/HeJ to produce
negligible (< 1 pmol/ 106 cells/ day) amounts of NO. E. coli was the most potent
organism in stimulating peritoneal macrophages of C3H/HeJ to produce NO. N.
meningitidis also stimulated substantial amounts of NO. Again as with other mouse
strains Staph, epidermidis and B. fragilis were the least stimulating organisms for the
production of NO. The level of NO produced by peritoneal macrophages of C3H/HeJ
mice was similar to the NO level produced by peritoneal macrophages of CBA mice.
Other investigators (Zhang et al, 1994) used thioglycollate elicited peritoneal
macrophages of C3H/HeJ mice in their work. They stimulated the thioglycollate-elicited
C3H/HeJ peritoneal macrophages with either free S. minnesota Ra LPS (Ra-LPS) or free
E. coli smooth LPS (S-LPS) and measured NO production. They found that neither Ra-
LPS nor S-LPS could initiate the production of NO in those macrophages when used as
stimuli on their own at 10 pg ml"1. This finding is in agreement with my work on resident
peritoneal macrophages of C3H/HeJ mice using similar concentration of free S.
minnesota Ra LPS. Zhang and co-workers (1994) found that the ability of thioglycollate
elicited peritoneal macrophages of C3H/HeJ to produce NO in response to free LPS was
restored when LPS was used in combination with IFN-P or IFN-y. Other forms of LPS
have not been used in their study. These studies agree with in vivo response seen in
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C3H/HeJ mice to LPS. However it appears that these mice respond to whole bacteria and
outer membrane preparations by producing NO.
Human cells such as hepatocytes, endothelial cells and neutrophils have been shown to
express an inducible NO synthase (NOS), but the presence of a similar pathway in human
monocytes/macrophages has been questioned by many investigators and is a subject of
great controversy.
THP-1 cells and human peripheral blood monocytes were used to investigate whether
human mononuclear phagocytes can produce NO in response to various forms of LPS
and other bacteria. THP-1 cells did not produce any significant amounts of NO in
response to stimulation with different concentrations of free S. minnesota Ra LPS. In
contrast these cells produced significant amounts of NO in response to the three
concentrations of OM and whole S. minnesota Ra used. A dose of 108 ml"1 whole S.
minnesota Ra was the most potent stimulus of NO from THP-1 cells. Whole E. coli also
stimulated the production of significant amounts of NO from THP-1 and was more potent
than other organisms except for S. minnesota Ra. THP-1 cells also responded to the
stimulation of whole N. meningitidis, B. fragilis and Staph, epidermidis by producing
small significant amounts of NO.
Human peripheral blood monocytes (PBMC) were tested to find if they could produce
NO in response to various forms of LPS and different bacteria. In response to free LPS
human peripheral blood monocytes did not produce any significant amounts of NO. In
response to all OM preparation concentrations used human PBMC produced significant
amounts of NO. The production of NO from human PBMC was dose-dependent. Human
PBMC also produced significant amounts of NO in response to whole S. minnesota Ra at
doses of 108 ml"1 and 109 ml"1.
Both THP-1 and human PBMC behaved comparably in that both responded to OM
preparation and whole S. minnesota Ra by producing NO and both of them did not
produce NO in response to free LPS. OM preparation was more potent in stimulating the
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production of NO from PBMC than whole S. minnesota Ra which was more potent than
OM in stimulating the production of NO from THP-1 cells.
Other investigators (Schneemann et ah, 1993) reported that both human PBMC and
human peritoneal macrophages were unable to produce NO in response to either free E.
coli LPS alone or free LPS combined with IFN-y or in response to a combination of free
LPS with IFN-y and tetrahydrobiopterin (BH4). These investigators claimed that human
mononuclear phagocytes do not synthesise BF14 (an essential cofactor of NOS); therefore,
they supplemented human mononuclear phagocytes with exogenous BH4 to investigate if
it would give rise to NO production. They concluded that human mononuclear
phagocytes cannot produce NO under the conditions tested and that inducible NOS was
not a constituent of the antimicrobial system of human mononuclear phagocytes. Part of
our work agrees with Schneemann and co-workers (1993) in that human mononuclear
phagocytes do not produce NO in response to free LPS; however this study shows that
human mononuclear phagocytes have the ability to produce NO in response to bacterial
OM preparations and whole bacteria of different species. Other investigators (Munoz-
Fernandez et al, 1992) have reported that human PBMC can kill intracellular
Trypanosoma cruzi by NO dependent mechanism when activated by IFN-y and TNF-a.
They also reported that NO production and trypanocidal activity induced in these
monocytes by TNF-a or IFN-y alone or in combination, were inhibited by N-
monomethyl-l-arginine (A-MMLA), a competitive inhibitor of NO synthase activity.
In this work formaldehyde-killed bacteria were used to stimulate host cells. Heat killing
is another method of killing bacteria but it has not been used because this method might
cause the shedding of LPS from Gram-negative bacteria. The shed LPS would be washed
away during the washing of bacteria and consequently would affect the results of
experiments in which whole Gram-negative bacteria were used as another form of LPS.
Heat killing of bacteria might also cause lysis that might affect the results of experiments
in which whole Gram-positive and Gram-negative bacteria were used to stimulate host
cells. The effect of both methods of killing of bacteria on NO production from THP-1
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cells was investigated in this work. There was no significant difference in NO release
from THP-1 cells in response to both formaldehyde-killed and heat-killed bacteria. This
applied to both Gram-negative and Gram-positive bacteria; therefore, the work continued
using formaldehyde-killed bacteria.
IFN-y was reported to activate murine macrophages to produce NO in response to
bacterial products (Amber et al, 1988; Schneemann et al, 1993). THP-1 cells and
human PBMC were used to determine if they behave similarly to murine macrophages in
response to activation with human recombinant IFN-y. IFN-y alone or in combination
with free LPS did not induce the cells to produce NO. Also IFN-y did not enhance the
production of NO from either THP-1 or humaii TBMC in response to OM preparation or
whole S. minnesota Ra. This work is in agreement with other investigators (Schneemann
et al, 1993; Murray and Teitelbaum, 1992; Padgett and Pruett, 1992) who reported that
human mononuclear phagocytes treatment with IFN-y alone or in combination with LPS
did not induce these cells to produce NO. In contrast to our results, other investigators
(Munoz-Fernandez et al, 1992) reported that IFN-y-stimulated human PBMC-derived
macrophages produce NO in response to an infection with Trypanosoma cruzi. The
rlFN-y used in my work was not tested in other assays; therefore, it is possible that it was
inactive.
The possible role for CD14 receptors in signalling THP-1 cells to produce NO was also
investigated. It seems that CD 14 receptors are not involved in the process of producing
NO from THP-1 cells because increased expression of CD14 on THP-1 did not enhance
NO production from these cells. Also anti CD 14 monoclonal antibodies failed to inhibit
NO production from THP-1 cells in response to OM preparation and whole bacteria (data
not shown).
The role of LPS in OM and whole bacteria preparations in inducing THP-1 cells to
produce NO was investigated using polymyxin B sulphate. Polymyxin B sulphate at
concentrations of 1 jug ml-1, 10 pg ml"1 and 100 pg ml"1 completely blocked NO
production from THP-1 cells in response to OM preparation, this finding points to the
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involvement of the LPS molecule, in particular the lipid A region, in the induction
process of THP-1 to produce NO. As for TNF polymyxin B sulphate did not inhibit NO
production in response to whole S. minnesora Ra probably for the same reasons. Two
monoclonal antibodies (SZ 27.19 and WN1) directed against Salmonella and E. coll LPS
were used to inhibit the production of NO from THP-1 cells. Both antibodies at several
dilutions failed to inhibit NO production from THP-1 cells in response to OM preparation
and whole S. minnesora Ra. This might be because these antibodies were binding to an
epitope on the LPS core that is different from the one which is recognised by host cell
receptors. SZ was also used to inhibit NO production from PBMC in response to OM
preparation and S. minnesora Ra. SZ did not inhibit NO production from PBMC at any
dilutions used. Interestingly, SZ was found to stimulate PBMC to produce small amounts
of NO in control samples (data not shown). The results with polymyxin B also suggest
that the results with OM and whole bacteria are due to LPS and not other molecules.
Gram-positive bacteria were previously reported to induce the production of NO from rat
bone marrow derived mononuclear phagocytes (Keller et al, 1991); therefore, the ability
of Gram-positive bacteria to stimulate host cells to produce NO was investigated. In this
work Gram-positive bacteria represented by Staph, epidermidis stimulated peritoneal
macrophages of different mouse strains and human macrophage cell line (THP-1) to
produce small amounts of NO. Keller and co-workers (1991) used several Gram-positive
and Gram-negative bacteria in their investigations of the interaction between bacteria and
macrophages by measuring NO production and macrophage-mediated tumouricidal
activity. They reported that several Gram-positive bacteria including a strain of Staph,
epidermidis stimulated bone marrow-derived mononuclear phagocytes of rats to produce
NO which is in agreement with the results of this work on mouse macrophages.
Free LPS did not stimulate human peripheral blood monocytes or THP-1 cells to produce
NO, but whole bacteria and OM preparation stimulated these cells. Also NO production
from murine resident macrophages was greater in response to whole bacteria and OM
preparation than free LPS. This might indicate that other bacterial cell surface
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component/s are stimulating host cells to produce NO by themselves and therefore
enhancing the effect of LPS or they might synergise with LPS to stimulate host cells to
produce NO. Because of the lack of an accurate method to estimate the amount of LPS
attached to whole bacteria (the KDO assay is not accurate with whole bacteria), whole
bacterial preparations might have greater amount of LPS than the amount used as free
LPS or the amount of LPS attached to OM preparation.
In this chapter the production of TNF from the human monocytic cell line (THP-1) and
NO from murine macrophages in response to various forms of LPS and different bacteria
was investigated. The ability of human mononuclear phagocytes to produce NO in
response to particular forms of LPS and to different bacteria was shown indicating that





Lipopolysaccharides (endotoxins) are major components of the outer membrane of
all Gram-negative bacteria. They are essential for the physical organisation and
function of these membranes and for bacterial growth and multiplication (Rietschel
et al., 1990). They form a hydrophobic barrier that restricts the entry of harmful
substances. The O-side chains (O-antigen) of LPS form a carbohydrate layer in
organisms lacking capsules. This layer increases the hydrophilicity of the cell surface
enabling the cells to avoid phagocytosis. Avoiding phagocytosis is necessary for
survival of pathogens of animals (Cunningham et al, 1975). Endotoxins have the
ability to influence both cellular and humoral limbs of the immune response
(Rapson, 1988). The endotoxicity is determined mainly by the structure of the lipid
A with the determining factor being the fatty acid composition and substitution
pattern and the phosphate substitution.
Endotoxins have been implicated in the pathogenesis of several clinical disorders.
Of these the most familiar is Gram-negative septic shock in which the role of
endotoxins is most clearly established (Morrison and Ryan, 1987). Gram-negative
septic shock is a life-threatening disease associated with high mortality especially in
immuno-compromised patients. The mechanism by which Gram-negative bacteria
induce septic shock is complex with little experimental evidence pointing to a single
toxic factor. When purified from organisms and injected into experimental animals,
endotoxin induces many of the same pathophysiological changes seen during Gram-
negative infections (Manthey and Vogel, 1992). Based on an increasing body of
data, it is now felt that many of the symptoms of septic shock are mediated by the
action of host-derived mediators released in response to endotoxin. These mediators
play important roles in the normal host response to insult but their overproduction
can have important consequences for the host. Several of these mediators have been
recognised for some years. Macrophages are the principle source of endotoxin-
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induced mediators which include tumour necrosis factor (TNF) (Manthey and Vogel,
1992).
For these mediators to be released LPS must interact with host cells. At least three
classes of molecules on leucocytes have been recognised to be LPS receptors. CD18
molecules and the scavenger receptor are involved in the recognition and disposal of
LPS without initiating mediator release. CD 14 recognises LPS complexed to a
serum protein, lipopolysaccharide binding protein (LBP) and this leads to both
phagocytic uptake of bacteria and TNF release in response to very low
concentrations of LPS-LBP complexes. High concentrations of LPS might initiate
TNF release in the absence of serum or CD14 therefore another LPS receptor of low
affinity might exist (Wright 1991). The pathways used by different forms of LPS
(pure, OM and bacterial-associated) to signal release of mediators are not known.
Also differences between LPS from different bacteria exhibit different levels of
endotoxicity. It is important to know if variation in responses is linked to differences
in interaction of LPS with cells.
In this study the binding of S. minnesota Ra to mouse peritoneal macrophages was
studied to investigate the role of LPS in mediating the binding of Gram-negative
bacteria to macrophages. The outcome of the interaction between LPS and host
macrophages was also studied by measuring TNF and nitric oxide (NO) release
following the stimulation of macrophages using various forms of LPS. An attempt
was made to investigate the role of CD 14 in signalling of macrophages to release
TNF and NO.
The binding of Gram-negative bacteria to mouse peritoneal macrophages, human
macrophage cell line (THP-1), human peripheral blood monocytes and neutrophils
was measured using flow cytometry. This method apparently overcame some of the
difficulties concerning the study of bacterial binding to host cells. One important
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advantage of flow cytometry is that it allowed studies involving mixed cell types that
can be distinguished on the basis of light scatter. Flow cytometry is objective; it is
free of the possible experimental bias of microscopic binding studies. Flow
cytometry also allowed the analysis of a large number of samples as well as a large
number of cells in each sample in a short period of time. By using flow cytometry
the optimum binding conditions of S. minnesota Ra to peritoneal macrophages of
C3H mouse strain were determined. THP-1 cells exhibited similar binding pattern to
those of mouse peritoneal macrophages when tested under the same conditions;
however, the level of the binding of S. minnesota Ra to THP-1 cells was lower than
the level of the binding of S. minnesota Ra to mouse peritoneal macrophages. This
might be because of the maturation state of THP-1 cells which are immature
macrophages probably expressing fewer receptors than the mature mouse peritoneal
macrophages or it might be due to a variation in the binding ability between different
species. Human peripheral blood monocytes and neutrophils from different
individuals showed variable binding characteristics. This variation in the ability of
cells from different individuals to bind bacteria could be because of genetic and/or
environmental factors.
In this work the role of LPS in mediating the binding of Gram-negative bacteria to
host macrophages was investigated using various forms of LPS. Free S. minnesota
Ra LPS and outer membrane fraction from S. minnesota Ra inhibited significantly
the binding of FITC-labelled S. minnesota Ra to mouse peritoneal macrophages.
This clearly indicated the involvement of LPS in the attachment of FITC-labelled
Gram-negative bacteria to mouse peritoneal macrophages. The inhibition of binding
of FITC-labelled bacteria by using whole unlabelled bacteria (as another form of
LPS) produced unexpected results in that whole unlabelled S. minnesota Ra failed to
inhibit the binding of FITC-labelled S. minnesota Ra. This finding raised a few
questions. First, the binding of unlabelled bacteria to mouse peritoneal macrophages
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was questioned; therefore, the binding of unlabelled bacteria was investigated using
mAb directed against Salmonella LPS and FITC-conjugated antimouse
immunoglobulin. Although the level of the binding detected using this method was
lower than that seen by using directly labelled bacteria with FITC (see section
3.3.3.4), this method confirmed that unlabelled bacteria were binding to mouse
peritoneal macrophages in the absence of serum. This method was not suitable for
inhibition work in which various forms of LPS were used to inhibit the binding of S.
minnesota Ra to host cells.
Other questions concerning the specificity of the binding of FITC-labelled bacteria to
macrophages were also raised. To investigate this a visual assay was used. With this
method a direct comparison between the binding of FITC-labelled and unlabelled
bacteria was possible. Using the visual assay, FITC-labelled S. minnesota Ra were
found to bind to macrophages at much higher levels than unlabelled S. minnesota Ra.
This enhancement of the binding seen with FITC-labelled bacteria was further
investigated to find out whether this enhancement was specific to the FITC itself or it
was because of the high pH of FITC coupling buffer. The effect of FITC labelling of
other bacterial species on their binding to mouse peritoneal macrophages was also
investigated. The enhancement of binding seen with FITC-labelled bacteria was
found to be specific to the FITC itself and not to the FITC coupling buffer and also
was not specific to the strain of S. minnesota Ra used in this study but was also
applied to other bacterial species. The mechanism by which FITC enhanced bacterial
binding is not known. It might be that FITC is non-specifically recognised by
macrophages or have some kind of charge effect. FITC might also be altering the
structure of bacterial cell surface component/s or it might be changing the
hydrophobicity of bacterial cells. Because the results obtained using flow cytometry
were brought into question, the visual assay was used to re-investigate the role of
LPS in mediating the binding of Gram-negative bacteria to mouse peritoneal
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macrophages. With the visual assay free S. minnesota Ra LPS inhibited the binding
of unlabelled and FITC-labelled S. minnesota Ra to macrophages. These results
confirmed the inhibition results obtained by using flow cytometry and also
confirmed the conclusion that LPS is involved in mediating the binding of Gram-
negative bacteria to macrophages. Consistent with this observation is the work of
Wright and Jong (1986) who concluded that human peripheral blood-derived
macrophages recognised E. coli in the absence of serum opsonins by recognising
LPS. They reported that free S. minnesota R595 (Re) LPS and a biosynthetic
precursor of LPS termed lipid IVa inhibited the binding of E. coli to human
macrophages.
It has been found in this work that FITC labelling of different bacteria increased their
binding capacity to host cells. Many other investigators (Wright and Jong, 1986;
Zorgani et al., 1994; Raza et al., 1993; Saadi et ai, 1993; Raybourne and Bunning,
1994) have used FITC-labelled bacteria in their studies on bacterial binding to host
cells. The results of their studies using FITC-labelled bacteria in vitro might be
affected by the use of FITC and might not apply in vivo since FITC-labelled bacteria
do not exist physiologically. Therefore it might be important to re-evaluate their
results.
Free LPS and outer membrane fraction inhibited the binding of S. minnesota Ra to a
similar degree. Both preparations did not block the binding of bacteria to host cells
completely which can be explained by the presence of other bacterial cell surface
component/s that are also involved in part of the binding such as carbohydrate
residues which recognised by mannose-fucose receptors. Free S. minnesota Ra LPS
also inhibited the binding of other FITC-labelled bacteria (E. coli, Pseudomonas
aeruginosa and Bacteroides fragilis) to a variable degree (data not shown). This
indicated that the inhibition of binding by free LPS from S. minnesota Ra was
relatively non-specific as far as the LPS is concerned. It therefore appears probable
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that conserved parts of the LPS, i.e. core and lipid A, are involved in the binding.
Because of the difficulties in the use of FITC-labelled bacteria and because the use of
direct microscopy is time consuming and also subjective to some extent, this line of
investigation was abandoned.
The outcome of the interaction between LPS and host macrophages is the release of
cytokines and other mediators by host macrophages. In this study the release of TNF
from THP-1 cells was studied briefly. Nitric oxide release from different mouse
strains and from human peripheral blood monocytes and THP-1 cells was also
investigated. This afforded another reao out system to study the interaction of
various forms of LPS with host cells.
THP-1 cells released significant amounts of TNF in response to all forms of S.
minnesota Ra LPS used. TNF release from THP-1 cells was dose dependent and
peaked after 4 hours of stimulation of the cells. It seems that other bacterial cell
surface component/s synergise with LPS in inducing TNF in that outer membrane
fraction and whole S. minnesota Ra were more potent than free S. minnesota Ra LPS
in this respect. It was hoped to use murine macrophages to measure TNF release
upon stimulation with various forms of LPS, but it was not possible at the time due
to a high background of TNF production by control samples. This might have been
due to an infection in mouse colony or contamination with LPS during the harvesting
and handling of the macrophages.
It has been established that bacterial LPS binds to the plasma protein LPS-binding
protein (LBP) forming high affinity complexes (LPS-LBP) which are potent agonists
for monocytic cells. CD14 has been reported to mediate monocyte recognition of
LPS-LBP complexes leading to cytokine production (Wright et al 1990b); therefore,
a role for CD14 receptors in the production of TNF in response to different forms of
S. minnesota Ra was investigated. THP-1 cells with enhanced expression of CD14
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were stimulated with various forms of LPS and produced amounts of TNF
comparable to those produced by unenhanced THP-1 cells in response to the same
forms and concentrations of LPS. One possible explanation for this finding is that
CD14 receptors expressed on normal THP-1 cells were sufficient to mediate
maximum stimulation of the cells and therefore, an increased expression of CD14
receptors does not have an effect. An other explanation is that other pathways for the
stimulation of the cells to produce TNF might be of importance. In line with this
hypothesis is the finding that anti-CD 14 mAb did not block or inhibit the production
of TNF. This is consistent with other investigators' work (Lynn et al, 1993) in
which they reported that CD14 and serum were not absolutely necessary for the
activation of mononuclear phagocytes by bacterial LPS. They also suggested that a
CD14-independent pathway might be of importance in local sites of infection where
the concentration of LPS might be high.
The role of various forms of LPS in stimulating THP-1 cells to release TNF was
investigated using polymyxin B sulphate, an agent known to bind to the lipid A
region of the LPS molecule. Polymyxin B completely blocked TNF production from
THP-1 cells in response to free S. minnesota Ra LPS and to the outer membrane
fraction of S. minnesota Ra. The blockage of TNF production from THP-1 cells
caused by polymyxin B indicated that lipid A is the active part of LPS molecule in
stimulating the cells. It also seems that other bacterial cell surface components are
not involved in the process of stimulation of THP-1 cells in that polymyxin B
blocked TNF release in response to outer membrane fraction of S. minnesota Ra;
however, polymyxin B did not block or inhibit TNF production from THP-1 cells in
response to whole S. minnesota Ra. One possible explanation is that the whole
bacteria might have been phagocytosed and polymyxin B might be released or
inactivated after the binding or internalisation of whole Gram-negative bacteria by
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host cells. In this situation the bacteria might then stimulate host cells via an intra-
or extracellular mechanisms.
The production of NO and other reactive nitrogen intermediates by cytokine-
activated rodent cells is an important component of antimicrobial and/or
antineoplasic activities of these cells. The pathway of production involves the
oxidation of arginine to citrulline with the concomitant release of NO by the
inducible form of NO synthase (iNOS) (Denis, 1994). Numerous cell types express
iNOS after stimulation with bacterial products such as LPS and/or cytokines.
Although human cells such as hepatocytes and endothelial cells have been shown to
express iNOS, the presence of such a pathway in the human monocyte/macrophage
lineage has been questioned and is the subject of great controversy (Denis, 1994).
In this work NO release from different mouse strains including LPS hyporesponsive
strain (C3H/HeJ), human macrophage cell line (THP-1) and human peripheral blood
monocytes was investigated using various forms of S. minnesota Ra LPS and other
bacteria. Peritoneal macrophages of CBA and BALB/c mice responded to various
forms of S. minnesota Ra LPS by producing measurable amounts of NO. In both of
these mouse strains whole S. minnesota Ra organisms were the most potent form of
"LPS'" in stimulating NO production. In CBA mice the OM fraction from S.
minnesota Ra was more potent than purified S. minnesota Ra LPS. Different
bacteria were also used to stimulate NO production from the peritoneal macrophages
of CBA and BALB/c mice. E. coli was more potent than N. meningitidis in
stimulating peritoneal macrophages of CBA mice whereas N. meningitidis was more
potent than E. coli in stimulating peritoneal macrophages of BALB/c mice; however
peritoneal macrophages of BALB/c mice produced larger amounts of NO than those
of CBA mice in response to all forms of LPS and different bacteria used. B. fragilis
and Staph, epidermidis were the least potent stimuli in both mouse strains.
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Other investigators (Delahooke et al, 1995) have reported that B. fragHis and E. coli
018K" LPS stimulated TNF production from peritoneal macrophages of C3H/HeN
mice (responder) and also reported that peritoneal macrophages of C3H/HeJ mice
(hyporesponsive) produced TNF in response to B. fragilis LPS but not to E. coli
LPS. Other workers (Schneemann et al., 1993) have used E. coli 026: B6 LPS to
stimulate NO production from resident and thioglycollate elicited peritoneal
macrophages of BALB/c and C3H/HeN mice. They reported that peritoneal
macrophages of both mouse strains produced NO in response to E. coli LPS and also
reported that IFN-y enhanced the production of LPS-induced NO from these
macrophages. These investigators work support the results of my work on peritoneal
macrophages of different mouse strains when stimulated with LPS.
The C3Fl/HeJ mouse strain is a mutant inbred strain which has been demonstrated to
have an inherited defect in the ability to respond to LPS. Recently, specific LPS
binding proteins have been isolated on lymphocytes and other cells of C3H/HeJ.
However a receptor which transduces an activation signal has not been isolated yet.
It appears that the defect in C3H/HeJ cells resides in the signal pathway leading to
gene activation and proliferation (Sultzer et al., 1993). However there is growing
experimental evidence that C3H/HeJ mice can recognise R-chemotype LPS.
In this work peritoneal macrophages of C3H/HeJ responded to the stimulation of
whole S. minnesota Ra and OM fraction from S. minnesota Ra by producing NO, but
they did not respond to the stimulation by free LPS. Peritoneal macrophages of
C3H/HeJ also responded to different bacteria by producing NO. As for the other
mouse strains used whole S. minnesota Ra bacteria were more potent than the OM
fraction. E. coli was the most potent organism in stimulating C3H/HeJ whereas S.
minnesota was more effective than N. meningitidis. Again B. fragilis and Staph,
epidermidis were the least potent stimuli for NO production from C3H/HeJ mice. It
seems that free LPS lacks a necessary component/s required to initiate LPS-induced
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NO from C3H/HeJ and that this component/s is present in OM fraction and whole
bacteria. Others (Zhang et al., 1994) have reported that peritoneal macrophages of
C3H/HeJ mice did not respond to stimulation with either E. coli S-LPS or S.
minnesota R60 LPS. They also reported that addition of exogenous IFN-p or IFN-y
corrected the hypo- responsiveness of C3H/HeJ macrophages enabling them to
produce TNF and NO.
In this work NO production from human cells (THP-1 and peripheral blood
monocytes) was investigated using various forms of LPS and different bacteria.
Both THP-1 cells and human monocytes did not respond to free S. minnesota Ra
LPS. THP-1 cells responded to the stimulation of whole S. minnesota Ra bacteria
and the OM fraction from S. minnesota Ra by producing NO. THP-1 also responded
to other bacteria by producing measurable amounts of NO. S. minnesota Ra was the
most potent organism in stimulating THP-1 cells. E. coli was more potent than the
other organisms used. N. meningitidis, B. fragilis and Staph, epidermidis were the
least potent organisms in stimulating THP-1 cells. Similar to THP-1 cells human
peripheral blood monocytes produced NO in response to whole S. minnesota Ra and
OM fraction from S. minnesota Ra. Although THP-1 cells and human monocytes
behaved comparably in that both released NO in response to whole S. minnesota Ra
and OM fraction, THP-1 cells produced greater amounts of NO than human
monocytes. This might be due to differences in the state of maturation between
THP-1 cells and human monocytes. The inability of free LPS to stimulate human
cells might be because of the binding of free LPS to the cells was not efficient
enough to stimulate these cells to release NO.
It appears that a variation exists in the ability of different bacteria to stimulate TNF
and NO production from host cells. This might be due to variations in the structure
of LPS in different Gram-negative bacteria, and Gram-positive bacteria must use
entirely different stimulus. It might be due to a variation in the ability of host cells to
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bind to different bacteria due to genetic and/or environmental factors. A study of
this was part of the aims of this thesis. The binding of different bacteria to peritoneal
macrophages of C3H mice (Figure 3.12) showed different levels of binding (this part
of the work could not be extended due to the difficulties of using flow cytometry and
visual assay).
It has been reported that B. fragilis contains different fatty acids from enterobacterial
LPS, is monophosphorylated and generally accepted as being less endotoxic
(Lindberg et al., 1990). In this work B. fragilis stimulated mouse macrophages and
THP-1 cells to produce NO. Other workers (Delahooke et al., 1995) also reported
that B. fragilis LPS extracted by the aqueous phenol method was as effective as E.
coli 018K" LPS in stimulating TNF production from THP-1 cells. These
observations might be of clinical significance when we consider that Bacteroides
species are 1000-fold greater in number than E. coli in the gut. Although it is not
known if these in vitro observations will occur in vivo, it could be of importance in
terms of immunotherapy if bacteria or bacterial products translocate from the gut into
the circulation; therefore, if Bacteroides LPS is a major inducer of cytokine and
mediator responses, it should be targeted with antibody therapy instead of E. coli
LPS.
The most potent form of LPS in stimulating TNF and NO was whole bacteria and the
OM fraction was more potent than free LPS. This might be due to different
signalling mechanism or pathways (bacteria might stimulate the cells after being
internalised) or the ability of host cells to bind whole bacteria might be greater than
that of the OM fraction and free LPS. The binding of OM fraction to host cells
might also be more efficient than free LPS. Also there might be more LPS in whole
bacteria than free LPS and OM fraction used in the same experiments. This is
because of the lack of an accurate procedure to determine the amount of LPS in
whole bacteria.
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The production of NO from murine peritoneal macrophages in response to free S.
minnesota Ra LPS is in contrast to the apparent hyporesponsiveness of human cells
(THP-1 cells and human peripheral blood monocytes). Differences in the maturation
and specialisation of the cells (THP-1 cells are immature macrophage cell line) could
be one reason for the observed differences between species. Although human
monocytes are mature cells, they did not respond; however, mice are much more
resistant to the toxic effects of LPS. Mice will survive challenge with the same
amount of LPS that would kill an adult human being. More work is needed on the
signalling pathways in the two species to give possible insight into the mechanisms
that mediate more production of cytokines by murine cells but make human beings
more susceptible to the endotoxic shock.
Interferon-gamma was reported to enhance NO production from murine
macrophages (Schneemann et al, 1993; Zhang et al, 1994). In this work human
recombinant INF-y did not enhance NO production from THP-1 cells. This might
possibly be because the INF-y used in this work was inactive.
The role of CD14 receptors in signalling THP-1 cells to produce NO was
investigated. As with TNF production enhanced expression of CD 14 on THP-1 cells
had no effect on NO production as compared to THP-1 cells without enhancement
for CD14.
The role of various forms of LPS in stimulating the production of NO was
investigated using polymyxin B sulphate. As with TNF, polymyxin B completely
blocked NO production from THP-1 cells in response to free S. minnesota Ra LPS
and OM fraction from S. minnesota Ra but it did not block NO production from
THP-1 cells in response to whole S. minnesota Ra.
In conclusion, LPS has been shown to interact directly with host cells and, therefore,
probably plays a role in mediating the attachment of Gram-negative bacteria to host
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macrophages. Host macrophages responded to the interaction with LPS by releasing
p
TNF and NO. The lipid A region of the LPS molecule has been shown to be the
active part in stimulating these responses. There is variation in the response of
macrophages to stimulation by various forms of LPS and by different bacteria. The
work suggests that pathways independent of CD 14 are of importance in stimulating
TNF and NO production. It might prove of importance to investigate the role of
other LPS receptors in stimulating host responses. More knowledge of the
mechanisms by which LPS stimulates host responses is necessary for the
development of new strategies to neutralise the biological effects of endotoxins in
Gram-negative bacterial infections and septic shock.
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